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Abstract:  The mononuclear phagocyte system in 
Graft-versus-Host-Disease 
 
 
The human mononuclear phagocyte system of monocytes, macrophages and 
dendritic cells participates in both innate and adaptive immune responses.  However, 
the accurate identities, functions and inter-relationships of these crucial immune cells 
during inflammation are poorly defined.  Two inflammatory settings were examined in 
this work: the skin in acute Graft-versus-Host Disease and the lung during 
experimental inflammation induced by LPS inhalation.  The purpose of this enquiry 
was to characterize inflammatory mononuclear phagocytes in tissue, investigate their 
origins and explore their contribution to disease pathogenesis. 
 
In the skin GvHD study, shave biopsies were obtained from 73 individuals on 
presentation with acute rash following bone marrow transplantation (BMT).  Controls 
were obtained from 19 BMT recipients at matched time points without rash and 26 
healthy individuals undergoing plastic surgery.  Tissue was digested and the 
leukocyte composition analysed by flow cytometry/ sorting.  Sorted populations were 
used in functional assays or in gene expression experiments performed using 
NanoString technology.  An in vitro equivalent of CD14-expressing mononuclear 
phagocytes (MPs) was developed using HLA-matched mixed leukocyte reactions.  
Gene expression was measured and the function of these equivalents in a skin 
explant model of GvHD was tested.  GvHD lesional skin was characterized by 
expansion of CD14-expressing MPs (GVH14) and a reduction in CD1c-expressing 
MPs.  GVH14 were identified as donor monocyte-derived macrophages.  
Functionally, GVH14 could produce chemokines to recruit T lymphocytes to lesions.  
They were capable of activating and expanding T lymphocytes in vitro.  GVH14 
equivalents could damage basal keratinocytes of the epidermis without the presence 
of T cells.  This characterization has identified a novel pathogeneic role for 
macrophages in acute GvHD.    
 
In the LPS inhalation study, 13 healthy individuals received saline (0.9% sodium 
chloride) and 13 received LPS (0.9% sodium chloride with 2mg LPS from E.coli 
026:B6) by dosimeter nebulizer.  Blood samples were obtained at 2, 4, 6 and 24 
hours following inhalation.  Between 7 and 8 hours post-inhalation, bronchoalveolar 
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lavage (BAL) of a sub-segment of the right middle lobe was performed.  BAL fluid 
supernatant chemokines and cytokines were analysed by multiplexed ELISA.  The 
cellular component of BAL was analysed by flow cytometry/ sorting.  Sorted 
populations were used in functional assays or in gene expression experiments 
performed using NanoString technology.  Seven distinct MPs were identified in 
steady state (i.e. following saline inhalation).  Following LPS inhalation, neutrophils, 
CD14-expressing MPs and CD1c-expressing MPs were expanded.  Phenotypically, 
CD1c expressing MPs resembled blood cDC2.  Both subsets of blood cDC2 were 
recruited to the airspace but their distinct functions and gene expression profiles 
converged upon recruitment.  This analysis provides the first detailed 
characterization of BAL fluid MPs.  As such it provides a foundation for studying MPs 
in human lung diseases, including the Idiopathic Pneumonia Syndrome occurring 
after BMT.  It detailed the surprising observation that blood cDC2 can be recruited to 
tissue in inflammation, challenging the dogma that inflammatory MPs must be 
monocyte-derived. 
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Chapter 1. Introduction 
 
This chapter will begin with an introduction to the concepts in immunology most 
relevant to mononuclear phagocyte (MP) biology.  An overview of the mononuclear 
phagocyte system (MPS) will follow, structured by detailing its cell subsets, their 
functions and origins.  Following a summary of the steady state MPS, features in 
inflammation will be explored.  Tissue specific considerations of the MPS will be 
discussed for the two organs examined in this work:  skin and lung.  Graft-versus-
host disease (GvHD) will be introduced, before summarizing the hypotheses and 
general aims of this thesis.  
 
1.1 Relevant concepts in immunology 
 
1.1.1 Innate and adaptive immunity 
 
To protect an organism against damage from infectious or harmful agents, the 
immune system must provide a rapid response.  This ability is termed the innate 
immune response and is shared by all multicellular organisms, from nematodes to 
humans.  At its most primitive, the innate immune system comprises receptors that 
bind pathogen-associated molecules, signaling cascades and antimicrobial effector 
molecules (Schulenburg et al., 2008).  Cells capable of engulfing foreign particles 
(phagocytes) were initially discovered in starfish larvae and have evolved into a 
critical aspect of innate immunity in vertebrates (Tauber, 2003).  Non-phagocytic cells 
(basophils, mast cells, innate lymphoid cells) contribute to innate responses via 
release of effector and signaling molecules (Murphy, 2011).   
 
Dogma that the innate immune system responds without memory of prior events has 
been challenged in recent years (Saeed et al., 2014),!(Cheng et al., 2014).  However, 
the principal repository of immune memory in vertebrates is the adaptive immune 
system.  Lymphocytes of the adaptive immune system have vast diversity of antigen-
specific receptors, can persist long-term and can respond rapidly to antigen re-
challenge via population expansion, cytokine and antibody production and cytotoxic 
function.  MPs of the innate immune system are pivotal regulators of adaptive 
immunity via antigen presentation (Steinman and Hemmi, 2006). 
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1.1.2 Antigen presentation  
 
To initiate an adaptive immune response, a naïve T cell must receive three signals 
from an antigen-presenting cell (APC).  First, an antigenic peptide is presented via a 
major histocompatibility complex (MHC) protein specific for the T cell receptor.  
Second, an activation signal (e.g. CD80 and CD86 binding CD28) promotes T cell 
survival and proliferation.  Third, a cytokine signal activates a specific differentiation 
program in the T cell (Murphy, 2011).  In situations where signal 1 is provided in 
isolation, anergic (non-responsive) T cells result (Quill and Schwartz, 1987). 
 
While most somatic cells express MHC proteins, only macrophages, dendritic cells 
(DCs) and B-lymphocytes are competent APCs.  Naïve T cell stimulation is a 
specialized function of DCs and occurs primarily in lymphoid tissue (Steinman and 
Witmer, 1978).  Memory T cells encounter both macrophages and DCs in non-
lymphoid tissues and antigen presentation in this context may contribute to 
lymphocyte responses (Wakim et al., 2008).  B cells present antigen to enlist T cell 
help for antibody production. 
 
Proteins within cytosolic and endocytic compartments are processed and presented 
differently.  Cytosolic proteins are presented on MHC class I proteins (HLA-A, B and 
C in humans) to CD8 T cells.  Endocytic proteins are presented on MHC class II 
proteins (HLA-DR, DQ, DP in humans) to CD4 T cells.  Phagocytosis by 
macrophages and DCs delivers pathogenic/ immunogenic antigens to the endocytic 
compartment, but not all antigens are capable of entering the cytosolic compartment.  
For example, viruses that do not directly infect a DC/ macrophage, solid tumour-
associated antigens and vaccine-delivered antigens cannot become cytosolic in the 
APC.  Some DCs are capable of presenting exogenous antigen on MHC class I to  
CD8 T cells: a process termed cross-presentation.  Transfer of entire MHC-peptide 
complexes to the surface of APCs may also occur, and is referred to as cross-
dressing (Wakim and Bevan, 2011).   
 
1.1.3 Non-self and danger recognition  
 
Matzinger’s Danger model is the most comprehensive explanation of how the 
immune system responds to cells from another individual or species.  The model is 
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based on Janeway’s theory that APCs require stimulation to generate an adaptive 
immune response (Matzinger, 2002).  While APCs continually ingest dying or 
damaged tissue cells in addition to pathogens, auto-immunity is not ubiquitous.  
Janeway proposed that productive immunity only occurs when pattern recognition 
receptors (PRRs) on APCs are stimulated.  Conserved pathogen associated 
molecular patterns (PAMPs) provide this stimulus.  Matzinger added the refinement 
that stimuli do not have to be pathogen-associated!(Matzinger, 1994).  ‘Danger 
signals’ or damage-associated molecular patterns (DAMPs) are released by tissue 
necrosis.  Recognized danger signals include heat shock proteins and uric acid.  
DAMPs and PAMPs together are referred to as ‘alarmins’ (Oppenheim and Yang, 
2005).  
 
1.1.4 Acute inflammation 
 
Activation of alarmins must induce rapid local changes to contain foreign antigen.  
Three of the clinical signs of acute inflammation described by Celsus two thousand 
years ago (calor/ heat, rubor/ redness and tumor/ swelling) indicate that a vascular 
response is critical.  Reduced vascular flow rate, increased endothelial permeability 
and endothelial activation permit leukocyte entry to tissue.  Neutrophils are recruited 
first, initiating a cellular innate immune response.  Monocytes follow within hours (Shi 
and Pamer, 2011).  In addition to leukocytes, plasma proteins, such as complement, 
are key effectors.  Tissue resident leukocytes, including macrophages, contribute by 
producing cytokines such as interleukin-6 (IL-6) and tumour necrosis factor alpha 
(TNFα) and chemokines that recruit other leukocytes to the inflamed site (Davies et 
al., 2013). 
 
 
1.2 The mononuclear phagocyte system 
 
A scheme of the human MPS is depicted in Figure 1.1.  The following sections 
discuss the foundation for classifying these cells as a system and review the defining 
features of each member.  Figure 1.1 contextualizes how each member fits within the 
organization of the MPS. 
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Figure 1.1 Organization of the human MPS  
Image modified from (Haniffa et al., 2015a).  HSC= haematopoietic stem 
cell, GMP= Granulocyte macrophage precursor, MLP= Multi-lymphoid 
progenitor.  Dashed arrows indicate possible precursor-progeny 
relationships 
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Figure 1.1 Organization of the human MPS 
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1.2.1 Historical description 
 
The MPS was proposed in 1972 in order to describe phagocytic cells sharing similar 
phenotype and function (van Furth et al., 1972).  The system recognized bone 
marrow precursors, circulating monocytes and tissue specific macrophages as a 
continuum that was distinct from polymorphonuclear phagocytes (granulocytes/ 
neutrophils).  In contrast to earlier attempts at classification, van Furth and 
colleagues excluded non-immune cells such as fibroblasts and endothelial cells.  
When Steinman and Cohn isolated a novel cell type from mouse spleen in 1973-79, 
the DC was added to the MPS, even thought it had limited capacity for phagocytosis 
and properties that clearly distinguished it from macrophages (Steinman and Cohn, 
1973),!(Steinman and Cohn, 1974).  Ongoing support for classifying monocytes, 
macrophages and DCs as part of a unified system is mixed (Geissmann et al., 2010).  
In the past decade, clear differences in the origins of monocytes, macrophages and 
DCs have been identified (Naik et al., 2007),!(Ginhoux et al., 2010),!(Hettinger et al., 
2013),!(Lee et al., 2015),!(Breton et al., 2015).  Developmental relationships between 
cells are still being dissected, particularly in inflammation.  The “MPS” has been used 
in this thesis as a synonym for monocytes, macrophages and DCs.  Applying false 
identifiers to cell populations can be highly misleading, and MP is a useful moniker in 
the absence of a definite identity.  
 
1.2.2 Dendritic cell subsets and functions 
 
DCs are rare leukocytes with innate immune functions.  They are distinct from 
monocytes and macrophages in their ability to bridge innate and adaptive immunity 
by migrating from tissue to draining lymph node and priming naïve antigen-specific T 
cells (Steinman and Witmer, 1978).  Numerous subsets of DCs exist, which are 
stable over time and conserved across species (Robbins et al., 2008),!(Haniffa et al., 
2012),!(Satpathy et al., 2013),!(McGovern et al., 2014).  Subsets can perform specific 
functions in the immune response and, while there is some overlap and plasticity, it is 
likely that a full complement of subsets is required for normal immune function 
(Merad et al., 2013). 
 
DC subsets were originally defined by expression patterns of surface antigens.  
However, antigen expression patterns vary between tissues and species making it 
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difficult to identify lineage similarity (Vu Manh et al., 2015).  A recent system of 
nomenclature categorizes DCs into three subsets based on evidence for distinct 
developmental pathways in the mouse.  The nomenclature has been extended to 
human subsets through cross-species gene expression profiling!(Guilliams et al., 
2014).  Phenotype and reported functions of the three subsets- plasmacytoid DC 
(pDC), classical DC 1 (cDC1) and classical DC 2 (cDC2)- are summarized in Table 
1.1.  Langerhans cells (LCs) are APCs found in epithelia, particularly the epidermis of 
the skin.  While they exhibit DC functions, LCs have developmental similarities with 
macrophages: they are seeded during embryonic development and are maintained 
independently of adult haematopoiesis during steady state (Hoeffel et al., 2012),!
(Bigley et al., 2011).  For this reason, current nomenclature does not include them as 
a DC subset. 
 
While this system of nomenclature has brought clarity, it conceals certain points of 
complexity.   Subsets were defined by transcription factor dependence, based on 
studies in gene-targeted mice but this dependence is neither as exclusive nor 
absolute as the nomenclature implies.  For example, the transcription factor Batf3 is 
required for cDC1 development in steady state.  During inflammation, cDC1 develop 
in Batf3-/- mice due to compensation by related transcription factors (Tussiwand et 
al., 2012).  Subsets defined by the nomenclature are not entirely homogeneous.  For 
example, a proportion of cDC2 in mouse is dependent on the transcription factor Klf4 
(Tussiwand et al., 2015).   When deleted, Th2 responses are diminished but Th1 and 
Th17 responses are maintained.  In humans, cDC2 can be split into two subsets 
based on expression of surface antigen B and T lymphocyte attenuator (BTLA) 
(Reynolds G, personal communication).  BTLA+ cDC2 support regulatory T cell 
(Treg) induction whereas BTLA- cDC2 support types 1 and 17 T helper cell (Th1/ 
Th17) induction.  Finally, the nomenclature implies cross-species homology.  The 
functional specialization of subsets may be subtly different between mice and 
humans.  Teasing apart genuine differences from those introduced by experimental 
approaches (in vivo in mice versus in vitro in humans) is challenging.  Antigen cross-
presentation capacity, for example, is focused in cDC1 in mouse but may be seen in 
LCs and cDC2 in humans (Haniffa et al., 2015a),!(Malissen et al., 2014). 
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Table 1.1 Dendritic cell subsets and functions 
References: cDC1 (Bachem et al., 2010),!(Crozat et al., 2010),!(Poulin et 
al., 2010),!(Jongbloed et al., 2010); cDCs (Merad et al., 2013),!(Reynolds 
and Haniffa, 2015); pDCs (Reizis et al., 2011); gut DCs (Watchmaker et 
al., 2014) 
 
 
1.2.3 Dendritic cell origins and mobilization 
 
DC populations are bone marrow-dependent in that they require ongoing 
haematopoiesis to survive (Steinman et al., 1974).  In mice, DCs share a common 
precursor with monocytes: the macrophage and DC progenitor (MDP) (Fogg et al., 
2006).  The more proximal precursors- common dendritic cell precursor (CDP) and 
precursor dendritic cell (pre-DC) are DC-restricted (Naik et al., 2007),!(Onai et al., 
2007).  Recent evidence from single cell precursor analysis suggests that 
commitment to cDC1 or cDC2 lineage occurs in the bone marrow at the CDP stage 
(Schlitzer et al., 2013).  In humans, a bone marrow precursor common to both 
monocytes and DCs can also be identified (Doulatov et al., 2010),!(Lee et al., 2015).  
A precursor with DC commitment, (the hCDP) has been proposed to remain the in 
the bone marrow and a precursor with cDC1 and cDC2 potential (hpre-CDC) has 
been identified in the periphery (Breton et al., 2015). 
 
Table 1.1 Dendritic cell subsets and functions !
Group Species Subset Surface antigens Pattern 
recognition 
receptors                          
Key functions 
cDC1 Mouse CD8+ (lymphoid 
tissue) 
 
CD103+ (non-
lymphoid tissue) 
MHC II+, CD11c+, 
Flt3+ 
XCR1+ 
CLEC9A+ 
CADM1+ 
TLR 3 
TLR 8 
Induction of CD8 T cell immunity 
Cross-presentation  
Th1 polarization (some studies)  
 
Human CD141++ 
 
 
MHC II+, CD11clo 
CD103+, SIRPa- (gut) 
XCR1+ 
CLEC9A+ 
CADM1+ 
cDC2 Mouse CD11b+  
 
 
 
MHC II+, CD11c+ 
CD103+ (in gut) 
SIRPa+ 
 
 
TLR 1-8 Activation of CD4 T cells 
Peripheral Treg induction 
Th2 and Th17 induction 
 
 
Human CD1c+ 
 
 
 
MHC II+, CD11c+ 
CD103+SIRPa+ (gut) 
SIRPa+ 
pDC Mouse pDC CD11clo 
MHC IIlo 
B220+ 
Siglec H+ 
TLR 7 
TLR 9 
 
Abundant IFN-α secretion  
Antigen presenting capacity (upon 
activation) 
 
Human pDC 
 
CD11clo 
MHC II+ 
CD123+  
BDCA-2+ 
BDCA-4+ 
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Extrapolation from mouse to human would suggest that human tissue DCs are 
maintained by circulating DC precursors (Bogunovic et al., 2009).  Humans have a 
larger blood DC complement than mice (Haniffa et al., 2015a).  Blood and tissue DCs 
share similarities in gene expression (Robbins et al., 2008).  Comparison of surface 
phenotype fits with a sequential acquisition of activation markers and lymph-node 
migratory function between blood and tissue (Haniffa et al., 2012).  However, the 
relative contribution of DC precursors and blood DCs to tissue in humans remains 
uncertain.     
  
In steady state, DCs are concentrated beneath host-environment interfaces and in 
lymphoid tissues (Merad et al., 2013).  This location permits immediate response to 
immunogenic stimuli without a mobilization phase.  DCs in non-lymphoid tissue 
respond to PRR ligation by migrating to draining lymph nodes through up-regulation 
of CC chemokine receptor 7 (CCR7) and response to a CC chemokine ligand 19/21 
(CCL19/21) gradient.  They prepare for T cell interactions by up-regulating co-
stimulatory ligands and MHC class II (Inaba et al., 1990).  However, tissue DC 
populations may appear unchanged or expanded during inflammation (Lowes et al., 
2005),!(Tamoutounour et al., 2013).  Monocyte-derived DCs can be identified in 
inflamed tissue but the precise contributions of resident and recruited, classical and 
monocyte-derived DCs to the inflamed tissue pool and the immune response have 
been poorly characterized. 
 
1.2.4 Macrophage diversity and functions  
 
Macrophages are tissue-resident MPs with important functions in tissue homeostasis 
and the innate immune response.  Specific immune functions include phagocytosis, 
microbial killing, cytokine production, effector T cell re-stimulation and organization of 
DC-T cell interactions (Takemura and Werb, 1984),!(Natsuaki et al., 2014).  The 
diversity of macrophages is underpinned by niche requirements of specific tissues.  
Therefore, nomenclature follows site of residency rather than developmental origin, 
phenotype or function (Guilliams et al., 2014).   
 
To provide an example of niche specialization, alveolar macrophages (AM) are the 
resident macrophage of the lung alveolar space.  They are required to protect the 
respiratory epithelium from inhaled insults, such as particulates and pathogens, 
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without triggering inflammation that may impair gas exchange or damage the 
epithelium (Lambrecht, 2006).  To fit this niche, AM phagocytose material without 
producing pro-inflammatory cytokines and may directly suppress DC activation of T 
cells (Lambrecht, 2006).  AM also clear and catabolize pulmonary surfactant 
(Trapnell and Whitsett, 2002), required for maintaining physiological surface tension 
and lung compliance.  The specialization of AM is detectable at the transcriptional 
and epigenetic level.  Only monocytes or yolk sac macrophages can fully colonize an 
empty AM niche, faithfully reproduce AM gene expression and protect from alveolar 
proteinosis (van de Laar et al., 2016).  However, mature peritoneal macrophages 
transferred into the airway adopt many features of an AM-specific signature, 
emphasizing the importance of tissue education in defining macrophage identity 
(Lavin et al., 2014),!(Lavin et al., 2015). 
 
1.2.4 Macrophage origins and activation 
 
Macrophage populations in many murine tissues are bone marrow-independent, in 
that they persist and self-renew without input from circulating monocytes or from any 
adult haematopoiesis (Yona et al., 2013), (Ginhoux et al., 2010),!(Hashimoto et al., 
2013).  These macrophage populations, for example microglia of the brain and AM of 
the lung, are embryonically derived, either from primitive haematopoiesis (yolk sac 
macrophages) or from transient definitive haematopoiesis (fetal liver monocytes) 
depending on the tissue (Ginhoux and Guilliams, 2016).  Macrophages in the gut and 
heart have ongoing input from circulating monocytes (Epelman et al., 2014a),!(Bain 
et al., 2014).   
 
The differences in macrophage origin between tissues have been proposed to result 
from whether a tissue niche remains open or closed to competition from circulating 
monocytes (Scott et al., 2014),!(Ginhoux and Guilliams, 2016).  Brain microglia, for 
example, are isolated behind the blood brain barrier and are the archetypal 
embryonically derived, self-renewing macrophage (Ginhoux et al., 2010).  Gut and 
lung however are equally exposed to circulating monocytes, but retain different levels 
of embryonic macrophages.  Additional factors that determine macrophage 
composition are unknown at present. 
 
Macrophages with distinct kinetics have also been demonstrated in humans.  In the 
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dermis, CD14+ monocyte-derived macrophages (CD14 MDM) exist along side factor 
thirteen A-positive (FXIIIa+) dermal macrophages (McGovern et al., 2014).  Bone 
marrow transplantation restores CD14 MDM from donor haematopoiesis, but 
recipient FXIIIa+ dermal macrophages can persist for months to years (Haniffa et al., 
2009).  Patients with prolonged monocytopaenia (up to 10 years in one case) have 
been reported who lack CD14 MDM but retain dermal macrophages in their skin 
(Bigley et al., 2011). 
  
The importance of ontogeny in ultimate macrophage function is unclear.  While AM 
derive from fetal liver monocytes (Guilliams et al., 2013), yolk sac macrophages and 
adult monocytes are equally capable of colonizing an empty AM niche with no 
discernible differences in gene expression or function (van de Laar et al., 2016).  
Further, the ability of mature macrophages to adopt new tissue identities suggests 
nurture may be a stronger factor than nature (Lavin et al., 2014).  
 
Unlike DCs and monocytes, macrophages do not mobilize in response to 
inflammatory stimuli.  They remain within their tissue, but undergo a change in 
activation state, depending on the combinations of stimuli they receive from 
pathogens, host and other leukocytes.  The concept of macrophage activation arose 
from observations that pathogen-exposed macrophages adopted more potent (but 
not antigen-specific) effector functions (Mackaness, 1962),!(Martinez and Gordon, 
2014).  Different immune stimuli were noted to produce contrasting activation states 
in vitro, and the M1/ M2 paradigm was proposed to explain these contrasts, mirroring 
the Th1/ Th2 nomenclature for T helper cells (Figure 1.2) (Mantovani et al., 2004).  It 
is increasingly recognized that M1 and M2 represent two poles, between which 
stimuli and combinations of stimuli can produced a spectrum of activation states (Xue 
et al., 2014).  M1/ M2 macrophage activation states have been observed in vivo, but 
the majority of disease states exhibit mixed profiles (Sica and Mantovani, 2012).  As 
highlighted by Martinez and Gordon, M1/ M2 was based upon macrophage response 
to individual immune signals (e.g. IL-4), removed from the context of a physiological 
immune response (Martinez and Gordon, 2014).  In reality, macrophages are 
exposed to a wide range of stimuli including combinations of M1 and M2 stimuli 
simultaneously.  Micro-geographical variations in these stimuli and cryptogenic 
heterogeneity amongst macrophages result in gradations of activation in a given 
tissue (Pettersen et al., 2011). 
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Figure 1.2 Models of macrophage activation 
Left panel simplifies the M1/ M2 model of macrophage activation.  M1= 
classically activated macrophage, M2= alternatively activated macrophage 
(Mantovani et al., 2004).  Right panel simplifies the spectrum model of 
macrophage activation, based on transcriptome profiling of in vitro 
monocyte-derived macrophages (Xue et al., 2014).  PGE2 = prostaglandin 
E2; LPS=lipopolysaccharide; TNF= tumour necrosis factor; IFN=interferon. 
 
 
1.2.6 Monocytes subsets and functions 
 
Monocytes are a circulating population of MPs that can be rapidly recruited to tissues 
in inflammation.  Monocyte contribution to the immune response is tissue and 
context-specific.  This is largely attributable to the plasticity of monocytes in response 
to environmental cues. 
 
There are at least two functionally distinct subsets of monocytes in mice and 
humans.  In mice, monocyte subsets are separated by expression of a glycoprotein 
named lymphocyte antigen 6 complex, locus C1 (Ly6C).  A major Ly6Chi population 
and a minor Ly6Clo population exist (Geissmann et al., 2003),!(Shi and Pamer, 2011).  
In humans, monocytes subsets are identified by expression of CD14 and the low 
affinity Fcγ receptor CD16 (Ziegler-Heitbrock et al., 2010).  CD14++CD16- cells, 
termed classical monocytes are transcriptionally similar to mouse Ly6Chi monocytes 
(Geissmann et al., 2003),!(Ingersoll et al., 2010).  CD14+CD16++ cells, termed non-
monocyte(
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classical monocytes, overlap transcriptionally with mouse Ly6Clo monocytes.  An 
intermediate population of CD14++CD16+ monocytes can also be identified. 
 
Ly6Chi monocytes extravasate into tissue in steady state, with different fates 
depending on the tissue.  In gut, Ly6Chi cells differentiate into macrophages that 
maintain epithelial integrity, ingest free bacteria and sustain immune quiescence 
(Bain and Mowat, 2014).  In skin, Ly6Chi monocytes adopt DC or macrophage- 
specific transcriptional programmes and functions (Tamoutounour et al., 2013).  In 
lung, monocytes with minimal differentiation can be identified (Jakubzick et al., 2013).  
 
Ly6Chi monocytes are rapidly recruited to tissue in acute inflammation.  They are 
phagocytic, produce pro-inflammatory cytokines (TNFα, IL-1α/β, IL-6), nitric oxide 
and reactive oxygen species that may damage tissues, for example in inflammatory 
bowel disease, or aid resolution of infection (Bain and Mowat, 2014).  Activated cells 
resembling Ly6Chi monocytes are found in chronic inflammation, autoimmune 
disorders and cancer (Condamine et al., 2015).  Termed mononuclear myeloid 
derived suppressor cells (M-MDSC), they inhibit T cell function via soluble factors 
such as nitric oxide and arginase-1 (Condamine et al., 2015).   
 
Ly6Clo and non-classical monocytes patrol the vascular endothelium (Auffray et al., 
2007) and phagocytose damaged endothelial cells (Carlin et al., 2013).  In steady 
state, they do not readily cross endothelium (Collison et al., 2015).  Whether they 
enter tissues after adoptive transfer is disputed!(Geissmann et al., 2003),!(Bain and 
Mowat, 2014).  In inflammation they may be recruited into tissues and produce TNFα 
(Auffray et al., 2007),!(Cros et al., 2010).  There is heterogeneity within the non-
classical monocyte population:  a proportion of cells have a carbohydrate-
modification of P-selectin, termed 6-Sulfo LacNac  (SLAN) (Schakel et al., 2002).  
The term ‘SLAN-DC’ arises in the literature as these cells exhibit some DC features, 
such as high levels of MHC class II, co-stimulatory ligand expression and the ability 
to drive Th1 responses (Hansel et al., 2011).  By gene expression analysis, all 
monocyte subsets are distinct from DCs so the term does not have solid foundation 
(Robbins et al., 2008),!(Haniffa et al., 2012). 
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1.2.7 Monocyte origins and mobilization 
 
Ly6Clo populations have been shown to depend on Ly6Chi monocyte populations 
through fate mapping studies (Yona et al., 2013).  Restoration of non-classical 
monocyte populations lags behind appearance of classical monocytes following bone 
marrow transplantation (McGovern et al., 2014).  A similar trend is seen with uptake 
of deuterium-labelled glucose (Yona S, unpublished communication), supporting a 
parallel dependence of monocyte subsets in humans.   
 
Proximal to Ly6Chi monocytes is a common monocyte precursor (cMOP) arising from 
an oligopotent DC/ monocyte/ macrophage precursor (MDP) (Hettinger et al., 2013),!
(Fogg et al., 2006).  In humans, monocyte potential has been identified in the 
granulocyte monocyte precursor (GMP) (Doulatov et al., 2010), but the more 
proximal precursors of monocytes remain undefined.  
 
Monocytes are capable of rapid mobilization in response to stress.  There is evidence 
from murine studies that marginal pools of monocytes exist in low velocity vascular 
beds such as those found in spleen and lung (Swirski et al., 2009).  These pools may 
be rapidly released by neural stimulation (Steppich et al., 2000).  Release of 
monocytes from the bone marrow can be triggered by low levels of circulating toll-like 
receptor (TLR) ligands.  These levels are sufficient to promote monocyte 
chemoattractant protein-1 (MCP-1/ CCL2) secretion by marrow stromal cells and 
cause adjacent monocytes to up-regulate CCR2 and exit!(Shi and Pamer, 2011).  
Myelopoiesis may also be altered during conditions of stress, skewing GMP outputs 
in favour of monocytes (Courties et al., 2015). 
 
1.2.8 Monocyte-derived cells in vitro 
 
Monocytes, though divergent from DCs during haematopoiesis, may adopt DC 
characteristics in vitro.  In the Journal of Experimental Medicine’s most cited article, 
Sallusto and Lanzavecchia described monocyte-derived DC (moDC) generation from 
blood monocytes using granulocyte macrophage colony stimulating factor (GM-CSF/ 
CSF2) and IL-4 (Sallusto and Lanzavecchia, 1994).  These cells had dendritic 
morphology, the ability to stimulate naïve T cells, high expression of MHC class II, 
co-stimulatory molecules CD40 and CD80/86, cDC2 antigen CD1 and absence of 
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monocyte antigen CD14.  Similar culture systems were used to generate DCs from 
mouse bone marrow (Inaba et al., 1992).  More recent gene expression studies have 
shown that moDCs are distinct from primary lymphoid tissue DC, but do share 
expression of DC-specific genes (Robbins et al., 2008).  It is recognized that 
monocytes may contribute to steady-state DC populations in mucosal tissues but not 
lymphoid tissue (Varol et al., 2007).    
 
Monocytes cultured with GM-CSF or macrophage colony stimulating factor (M-CSF/ 
CSF1) adopt the morphology and functional characteristics of macrophages.  GM-
CSF, lipopolysaccharide (LPS), interferon-gamma (IFNγ) and TNFα skew 
macrophages towards a classically-activated (M1) state and M-CSF, IL-4, IL-10, IL-
13, glucocorticoids and vitamin D towards an alternatively-activated state (Martinez 
and Gordon, 2014).  In vitro M1 polarization of human monocytes incurs profound 
changes gene expression (5.2% of transcripts) while the effect of M2 polarization is 
less marked (0.3% of transcripts)!(Martinez et al., 2006).  Hallmark M1 and M2 genes 
in this setting are CXCL11, CCL19, IDO and CCR7 (M1) and MRC1, CCL13, CD36 
and CD209 (M2). In the murine setting only, Ym1 and Arg are key discriminators of 
an M2 state (Raes et al., 2005). 
 
While the plasticity of the monocyte allows differentiation and polarization into these 
distinct states, using them to understand inflammatory processes in vivo is 
challenging.  In certain contexts, comparison to in vitro-derived monocytes or 
macrophages has clarified our understanding of inflammatory myeloid cells (Segura 
et al., 2013),!(Sica and Mantovani, 2012).  Yet, many oppose such comparisons as 
an oversimplification of the biology of inflammation and heterogeneity of myeloid 
populations (Hume, 2015), (Martinez and Gordon, 2014).    
 
1.2.9 Inflammatory mononuclear phagocytes in vivo 
 
Murine inflammatory MPs have been described in numerous infection and sterile 
inflammation models, for example Leishmania major infection (Leon et al., 2007), 
allergic airway inflammation mediated by house dust mites (Plantinga et al., 2013) 
and contact hypersensitivity mediated by topical haptens (Tamoutounour et al., 
2013).  Reliable discrimination of inflammatory macrophages from inflammatory DCs 
has been challenging as both share high expression of MHC class II, and both may 
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express CD11c, CD11b, Ly6C and F4/80 (Merad et al., 2013), (Segura and 
Amigorena, 2013).  The combined expression of FcER1 and CD64 expression has 
been proposed the most reliable means of phenotypying inflammatory DCs 
(Plantinga et al., 2013).  Expression of DC-specific transcription factor ZBTB46 has 
clarified identity in some cases.  For example, the TNFα and inducible nitric oxide 
synthase (iNOS)- expressing DC (Tip-DC) does not express ZBTB46 and is most 
likely a macrophage (Satpathy et al., 2012a).  Supplementing phenotype and gene 
expression with confirmation of lymph node migratory potential (e.g. using CCR7-
deficient mice) and the ability to stimulate naïve T cells provides the most robust 
definition of a DC (Segura and Amigorena, 2013). 
 
In general, inflammatory macrophages do not migrate to lymphoid tissue (Segura 
and Amigorena, 2013).  Inflammatory macrophages can efficiently capture antigen 
and re-stimulate T cells but appear to be dispensable for T cell priming (Iijima et al., 
2011).  Inflammatory macrophages are efficient at phagocytosis but may also release 
lytic factors, reactive oxygen species and proteinases into the extracellular space 
(Narni-Mancinelli et al., 2011).  The precise activities of inflammatory macrophages 
are tissue and context-specific (Jung and Schwartz, 2012).  For example, monocyte-
derived macrophages generated in the central nervous system during experimentally 
induced autoimmune encephalomyelitis are pro-inflammatory (Mildner et al., 2009), 
but those generated in injured spinal cord promote tissue repair!(Shechter et al., 
2009).  Macrophages adopt various phenotypes during the resolution phase of 
inflammation, in part, instructed by the immune stimuli they have encountered!(Ariel 
and Serhan, 2012).  TGFβ production by persistent inflammatory macrophages has 
been implicated in tissue fibrosis, for example sclerodermatous chronic GvHD 
(Alexander et al., 2014).  
 
Inflammatory DCs can stimulate both CD4 T cells by indirect antigen presentation 
(Leon et al., 2007) and CD8 T cells by cross-presentation (Segura et al., 2009).  The 
polarization of CD4 T cells is context-dependent:  both Th1 (Leon et al., 2007) and 
Th2 responses (Plantinga et al., 2013) have been reported.  Inflammatory DCs can 
produce a range of inflammatory and T cell modulatory cytokines (type I interferon, 
IL-1, IL-12 and IL-23) (Plantinga et al., 2013).  The interaction between inflammatory 
DCs and T cells can occur in both lymphoid and non-lymphoid tissue (Wakim et al., 
2008).  In an experimental model of asthma, the site of interaction depended on 
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antigen load, with low-dose exposure leading to tissue interactions and high-dose to 
lymph node interactions (Plantinga et al., 2013).  Inflammatory DCs may also assist 
in the transport of antigen to lymphoid tissue!(Hohl et al., 2009).  !
 
Both inflammatory macrophages and inflammatory DCs are depleted in CCR2-
deficient animals (Iijima et al., 2011),!(Nakano et al., 2009),!(Bain et al., 2013) but 
they are unaffected in Flt3-deficient animals (Plantinga et al., 2013).  This sets them 
apart from classical DCs and supports their development from CCR2-dependent 
monocytes, but does not strictly exclude origin from non-monocytic CCR2-dependent 
precursors.  Ly6Chi monocytes adoptively transferred into inflammatory models can 
be seen differentiating into DCs and macrophages (Leon et al., 2007),!(Bain et al., 
2013).  This is highly suggestive that Ly6Chi monocytes are the precursor of both 
inflammatory MPs. 
 
Human inflammatory MPs found in skin and lung will be discussed in sections 1.4 
and 1.5, but the work of Segura et al. on chronic inflammatory effusions also requires 
consideration (Segura et al., 2013).  This study juxtaposed CD16+CD1c- 
inflammatory macrophages with CD16-CD1c+ inflammatory DCs detected in chronic 
rheumatoid joint effusions and malignant ascites.  Definitions of their MPs were 
supported by gene expression and in vitro functional assays.  Inflammatory DCs 
induced T cell proliferation, IFNγ and IL-17 production, while inflammatory 
macrophages only induced IFNγ production.  Comparison of the inflammatory DC 
gene expression signature to a moDC signature through gene-set enrichment 
analysis demonstrated similarity.  Inflammatory macrophages were enriched with a 
broadly-defined macrophage signature but had greater similarity to the moDC 
signature than to steady-state monocytes.  This study provides an important 
reference for inflammatory MP identification in humans.  However, their phenotypic 
definitions cannot be directly applied to tissues with resident macrophage and DC 
populations.  For example, a CD11c+HLA-DR+CD1c+CD16- gate in human skin 
would capture the steady state cDC2.  Furthermore, it may not reliably exclude the 
dermal macrophage, which is CD16- and can encroach upon a CD1c+ gate due to 
autofluorescence (personal observation). 
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1.3 Skin mononuclear phagocytes 
 
1.3.1 Resident cell architecture 
 
The skin is the largest barrier organ in the body and has unique physical and 
immunological adaptations to resisting infection.  Resident cells of the innate and 
adaptive immune system are an important part of this adaptation. 
 
The outer epidermis of the skin contains a network of interconnected LCs.  There are 
few other resident leukocytes in human epidermis, besides a modest number of 
effector memory T cells which are principally CD8+ (Spetz et al., 1996),!(Nomura et 
al., 2014).  In contrast, the murine epidermis has an abundant network of γδ cells or 
dendritic epidermal T cells (DETCs), which sense barrier breach and orchestrate 
early immune responses (Sharp et al., 2005). 
 
Beneath the epidermis, the dermis has an organized network of resident leukocytes 
that varies with depth (Wang et al., 2014).  DCs are distributed uniformly beneath the 
dermo-epidermal junction but form perivascular sheaths in the deeper reticular 
dermis.  FXIIIa+ macrophages and CD3+ T cells are found throughout the dermis, 
contributing to perivascular leukocyte architecture in the deeper layers.  Both DCs 
and T cells are enriched in the skin relative to the blood (Clark, 2010),!(Haniffa et al., 
2012).  Skin resident T cells comprise both CD4+ and CD8+ effector memory cells 
(Clark, 2010). 
 
1.3.2 Skin mononuclear phagocytes in steady state 
 
LCs are characterized by expression of non-polymorphic HLA CD1a and the C-type 
lectin receptor CD207 (Langerin).  By electron microscopy they contain characteristic 
organelles named Birbeck granules (Romani et al., 1989).  LCs are thought to 
maintain peripheral tolerance by transporting self peptides to the paracortex of skin-
draining lymph nodes in the absence of a co-stimulatory signal (Steinman and 
Nussenzweig, 2002).  Their necessity for induction of an adaptive immune response 
has been questioned as LC-depleted mice can generate effective antigen-specific 
responses (Bennett et al., 2005).    
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Steady state dermal DCs comprise at least two myeloid subsets (cDC1 and cDC2) 
but pDCs are not seen (Haniffa et al., 2012).  The cDC1 subset is characterized by 
high expression of CD141 in humans and expression of CD103 in mice (Haniffa et 
al., 2012),!(Merad et al., 2013).  In both species, this subset expresses TLR3 for 
sensing viral antigen, and Clec9A for apoptotic cell uptake as well as Necl2 and 
XCR1 (Bachem et al., 2010),!(Crozat et al., 2010),!(Jongbloed et al., 2010),!(Poulin et 
al., 2010),!(Haniffa et al., 2012).   Functionally, it can migrate to lymph nodes via 
CCR7, induce naïve T cell stimulation and cross-present exogenous antigen to CD8 
T cells (Haniffa et al., 2012).  The cDC2 subset is characteristically CD1c/ CD1a+ in 
humans and CD11b+ in mice (Merad et al., 2013).  It is the major DC population in 
skin, present in approximately similar numbers to dermal macrophages (Zaba et al., 
2007),!(Haniffa et al., 2009),!(Wang et al., 2014).  The cDC2 subset expresses 
pattern recognition receptors TLR1-8 in addition to Dectins (CLEC6A/ 7A), the 
endocytic receptor CD205 and the macrophage mannose receptor CD206 (Collin et 
al., 2013).  Like cDC1, it expresses CCR7 and can stimulate naïve T cell proliferation 
(Haniffa et al., 2009).  It is less effective at cross-presenting antigen and produces a 
different profile of cytokines on stimulation:  cDC1 produce TNFα and CXCL10 while 
cDC2 produce IL-10 and IL-12p70 (Haniffa et al., 2012),!(Collin et al., 2013). 
 
CD14 MDMs in humans skin were categorized as DCs for many years as they are 
morphologically distinct from FXIIIa+ macrophages and able to migrate out of skin 
explants (Nestle et al., 1993),!(Klechevsky et al., 2008),!(Haniffa et al., 2009).  Recent 
reanalysis has shown transcriptional similarity with the monocyte/ macrophage 
lineage, dependence on circulating monocytes and the absence of spontaneous 
migration to lymphoid tissue (McGovern et al., 2014).  This subset is analogous to 
the CD11b+CD64+/loLy6CloCCR2- (P4, P5) populations in mouse dermis (McGovern 
et al., 2014),!(Tamoutounour et al., 2013).  Monocytes and monocyte-derived DCs in 
mouse dermis (P1-3) do not yet have a recognized counterpart in human dermis 
(Tamoutounour et al., 2013).  CD14 MDMs are poor stimulators of naïve T cells 
(Haniffa et al., 2009),!(Klechevsky et al., 2008) but can induce differentiation into T 
follicular helper cells (Klechevsky et al., 2008).  The physiological relevance of this 
finding is unclear as CD14 MDMs do not migrate to lymph nodes (McGovern et al., 
2014).  CD14 MDMs produce TNFα, IL-1B, IL-6, IL-8, and IL-10 on stimulation 
(Haniffa et al., 2012). 
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Dermal macrophages can be distinguished from DCs and CD14 MDMs 
morphologically by their larger size and pigmented cytoplasmic granules (Haniffa et 
al., 2009).  By immunostaining they are clearly identifiable as FXIIIa+CD11c- spindle-
shaped cells, while the other resident myeloid populations are FXIIIa-CD11c+ (Zaba 
et al., 2007).  As FXIIIa is predominantly cytoplasmic, it is not a useful antigen for 
discriminating macrophages by flow cytometry (Zaba et al., 2007),!(Haniffa et al., 
2009).  Dermal macrophages can be distinguished by their autofluorescence (Haniffa 
et al., 2009).   Autofluoresence occurs when cytoplasmic components, including 
melanin granules in dermal macrophages, are excited by low wavelength light and 
emit a fluorescence signal, primarily detectable in the fluorescein isothiocyanate 
(FITC) channel (Baumgarth and Roederer, 2000).  There are few surface antigens 
differentially expressed by CD14 MDMs and macrophages (McGovern et al., 2014).  
Dermal macrophages are poor stimulators of naïve T cell proliferation but induce 
memory T cells to secrete IL-17 and interferon gamma (IFNγ) (Haniffa et al., 2009).  
Dermal macrophages produce IL-1 and IL-6 when stimulated (Haniffa et al., 2009). 
 
1.3.3 Skin mononuclear phagocytes in inflammation 
 
Superimposed on steady state MP subsets, monocytes enter inflamed skin and 
adopt macrophage or DC characteristics depending on the context.   In murine 
cutaneous Leishmania infection, monocytes primarily adopt a DC phenotype, migrate 
to lymph node and promote Th1-mediated parasite clearance (Leon et al., 2007).  In 
human cutaneous leprosy infection, monocytes may adopt either DC-SIGN+CD1b- 
macrophage or DC-SIGN-CD1b+ DC phenotypes in the localized tuberculoid form of 
the disease where effective Th1-mediated bacillus clearance occurs (Krutzik et al., 
2005).  In the lepromatous form, where bacillus is disseminated and an effective T 
helper response is lacking, monocyte-derived DCs do not occur.  This suggests that 
the fate of recruited monocytes impacts upon the tenor of the adaptive immune 
response. 
   
Considering non-infective inflammation, most studies of skin MP content have 
focused on psoriasis or atopic dermatitis (eczema).  DCs are abundant in psoriatic 
lesions, outnumbering lymphocytes (Lowes et al., 2005).  pDCs are recruited to early 
lesions (Albanesi et al., 2009).  The CD11c+ “DCs” lack CD14, CD1c/ CD1a and 
Langerin, setting them apart from resident DCs (Lowes et al., 2005).  They express 
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co-stimulatory ligands CD40 and CD86, SLAN, TNF and iNOS (Lowes et al., 2005),!
(Hansel et al., 2011).  The terms SLAN-DC and Tip-DC have been applied to these 
cells (Lowes et al., 2005), (Hansel et al., 2011).  Notably, the TipDCs originally 
described in murine Listeria monocytogenes infection!(Serbina et al., 2003) were 
subsequently found to lack ZBTB46 expression (Satpathy et al., 2012a).  On 
balance, they are likely to be monocyte-derived macrophages.  The transcriptional 
profile of the psoriatic inflammatory “DC” is most similar to that of a moDC, but some 
macrophage-related transcripts are present e.g. CD163 (Zaba et al., 2010).   In 
eczema lesions, both pDCs and myeloid DCs are found (Wollenberg et al., 1996),!
(Wollenberg et al., 2002a),!(Wollenberg et al., 2002b),!(Stary et al., 2005).  The 
myeloid DCs isolated from epidermal suspensions have been termed inflammatory 
dendritic epidermal cells (IDECs), but phenotypically, they resemble resident dermal 
cDC2 (CD11c+, CD1a/c+).  Studies that simultaneously identify steady state and 
inflammatory MPs, test expression of multiple surface antigens, assess function and 
use unbiased techniques to assess similarity to monocytes, DCs or macrophages are 
scarce. 
 
 
1.4 Lung mononuclear phagocytes 
 
1.4.1 Structure of the lung immune system 
 
The lung has more anatomical variation than the skin.  When considering the lung 
immune system, a distinction is made between the conducting airways and 
parenchymal lung (Holt et al., 2008). 
 
The conducting airways present a mucosal barrier to the environment.  The barrier 
has layers of defence against inhaled particulates and pathogens including surface 
mucus and IgA.  Within the epithelium, macrophages, memory T cells and layers of 
interdigitating DCs can be found that appear similar to the LC network in skin (Heier 
et al., 2011).  DCs extend projections through epithelial tight junctions into the airway 
lumen in order to constitutively sample antigen (Jahnsen et al., 2006).  Follicles of 
lymphoid cells are found within the mucosa in children, but decline with age (Heier et 
al., 2011).  The blood supply to the conducting airways is via the bronchial arteries 
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(systemic circulation) and the dogma of leukocyte migration through post-capillary 
venules applies (Holt et al., 2008).  
 
The parenchymal lung includes the airspaces distal to the respiratory bronchioles 
(alveoli) and the interstitial space.  The alveoli present a single layer of respiratory 
epithelium to the environment.  Adherent to this epithelium are AM.  DCs and T cells 
are also found within the alveoli (Holt et al., 2008).  Beneath the respiratory 
epithelium, the interstitium contains scattered macrophages, DCs and T cells.  
Immune cells sequestered within the low flow pulmonary capillary bed have been 
identified.  Marginated leukocytes represent 87% of total lung leukocytes (Barletta et 
al., 2012).  Partly due to biophysical properties, monocytes and DCs are 
preferentially sequestered, comprising 57% of the marginal pool (Doherty et al., 
1994),!(Barletta et al., 2012).  In contrast to the conducting airways, parenchymal 
lung receives blood supply from the low-pressure pulmonary arteries.  Leukocyte 
recruitment through pulmonary capillaries is thought to be less stringent and rely on 
different combinations of integrins than post-capillary venule migration (Holt et al., 
2008).       
 
1.4.2 Lung mononuclear phagocytes in steady state 
 
Insights into the MP content of human lung have come from studying digested lung 
tissue or bronchoalveolar lavage (BAL) fluid.  Lung tissue surplus to diagnostic 
requirements can be accessed from cancer lobectomy/ pneumonectomy surgery or 
from un-transplantable donor lungs.  Neither can be considered immunologically 
normal and both need enzymatic digestion to release leukocytes.  Without micro-
dissection, pulverizing parenchyma merges distinct anatomical compartments in the 
lung (alveoli, parenchyma, bronchioles).  The pulmonary vasculature can be flushed 
with intact lobes but not with lobectomy surplus.  This can minimize sampling of 
intravascular leukocytes, but if the sequestered leukocyte fraction is considered part 
of the lung immune system, this may not be desirable. 
 
Early studies on digested lung tissue identified two subsets of myeloid DCs and 
plasmacytoid DCs, equivalent to the DC subsets found in blood (Demedts et al., 
2005), (Masten et al., 2006).  Demedts et al. described BDCA1+ (CD1c+) and 
BDCA3+ (CD141+) myeloid DC, characterized their TLR expression and cytokine 
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response to TLR stimulation (Demedts et al., 2005),!(Demedts et al., 2006).  
Interpreting their results with a current understanding of DC subsets, they do not 
appear to have identified true cDC1 and cDC2 fractions.  Both fractions express 
CD14, suggesting monocyte-derived cells have not been excluded.  High production 
of TNFα, IL1B and IL-6 when stimulating cDC1 with LPS and limited TNFα when 
stimulating cDC1 with poly-IC does not occur in studies with stringent cDC1 isolation 
(Haniffa et al., 2012).  A contemporary study, which identified cDC2 more stringently 
as CD14-CD1c+ cells, found steady state expression of co-stimulatory ligand CD86 
and allostimulatory capacity, contrasting this with pDC which produced IFNα on TLR7 
ligation but did not stimulate T cells (Masten et al., 2006).  Both studies were limited 
by use of 4-parameter flow cytometry, which does not allow sufficient antigens to 
identify and discriminate DC subsets.   
 
More recent studies have leveraged multi-parameter flow cytometry to 
simultaneously identify lung MPs.  Desch et al. used intrabronchial versus 
intravascular antibody staining to demonstrate that CD1a and CD206 are expressed 
on airway but not blood MP (Desch et al., 2016).  Whole lobes were lavaged, 
principally yielding AM, then digested. Tissue monocytes (CD206+CD14+CD1c-
CD1a-), monocyte-derived cells (CD206+CD14+CD1c+CD1a+/-) and pulmonary DC 
(CD206-CD14loCD1c+CD1a+) were identified.  Cells expressing CD1c were most 
capable of stimulating allogeneic T cells, but the authors did not separate pulmonary 
DCs and monocyte-derived cells in these experiments.  The study addressed the 
confounding influence of blood DC subsets on our understanding of lung tissue DCs 
in an innovative way.  However, their approach left many questions about human 
lung DCs unanswered.  Their definition of blood versus lung DCs was too stringent.  
Applying topical antibody to an intact bronchial tree may label a proportion of 
bronchial leukocytes but will not reach the interstitium.  CD206-CD1a- DCs within the 
interstitium may therefore have been disregarded as blood DCs.  By defining their 
own DC subsets, without reference to literature on DCs in human blood and other 
tissues, we are left struggling to align subsets across compartments.  The absence of 
pDCs and cDC1 in lung tissue has not been explored.  The assumption that 
CD206+CD14+CD1c/a+ cells are monocyte-derived is unfounded as CD14 is a labile 
antigen and cannot be used to presume monocyte derivation.  Overall, it is not a solid 
foundation for discussing recruitment and fate of DCs in inflammation. 
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By defining lung DCs in line with blood DCs, Schlizter et al. and Yu et al. identified 
two subsets of myeloid DCs: CD141-expressing cDC1s and CD1c-expressing cDC2s 
in a 1:3 ratio (Schlitzer et al., 2013),!(Yu et al., 2013).  Their immune functions were 
explored by parallel studies in mice.  The cDC1 subset was primarily interstitial, 
perhaps explaining why they were not identified by the approach of Desch et al (Yu 
et al., 2013).  The cDC2s were closely associated with epithelial cells, and were 
instrumental in generating epithelial-adherent effector CD8 T cells (Yu et al., 2013).  
A role for cDC2s in producing a maximal Th17 response to Aspergillus fumigatus 
was identified (Schlitzer et al., 2013). 
 
BAL is a commonly used clinical procedure to sample the lumen of the lower airways, 
most commonly for the identification of pathogens.  BAL retrieves large numbers of 
AM and additional leukocytes in both steady state and inflammation.  It provides a 
more relevant and compartmentalized view of the airway immune system than 
digesting lung tissue as only the cells exposed to the lumen are sampled.  Early 
studies of DCs in human BAL have been constrained by the technical limitations of 
magnetic bead isolation or 4-parameter flow cytometry/ sorting, but have successfully 
identified allostimulatory cells (Havenith et al., 1994),!(van Haarst et al., 1994).  Both 
cDCs and pDCs have been noted, but further exploration has not been attempted 
(Bratke et al., 2007),!(Lommatzsch et al., 2007),!(Tsoumakidou et al., 2006),!(Ten 
Berge et al., 2009). 
 
In contrast to DC populations, AM are abundant in lung and readily distinguished.   
They express CD206 and CD169, whereas interstitial macrophages express CD206 
but not CD169 (Bharat et al., 2016),!(Yu et al., 2016).  AM adhere to alveolar 
epithelial cells and are maintained in a quiescent state through local TGFβ production 
(Munger et al., 1999).  They produce few inflammatory cytokines, suppress the 
activation of DCs and T cells (Thepen et al., 1989),!(Strickland et al., 1996), and do 
not migrate or participate in antigen presentation (Lambrecht, 2006). 
 
Monocytes have not been well characterized in human lung due to the confounding 
influence of large numbers of marginated blood monocytes in un-perfused tissue.  
When perfusion has been achieved, CD206+ monocytes expressing CD14 and 
variable CD16 have been identified (Desch et al., 2016).  In the absence of perfusion, 
reported CD206- monocytes are probably intravascular (Bharat et al., 2016).  In 
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steady state BAL, monocytes are predominantly CD14+CD16+, in contrast to blood, 
where classical monocytes dominate!(Brittan et al., 2012).  Classical monocytes most 
effectively migrate across non-pulmonary vascular endothelium (Collison et al., 
2015), and the equivalent Ly6Chi monocyte in mouse is the subset constitutively 
entering tissue (Jakubzick et al., 2013).  CD16 acquisition by classical monocytes 
entering lung is therefore more likely than preferential recruitment of intermediate 
monocytes.  CD16 is not readily up-regulated in co-culture of monocytes and human 
umbilical vein endothelial cells (HUVECs) (McGovern et al., 2014), but a specific 
effect of pulmonary vascular endothelium or lung tissue microenvironment may 
contribute.  In murine lung, Ly6Chi monocytes enter lung tissue during steady state 
without differentiating into macrophages or DCs (Jakubzick et al., 2013).  This 
appears to be a unique feature of the lung, as monocytes entering skin or gut 
differentiate rapidly into macrophages (Jakubzick et al., 2013).  
 
1.4.3 Lung mononuclear phagocytes in inflammation 
 
In a bacterial model of rat tracheitis, DCs are recruited to the mucosa very rapidly 
(between 4-8 hours) (McWilliam et al., 1994).  Bacteria applied to the skin or 
peritoneum do not induce rapid DC recruitment, suggesting this may be a unique 
feature of pulmonary mucosa.  In humans with allergic asthma, allergen challenge 
induces a similarly rapid accumulation of DCs in the bronchial mucosa.  These DCs 
have a cDC2 phenotype.  The time-course of accumulation is in keeping with direct 
recruitment from blood rather than differentiation from a precursor (Jahnsen et al., 
2001).  In mice challenged with intratracheal house dust mite (HDM), both CD11b+ 
DCs (cDC2) and moDCs accumulate within 16 hours (Plantinga et al., 2013).  While 
CD11b+ counts remain stable over the following days, moDC accumulation peaks at 
3 days.  CD11b+ DCs are capable of transporting antigen to draining lymph nodes at 
any antigen dose, but moDCs and CD103+ DCs (cDC1) transport antigen only at 
higher doses.  Both CD11b+ DCs and moDCs favour Th1 polarization in vitro, and 
are capable of HDM-sensitization in vitro.  MoDCs are more capable of monocyte 
and eosinophil recruitment to the airway!(Plantinga et al., 2013).  In the context of 
human allergic rhinitis, TLSP and Th2 cytokines inhibit CCR7 up-regulation and keep 
DCs in the tissue, where they interact with effector memory T cells (Melum et al., 
2014). 
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LPS inhalation in humans recruits monocytes to the airspace (Brittan et al., 2012).  In 
contrast to steady state monocyte-derived cells, inflammatory monocyte-derived cells 
are CD14+CD16-.  Recruited monocyte-derived cells produce pro-inflammatory 
cytokines IL-6, IL-8 and TNFα (Brittan et al., 2014).  They express lower levels 
macrophage markers than resident monocyte-derived cells (CD206, CD163), in 
keeping with more a recent derivation from monocytes. 
 
 
1.5 Bone marrow transplantation  
 
1.5.1  Autologous versus allogeneic transplant 
 
Bone marrow transplantation (BMT) is a curative treatment for haematological 
malignancies, congenital haematological disorders and immunodeficiency 
syndromes.  Two types of bone marrow transplant exist: autologous and allogeneic.  
In autologous BMT, stem cells are harvested prior to high dose chemotherapy and 
then reintroduced to salvage haematopoiesis.  In allogeneic BMT, stem cells are 
harvested from an HLA-matched related or unrelated donor and introduced to a 
conditioned recipient.  The indications for and complications of these two types of 
BMT differ substantially.  This work concerns allogeneic BMT only. 
 
1.5.2 Indications 
 
The commonest indication for an allogeneic BMT in adults is acute myeloid leukemia 
(AML), constituting approximately 40% of transplants (Pasquini and Zhu, 2014).  
Acute lymphoblastic leukaemia (ALL), myelodysplastic syndromes (MDS) and 
lymphomas each account for approximately 10% of transplants.  Less common 
indications include myeloma (MM), chronic myeloid or chronic lymphocytic 
leukaemias (CML/ CLL) and aplastic anaemia. The majority of patients approaching 
BMT will have been extensively pre-treated with variable combinations of 
chemotherapy, biological agents and radiotherapy- depending on disease type and 
risk stratification- in order to induce remission or reduce disease burden.  Patients 
with bone marrow failure syndromes e.g. aplastic anaemia or MDS, typically 
approach BMT without prior chemotherapy but may have a history of chronic or 
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recurrent infections.  The immunologic health of a patient prior to transplant reflects a 
combination of these factors: primary disease, pre-treatment and infection history.  
1.5.3 Donor selection 
 
HLA-compatible stem cells are sourced from a sibling or from an unrelated registry-
listed donor.  Use of unrelated donors now exceeds that of siblings (Pasquini and 
Zhu, 2014).  Donors are screened at 6 HLA loci:  HLA-A, B, C, DRB1, DQB1 and 
DPB1.  Matching all alleles is preferable, but DP mismatches can be tolerated 
(Petersdorf et al., 1993).  Choice of stem cell source (G-CSF mobilized peripheral 
blood stem cells or bone marrow harvest) currently rests with the donor, though the 
majority choose peripheral blood donation (Pasquini and Zhu, 2014).  Alternative 
sources include umbilical cord and haplo-identical donors. 
 
1.5.4 Conditioning 
 
Conditioning for BMT has a dual purpose: to deplete residual disease and to 
immunocompromise the host sufficiently for donor stem cells to engraft (Gratwohl 
and Carreras, 2008).  Historically, all BMT conditioning was myeloablative or ‘full-
intensity’, relying on intensive chemotherapy and radiotherapy to fully 
immunocompromise the host.  Approximately 6000 myeloblative transplants occur 
internationally each year and this figure has changed little in the past decade 
(Pasquini and Zhu, 2014).  The number of reduced intensity (RIC) transplants has 
almost doubled in the past decade, with the biggest expansion in patients over 50 
years old (Pasquini and Zhu, 2014).  RIC transplants typically prepare the host with 
myelosuppresive chemotherapy in combination with immunomodulatory drugs such 
as Alemtuzumab (Campath) or Methotrexate (Gratwohl and Carreras, 2008).  Early 
transplant-related toxicity is lower following RIC BMT (Deeg et al., 2006).  As a result, 
RIC BMT has become an option for an increasing number of patients with 
comorbidities, older age and intermediate risk conditions.   
 
1.5.5 Immune reconstitution 
 
After stem cell infusion, recipients remain pancytopenic for approximately 14 days 
(Mackall C, et al., 2009).  The first leukocytes detectable are monocytes.  Neutrophil 
recovery follows.  NK lymphocytes recover early but T and B lymphocytes remain 
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suppressed throughout the first year post-transplant (Mackall C, et al., 2009).  In the 
RIC setting, some recipient haematopoiesis initially recovers.  This results in mixed 
chimerism of bone marrow and peripheral blood leukocytes.  Mixed chimerism more 
commonly affects the lymphocyte compartment than the granulocyte compartment 
(Mackall C, et al., 2009). 
 
1.5.6 Graft-verus-leukaemia effect and Graft-versus-Host Disease  
 
The successful outcome of BMT involves a balance of competing risks.  Recurrence 
of primary disease is the greatest risk post-transplant:  37-48% of allogeneic BMT 
recipients die from relapsed disease!(Pasquini and Zhu, 2014).  Relapse is minimized 
when the donor immune system is competent to recognize disease-associated 
epitopes and generate graft-verus-leukaemia (GVL) immunosurveillance (Anasetti et 
al., 1990).  However, a GVL-competent immune system is generally capable of 
recognizing host tissue epitopes.  The resulting inflammation and tissue damage is 
known as graft-versus-host disease (GvHD) and is the major cause of non-relapse 
mortality (Pasquini and Zhu, 2014).  While 18-20% BMT recipients die from GvHD 
directly, deaths from infection (13-17% recipients) and organ failure (4-6% recipients) 
are intrinsically linked to GvHD and its treatments (Pasquini and Zhu, 2014). 
Manipulation of the graft and the immune system post-BMT can alter the balance 
between GvHD and GvL in clinical practice.  A key intervention that reduces GvHD is 
in vivo T cell depletion with Alemtuzumab or anti-thymocyte globulin (ATG) (Ho and 
Soiffer, 2001),!(Alousi et al., 2013).  Interventions that reduce relapse include 
immunosuppression withdrawal (Kekre et al., 2015), and donor lymphocyte infusion 
(DLI) (Roddie and Peggs, 2011).   
 
1.5.7 Donor lymphocyte infusion  
 
The strategy of T-cell depletion at the time of stem cell infusion combined with donor 
lymphocyte infusion six months later is common in UK transplant.  It provides 
effective GvHD prophylaxis with the option to manipulate chimerism and GvL at a 
later date!(Roddie and Peggs, 2011). 
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1.6 Graft-versus-Host Disease 
 
1.6.1 Historical descriptions 
 
In 1959, van Bekkum and colleagues noted that irradiated mice died if infused with 
bone marrow or splenocytes from another mouse (Van Bekkum et al., 1959).  Death 
was not a result of the primary intervention (irradiation or cell infusion), but occurred 
10-14 days later from a combination of weight loss, diarrhoea, skin changes and liver 
disturbance.  They named this syndrome secondary disease.  Parallels with GvHD 
following BMT in humans were noted.  Billingham condensed the required elements 
for secondary disease/ GvHD into three criteria (Billingham, 1966).  In the first, he 
stated that the infusion/ graft must contain immunologically active cells.   In the 
second, he noted that the host must express tissue antigens not present in the donor.  
In the third, he emphasized the importance of the host having a compromised 
immune system, or else the infusion/ graft would be rejected.  Half a century of 
immunology later, these criteria are still considered a true and comprehensive 
summary of GvHD requirements.  Adding to the detail, the immunologically active 
cells within the graft were identified as mature donor T cells (Korngold and Sprent, 
1978) and the tissue antigens were found to be MHC encoded in the most part 
(Krensky et al., 1990) with contributions from minor histocompatibility antigens 
(Korngold and Sprent, 1980),!(Middleton et al., 1998).  
 
1.6.2 Clinical descriptions 
 
GvHD has acute and chronic presentations.  Acute GvHD involves any combination 
of erythematous rash, watery diarrhoea and deranged liver function.  Chronic GvHD 
has a broader constellation of symptoms, which may involve dry or sclerotic skin, dry 
mucous membranes (eyes, mouth, genitals), diarrhoea and respiratory compromise 
(Ferrara et al., 2009).  Early descriptions stated that acute GvHD occurs within 100 
days of BMT and chronic GvHD occurs after 100 days.  A more recent description 
recognizes that the conditions may overlap and that acute GvHD can occur with later 
onset, for example following DLI (Filipovich et al., 2005) (Figure 1.3).   
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Figure 1.3 Overview of acute and chronic GvHD 
Key tissue targets of acute and chronic GvHD and systems for grading the 
severity of tissue involvement.  Schema of GvHD onset following BMT 
reproduced and modified from Pavletic and Fowler, 2012.  IPS= idiopathic 
pneumonia syndrome; BOS= bronchiolitis obliterans syndrome. 
 
 
The clinical severity of GvHD is graded according to modified Glucksberg criteria 
(Przepiorka et al., 1995), shown in Table 1.2.  Importantly, clinical severity correlates 
with mortality (MacMillan et al., 2002),!(Gratwohl et al., 1995)).  Transplant-related 
mortality (TRM) of 28%, 27%, 68 and 92% has been reported for GvHD grades I-IV 
respectively (Gratwohl et al., 1995). 
 
The incidence of acute GvHD in a 5000+ patient worldwide cohort is 39% in matched 
related donors and 59% in unrelated donors (severity grade I-IV) (Jagasia et al., 
2012).  In our centre, the incidence of acute GvHD ranges from 4% in matched 
related donors to 65% in unrelated donors (Jardine et al., 2015), (Green, K, personal 
communication).   The incidence of severe acute GVHD (grades III/IV) is around 2% 
(Green, K, personal communication).  
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Table 1.2 Modified Glucksberg criteria for staging acute GvHD 
According to Glucksberg criteria, an organ stage (1-4) is applied to each of 
the key target organs of GvHD.  An overall grade (I-IV) is then assigned 
according to the stage of involvement of each organ.  Reproduced from 
(Apperley and Masszi, 2012). 
 
The principal risk factor for developing acute GvHD is HLA disparity (Anasetti et al., 
1990).  HLA-being equal, unrelated donors typically incur a higher risk of GvHD than 
sibling donors!(Flowers et al., 2011).   Other risk factors less consistently reported 
include older recipient age, peripheral blood rather than bone marrow source of stem 
cells, female donors for male recipients, and prior alloimmunisation of donors 
(Anasetti et al., 1990), (Flowers et al., 2011).  Transplant protocol has been shown to 
influence GvHD risk: higher intensity conditioning regimen and the use of total body 
irradiation increase risk, whereas in vivo T cell depletion reduces risk (Anasetti et al., 
1990),!(Flowers et al., 2011),!(Remberger et al., 2008),!(Soiffer et al., 2011).  Post-
BMT management is also risk-modifying, with dual agent prophylaxis (Remberger et 
al., 2008), protective isolation and gut decontamination conferring protection against 
GvHD (Storb et al., 1983)!(Beelen et al., 1999). 
 
A reliable method of predicting GvHD in a given patient, particularly predicting 
treatment-resistant GvHD, is being actively sought.  Genetic polymorphisms in key 
components of the immune response, including IL-10 TNFα, IFNγ and IL-1, may 
Table 1.2 Modified Glucksberg criteria for staging acute GvHD!!
Organ Stage 
 Skin (extent of rash) Liver (serum bilirubin) Gut (diarrhoea volume) 
1 <25% body surface 34-50 µmol/L 500-100 mL 
2 25-50% body surface 51-102 µmol/L 1000-1500mL 
3 Generalized erythroderma 103-255 µmol/L >1500mL 
4 Erythroderma + blistering and 
desquamation 
>255 µmol/L Severe abdominal pain 
Overall grade 
I Skin stage 1-2 
II Skin stage 1-3 
Liver and or gut stage 1 
Mild reduction in performance status 
III Skin stage 2-3 
Liver and or gut stage 2-3 
Marked reduction in performance status 
IV Skin stage 3-4 
Liver and or gut stage 2-4 
Extreme reduction in performance status 
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influence GvHD risk, though correlations have been inconsistent (Middleton et al., 
1998),!(Harris et al., 2013).  Identifying incipient severe GvHD at an early stage 
through a combination of plasma biomarkers shows more promise and may allow 
clinicians to focus early interventions on high-risk patients (Levine et al., 2012). 
 
1.6.3 Histological descriptions 
 
Histologically, GvHD involves damage to the epithelia of target organs: the rete 
ridges of the epidermis, the crypts of intestinal mucosa and the ductal epithelium of 
the biliary tree (Sale et al., 1992),!(Heymer, 2013). 
 
Acute skin GvHD typically falls within a histopathological category termed acute 
lichenoid tissue reaction (LTR) or interface dermatitis (Sontheimer, 2009).   Diseases 
in this category have epidermal basal cell injury and variable inflammatory infiltrate in 
the papillary and upper dermis.  LTR infiltrates may include macrophages, DCs and T 
cells.  LTRs with florid dermal infiltrate include lichen planus, lichenoid drug reactions 
and discoid lupus.   Pauci-cellular LTRs include acute cutaneous lupus, erythema 
multiforme and acute GvHD (Sontheimer, 2009).  Less commonly, acute GvHD has 
an eczematoid pattern of injury.  In these cases, the mononuclear infiltrate is 
predominantly dermal and perivascular with less focus on the dermo-epidermal 
junction.  In contrast to LTRs, there is less basal cell damage and more marked 
upper dermal oedema (Sloane et al., 1984).  Sequential analysis suggests that 
eczematoid histology is a stable phenomenon within an individual rather than a 
transitional state towards an LTR (Thomas et al., 1984).  By Lerner’s criteria (see 
below), eczematoid changes can be difficult to diagnose as GvHD, but there is 
evidence of donor T cell dominance within lesions (Thomas et al., 1984) and 
fulminant progression (Creamer et al., 2007).   
 
The relevance of detecting an inflammatory infiltrate in acute skin GvHD has been 
debated (Heymer, 2013).  As donor T lymphocytes are considered the principal 
effector cell, some argue that a T cell infiltrate should be necessary for diagnosis.  
Other evidence suggests cytokines may be the principal effectors in some settings 
(Cohen, 1988), so detecting inflammatory cells may not be necessary.  The 
inflammatory infiltrate is often sparser when biopsied early after the onset of rash.  
Additional variability in the degree of cytopenia and the extent of immunosuppression 
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can alter the degree of inflammatory infiltrate between patients (Heymer, 2013).  The 
histological system for grading GvHD severity does not consider the inflammatory 
infiltrate.  Lerner’s classification, reproduced in Table 1.3 considers only the severity 
of damage to keratinocytes and the basal cell layer (Lerner et al., 1974),!(Heymer, 
2013).  The changes in grades I and II are subtle and not pathognomonic, which risks 
inter-observer variability and misdiagnosis (Massi et al., 1999).  Histological grading 
of GvHD does not correlate well with clinical severity and does not predict outcome 
(Ferrara and Deeg, 1991). 
 
 
Table 1.3.  Lerner’s criteria for histopathological grading of acute 
skin GVHD  
Lerner’s criteria classify the severity of skin damage in acute GvHD on a 4 
point-scale based on histological features of skin biopsies.  Reproduced 
and modified from Heymer, 2013. 
 
 
Biopsy specimens of GvHD are routinely examined by haematoxylin and eosin 
staining without specific immunostains.  However, the identity of infiltrating cells may 
add prognostic information and provide information about participating cell types in 
lesions.  The presence of MHC class II-expressing cells in the infiltrate has been 
recognized for decades (Sloane et al., 1984).  Use of a monoclonal antibody to the 
scavenger receptor CD163 has demonstrated macrophage-rich infiltration in more 
than a third of patients (Nishiwaki et al., 2009).  While dermal DC content (by CD1a 
staining) and CD8 T cell content was not prognostic, having many macrophages 
predicted steroid resistance.  Quantified as >200 macrophages per 4 fields at 200x 
magnification, macrophage-rich GvHD was significantly associated with worse 
survival (Nishiwaki et al., 2009).  This association has been confirmed in a separate 
Table 1.3.  Lerner’s criteria for histopathological grading of acute skin GVHD!!!
Grade Histopathological description/ plain language description 
 
I 
 
Mild changes characterized by focal or diffuse vacuolar degeneration of epidermal basal cells and 
acanthocytes 
 
Cells in the basal layer appear swollen and disconnected from each other  
II Moderate changes, characterized by focal or diffuse spongiosis and eosinophilic degeneration 
(apopotosis) of scattered individual epidermal cells 
 
Fluid accumulates around the epidermal cells.  Some can be seen undergoing programmed cell 
death. 
III Severe changes, characterized by separation of the dermo-epidermal junction and formation of clefts. 
 
Fluid accumulation is more severe, causing separation of dermis from epidermis. 
IV Maximal changes, characterized by extensive destruction and frank loss of epidermis. 
 
Epidermis becomes separated from dermis and dies. !
Jardine L, 2016 
! 33!
cohort, although the sensitivity, specificity and positive predictive value were not 
sufficient to suggest clinical utility (Terakura et al., 2015). 
 
1.6.4 Lung GvHD  
 
The lung is not considered a principal target organ in acute GvHD because epithelial 
apoptosis does not occur (Sloane et al., 1983).  However, alloreactive lung 
inflammation can be induced experimentally (Cooke et al., 1996),!(Srinivasan et al., 
2012) and clinical lung injury coincident with GvHD or DLI occurs in patients 
(Soubani and Pandya, 2010),!(Nishie et al., 2016). 
 
Clinically, alloreactive lung disease has been difficult to characterize.  While the 
manifestations of skin or gut GvHD are usually clinically evident, alloreactive lung 
injury can be insidious and occur with distinct anatomical and clinical patterns 
(Soubani and Pandya, 2010).  Three histopathological entities are seen: diffuse 
alveolar damage, organizing pneumonia and bronchiolitis (Xu et al., 2013).  The 
bronchiolitis can be lymphocytic (with intraepithelial lymphocytes, eosinophils and 
perivasculitis) or may be constrictive (with fibrous thickening and obliteration of 
bronchioles) (Holbro et al., 2013).  The constrictive appearance may represent a 
terminal stage of lymphocytic bronchiolitis, but no longitudinal studies have been 
performed to test this hypothesis.  Such varying patterns of lung involvement lead to 
distinct clinical presentations.  Diffuse alveolar damage presents as idiopathic 
pneumonia syndrome (IPS); organizing pneumonia presents as bronchiolitis 
obliterans organizing pneumonia/ cryptogenic organizing pneumonia (BOOP/ COP); 
and bronchiolitis presents as bronchiolitis obliterans syndrome (BOS).  The clinical 
features of the three conditions are compared in Table 1.4.  Accurate diagnosis of 
these conditions poses a major challenge. 
 
The principal challenge is distinguishing between infection and GvHD.  Diagnostic 
criteria for IPS and BOS require that bacterial, fungal and viral pathogens are reliably 
excluded (Panoskaltsis-Mortari et al., 2011).  In practice, immunosuppressed BMT 
recipients are given prompt broad-spectrum antimicrobial treatment when infection is 
suspected.  This reduces diagnostic yield from subsequent procedures such as BAL 
and makes accurate exclusion of infection difficult.  Even when pathogens are 
detected, it does not exclude concurrent alloreactivity as superimposed infection is 
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seen in up to 50% of patients with BOS (Holbro et al., 2013).  A clinical test for lung 
GvHD does not exist.  Transbronchial biopsies are rarely performed in BMT 
recipients due to unacceptable risks.  BAL is the safest window to the pulmonary 
immune system, but bronchoscopy/ BAL is not without risks in acutely unwell patients 
and cannot be performed if significant hypoxia is present.  Interpreting the cytokine 
and cellular profiles of BAL is hampered by a lack of understanding about the effects 
of conditioning and BMT and an incomplete understanding of steady state lung 
immunology. 
 
 
 
Table 1.4 Clinical features of pulmonary GvHD 
The three diagnoses encompassed by the term ‘pulmonary GvHD’ have 
distinct clinical features.  References: [1] Yoshihara et al., 2007, [2] 
Duque-Afonso et al., 2013, [3]!Holbro et al., 2013, [4] Freudenberger et al., 
2003, [5] Panoskaltsis-Mortari et al., 2011, [6] Tizon et al., 2012. 
 
 
Current understanding of alloreactive lung disease comes primarily from animal 
models, with very few quality studies in humans.  The most extensively reported IPS 
model is a complete MHC-mismatched murine BMT (Panoskaltsis-Mortari et al., 
1997).  Lung injury is T cell-dependent and associated with perivascular and 
peribronchiolar infiltrates of T cells (Th1 CD4 and CD8), and monocytes/ 
Table 1.4: Clinical features of pulmonary GVHD  
 
 BOS BOOP/COP IPS 
Incidence 1.7-26% [1] 1% [4] 2.2-15% [5] 
Average onset post-
BMT 
1 year (median) [1] 108 days (median) [4] 19 days (median) [5] 
Risk factors Chronic GVHD [1, 2]  
Prior acute GVHD [1, 2] 
Immunosuppression without in 
vivo T cell depletion [1, 2] 
Busulfan based conditioning [1] 
Respiratory infection within 100 
days post BMT [1, 2] 
Acute GVHD  
Chronic GVHD  
Unrelated donor [1] 
Full -intensity conditioning (with TBI) 
Acute GVHD 
Acute myeloid leukemia or 
myelodysplastic syndrome pre-BMT [5] 
 
Clinical features Non-productive cough, wheeze, 
dyspnea [1] 
Non-productive cough, dyspnoea, 
fever (no wheeze) [1] 
Cough, dyspnea, tachypnoea, 
hypoxaemia, crackles [5] 
PFT Obstructive (FEV1 <80% 
baseline) [1] 
Restrictive, reduced lung volumes 
and DLCO possible [1] 
Restrictive, reduced DLCO [5] 
CT findings Mosaic pattern of expiratory air 
trapping 
Bronchial wall thickening  
Bronchial dilation [1] 
Migratory consolidation 
Subpleural and 
peribronchovascular distribution 
Nodules and ground glass 
opacity [1] 
Multilobar infiltrates [5] 
 
BAL Neutrophilia or lymphocytosis [1] Lymphocytosis with relative 
increase in CD8 T cells [1] 
Nil consistent  
Histology 2 groups: lymphocytic or 
constrictive bronchiolitis [3] 
Organizing pneumonia [1] Biopsy rarely performed 
Diffuse alveolar damage [5] 
Treatment Immunosuppression- often 
prednisolone + calcineurin 
inhibitor + mycophenylate mofetil 
[1] 
Systemic steroid [4] Antimicrobials (broad spectrum) 
Steroids 
Etanercept  
Response/progression Reversibility in lymphocytic 
histological subtype [3] 
57% respond to steroid [4] 18% patients treated with steroid alone 
improve to allow ventilator wean; 53% 
in steroid+ etanercept [6] 
Survival 3 year mortality 65% [1] 5 year mortality 69% [4] 60-80% mortality [5] 
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macrophages (Panoskaltsis-Mortari et al., 1997).   A BOS-like pattern of injury can be 
achieved by delivering fewer T cells (Panoskaltsis-Mortari et al., 2007).  While the 
chemokine and cytokine profiles of the IPS and BOS models do not differ, infiltrating 
MPs are recipient in IPS and donor in BOS (Panoskaltsis-Mortari et al., 1997),!
(Panoskaltsis-Mortari et al., 2007).  In an MHC-matched, minor antigen-mismatched 
model with fractionated radiation to spare pulmonary toxicity, the pattern of injury and 
infiltration is similar (Cooke et al., 1996).  LPS and TNFα are detectable in the BAL 
fluid.   
 
Mice with GvHD outside the lung are more susceptible to developing lung-
involvement following LPS inhalation (Cooke et al., 1996).  This suggests that 
systemic GvHD confers vulnerability to a ‘second hit’.  Several studies have focused 
on LPS produced by translocated gut bacteria as the second hit (Nestel et al., 1992),!
(Cooke et al., 1996),!(Cooke et al., 2000).  The association between respiratory viral 
infection early after BMT and subsequent alloimmune lung injury suggests that other 
inflammatory stimuli may be capable of inducing damage (Versluys et al., 2010).  
Macrophage recognition of fungal polysaccharide α-mannan has recently been 
implicated in Th17 accumulation in lung and severe GvHD pathology (Uryu et al., 
2015).  
  
Human studies attempting to characterize lung GvHD have mainly reported BAL 
cytokines.  Yanik et al. found elevated TNFα, soluble TNF receptors (TNFRI/ 
sTNFRII), IL-6, soluble CD14, lipopolysaccharide binding protein (LBP), IL-1 receptor 
antagonist, IL-8, MCP-1, and total protein at the onset of IPS (Yanik et al., 2008).  
Clark et al found elevated IL-1, IL-6, TNFα and LBP in a cohort of biopsy-confirmed 
IPS patients (Clark et al., 1999).  Hauber et al compared BAL cytokines in lung 
infection and lung GvHD patients. TNFα and IL-18 did not discriminate between 
groups.  Higher lymphocyte: neutrophil ratio and lower IL-10 correlated with IPS/ 
BOS (Hauber et al., 2002).  The abundance of pro-inflammatory cytokines produced 
by MPs and MP-recruiting chemokine MCP-1 in BAL hints at the presence of MPs.  
Further high quality studies are required to deconvolute events and cellular players in 
post-BMT lung damage.  
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1.6.5 GvHD animal models 
 
Many insights into the pathogenesis of GvHD have arisen from studying animal 
models.  The advantages and limitations of these models deserve consideration 
before discussing GvHD pathogenesis in detail. 
 
Mouse models of GvHD are widely used.  They employ young, inbred mice housed in 
pathogen-free conditions.  Using manipulation of specific genes, conditional 
depletion, labelling or tracing techniques, adoptive transfer and parabiosis 
experiments, rigorous hypothesis testing can be performed.  Many mice can be 
transplanted in parallel, with in vivo tracing and sacrifice at various time-points giving 
insight into the dynamics of GvHD inflammation.  Target organs in murine GvHD 
models show similar damage to affected human tissues (Markey et al., 2014b).  HLA 
disparity in murine models affects the leukocytes involved in GvHD inflammation!
(Korngold and Sprent, 1985),!(Korngold and Sprent, 1982).  Minor antigen 
mismatched mouse models are more likely to reflect the type of inflammation seen in 
HLA-matched clinical BMT (Markey et al., 2014b). 
 
Canine models of BMT have been valuable for studying therapeutics but are less 
readily scaled and manipulated than murine models.   
 
Humans undergoing BMT tend to be older, sicker and exposed to a wide range of 
pathogens but, more importantly, undergo a procedure that is very different from a 
murine BMT.  Murine BMTs use irradiation for conditioning.  T cells or splenocytes 
are infused with the graft and post-BMT immunosuppression is not employed.  
Clinical BMT regimens are often radiation-free and T cell-depleted.  The use of 
immunosuppressive medications targeting IL-2 (ciclosporin, tacrolimus) or purine 
biosynthesis (mycophenolate mofetil, methotrexate) is universal.  While there is no 
dispute that murine models continue to provide unique mechanistic insight into 
GvHD, analysis of human tissues may reveal distinct pathways and cellular 
mediators operating in patients.    
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1.6.6 GvHD pathogenesis 
 
Integrating insights from animal models with clinical data, Ferrara and Deeg have 
summarized the immune mechanisms underlying GvHD (Ferrara and Deeg, 1991)!
(Ferrara et al., 2009).  Their model of GvHD induction recognizes three phases 
(Figure 1.4).  In phase I, APCs are activated.  In phase II, T cells are activated and in 
phase III, target organ damage occurs.  Evidence in support of this model and areas 
of uncertainty pertaining to MPs will be discussed below. 
 
 
 
Figure 1.4 Pathophysiology of acute GvHD 
Diagram of Ferrara’s three stage model GvHD pathogenesis: I) damage to 
recipient tissues caused by BMT conditioning, II) activation of donor T 
cells by host APC and III) apoptosis of target cells by cytotoxic lymphocyte 
and cytokine activity.  Image from Harris et al., 2013.  IDO= indoleamine 
2,3-dioxygenase; NOD2= nucleotide binding oligomerization domain 
containing 2  (a PRR); CTL= cytotoxic T lymphocyte; NK=natural killer 
lymphocyte.  
 
 
APCs within tissues may be activated by PAMPs, endogenous danger signals and 
cytokines.  Integrity of epithelial tissues, especially the gut, is damaged by intensive 
conditioning regimens (Hill et al., 1997),!(Keefe et al., 2000).  Damaged epithelial 
cells release alarmins and loss of barrier integrity can allow translocation of LPS and 
commensals across the mucosa (Zeiser et al., 2011),!(Hill et al., 1997).  Alteration to 
Figure 1.4: Pathophysiology of acute GvHD
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gut commensal populations may also create a pro-inflammatory environment (Jenq 
et al., 2012).  Activation of donor T cells has been demonstrated in gut draining 
lymph nodes (Murai et al., 2003).  LPS entering the systemic circulation has the 
ability to activate APCs at distant sites, for example the lung (Nestel et al., 1992),!
(Cooke et al., 1996).  TNFα, IL-1 and IL-6 in serum and colon are proportional to 
conditioning (Hill et al., 1997),!(Xun et al., 1994).   Cytokine production by innate 
lymphocytes may also tip the balance from mucosal protection to mucosal 
inflammation (Hanash et al., 2012).  In summary, there is good evidence that BMT 
conditioning can provide an environment capable of stimulating APCs.  The “cytokine 
storm” induced by irradiation and cyclophosphamide is likely to be less marked in 
RIC transplants.  These transplants still incur a risk of GvHD.  The “cytokine storm” 
cannot be an absolute requirement for GvHD induction as DLI, given more than six 
months after conditioning, is capable of inducing GvHD.  In murine models where 
APC signal 1 is inhibited (MyD88-/-) and APC signal 2 cannot be conveyed (in 
CD40L-/-), GvHD may still be induced (Shlomchik, 2003). 
  
During the second phase of GvHD induction, donor T cells reactive against host 
epitopes are activated and proliferate.  In murine BMT models, splenocytes or 
purified T cells are infused alongside bone marrow and their distribution can be 
tracked.  Donor T cells initially track to secondary lymphoid tissue (Beilhack et al., 
2005),!(Panoskaltsis-Mortari et al., 2004).  Naïve donor T cells proliferate (Beilhack et 
al., 2005).  Interaction with host APCs expressing co-stimulatory molecules and 
presenting host antigen are important triggers to this proliferation (Shlomchik et al., 
1999).  The type of T cells proliferating depends on the genetic backgrounds of the 
mice involved; with MHC I mismatches CD8 T cells are involved, with MHC II 
mismatches CD4 T cells are involved and with HLA-matched/ minor antigen-
mismatched combinations both subsets are (Korngold and Sprent, 1985)!(Korngold 
and Sprent, 1982).  Importantly, effector memory T cells do not proliferate within 
secondary lymphoid tissue or migrate to GvHD target organs (Beilhack et al., 2005).  
Naïve CD4 T cell polarization is skewed towards Th1 generation in GvHD (Yi et al., 
2009).  The Th1 subset and its cytokines (IFNγ, IL-2 and TNFα) are most strongly 
implicated in gut GvHD (Yi et al., 2009),!(Hill et al., 1997)) but Th17 and Th2 subsets 
may contribute to GvHD pathology in skin and lung (Yi et al., 2009).  Donor Tregs are 
capable of suppressing GvHD, in part through production of IL-10 (Hoffmann et al., 
2002).  The insights from murine models in this second phase of GvHD induction are 
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particularly difficult to translate to human BMT.  Rather than T cell infusion, many 
clinical BMTs involve T cell depletion with Alemtuzumab or ATG.  The contribution of 
mature donor T cells to GvHD induction is likely to be less prominent.  T cells emerge 
from new donor haematopoiesis at a very low level during the first year of transplant.  
In most transplanted adults, they encounter an involuted thymus and are constrained 
by IL-2 targeted immunosuppressive drugs.  The conditions for T cell activation and 
proliferation are consequently rather different in patients.  Cross-species 
interpretation aside, the details of T cell activation have been explored more fully 
than the details of the APCs they interact with.  The role of APCs will be discussed in 
more detail below, but in the context of Ferrara’s model of GvHD pathogenesis the 
following questions are raised.  What cell types present antigen?  Does all antigen 
presentation occur in secondary lymphoid tissue?  Is there a role for non-migratory 
APCs, namely macrophages?  Why does GvHD predominantly affect the skin if T cell 
priming occurs in gut draining lymph nodes?   What is the relative contribution of host 
and donor APC?  What is the relative contribution of resident APC and those 
recruited to tissue during inflammation?     
 
In the final phase of GvHD pathogenesis, effector cells and soluble factors induce 
target organ damage.  Trafficking of T cells out of secondary lymphoid tissue is an 
important step (Kim et al., 2003).  Expression of chemokine receptors such as CCR2, 
CCR5 and CXCR3 allows T cells to respond to cytokine gradients and enter target 
tissues (Wysocki et al., 2005).  Inflammation within target tissues may be required for 
optimal T cell recruitment (Chakraverty et al., 2006).  CD8 T cells and their cytotoxic 
products (perforin, granzyme and Fas ligand) mediate tissue damage (Braun et al., 
1996),!(Baker et al., 1996).  Soluble factors TNFα, nitric oxide and IFNγ can damage 
tissues directly (Piguet et al., 1987),!(Garside et al., 1992),!(Mowat, 1989).  
Neutralizing them can abolish GvHD (Teshima and Ferrara, 2002).  Soluble factors 
are also important in modifying the effector functions of resident and recruited 
leukocytes.  For example, IFNγ primes macrophages to produce TNFα in response to 
low levels of LPS (Nestel et al., 1992).  The relative importance of cytotoxic T cells, 
soluble factors and accessory leukocytes depicted in Ferrara’s scheme remains to be 
established in the human setting.  Clinical trials suggest that interrupting a single 
aspect of the effector machinery, such as TNFα, CCR5 or IL-1, has limited capacity 
to reduce GvHD (Couriel et al., 2009),!(Reshef et al., 2012),!(Antin et al., 2002).  
Targeting accessory cells such as macrophages has only been attempted in murine 
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models to date (Alexander et al., 2014) but has the potential to inhibit multiple 
effector mechanisms simultaneously. 
 
1.6.7 Mononuclear phagocyte turnover following BMT 
 
Before considering the role of MPs in GvHD, the turnover of these cell types after 
BMT requires consideration. 
 
Monocytes and DCs in blood and tissue are depleted by conditioning and are virtually 
absent for the first week after transplant (McGovern et al., 2014).  Macrophages are 
reduced in number, but not entirely depleted.  Recovery of classical monocytes is 
seen by about day 10, with pre-transplant levels rapidly achieved.  Blood DCs and 
non-classical monocytes remain at lower numbers on day 14, either due to slower 
recovery or immunosuppression.   CD14 MDM and DC populations in skin recover 
later than their blood counterparts.   Like blood DCs, dermal DCs do not rapidly 
achieve pre-transplant levels (McGovern et al., 2014). 
 
Following BMT, leukocytes transition from recipient to donor chimerism.  MP turnover 
is not uniform across cell types or across tissues.  GvHD inflammation is 
superimposed on this backdrop of transition. 
 
Blood monocytes have the fastest transition to donor chimerism, reaching 100% by 
day 28 in myeloablative BMT (Auffermann-Gretzinger et al., 2002).  Transition is 
slower after RIC, with only 10% donor chimerism at day 14 and 100% donor 
chimerism achieved by day 42!(Auffermann-Gretzinger et al., 2002).  Blood DCs also 
turn over rapidly, with 100% donor chimerism achieved by day 28 in myeloablative 
and day 42 in RIC transplants (Auffermann-Gretzinger et al., 2002).  Data from 
murine models suggests that recipient LCs can dominate for at least 2 months after 
BMT (Durakovic et al., 2006),!(Merad et al., 2004).  In a human transplant setting, 
turnover is more rapid, with >90% donor chimerism by 3 months post-BMT (Collin et 
al., 2006).  Recipient LCs are present between 0 and 3 months.  Their persistence is 
greater with RIC BMT and the absence of GvHD (Collin et al., 2006).  Replacement 
of dermal DCs and CD14 MDMs is more rapid, with close to 100% donor chimerism 
at day 40 (Haniffa et al., 2009).   Dermal macrophages are slowly replaced, with 
>10% recipient macrophages still present after 1 year (Haniffa et al., 2009). 
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While the fate of the human dermal APC compartment following BMT has been 
carefully mapped, data on turnover of lung APC subsets is scarce.  Early work 
looking at AM chimerism in myeloablative BMT showed that donor-derived AM 
appear following transplant (Thomas et al., 1976).  The dependence of this effect on 
conditioning (principally total body irradiation in this cohort) and the time course of 
reconstitution could not be determined.  Murine studies suggest that AM have 
capacity to self-renew if conditioning radiation is administered in fractionated doses 
(Tarling et al., 1987).  A small study in myeloablative BMT recipients demonstrated 
the proliferative capacity of AM, but a single sex-mismatched case showed that the 
proliferating population was donor-derived (Nakata et al., 1999).  In this study, blood 
monocytes were 100% donor 40 days after BMT, whereas AM showed mixed 
chimerism beyond 80 days.  The population dynamics of lung DCs have only been 
studied in rodents (Holt et al., 1994).  Tracheal DC populations decline by 85% in the 
first 72 hours after dexamethasone treatment or x-irradiation.  Donor cells repopulate 
the epithelium within 10 days.  The turnover of parenchymal DCs (though not 
convincingly distinguished from AM) and LCs took longer than 15 days.  Syngeneic 
mouse BMT models suggest that AM undergo functional changes as a result of BMT 
conditioning, with reduced capacity for phagocytosis and bacterial killing (Domingo-
Gonzalez and Moore, 2013). 
 
1.6.8 The role of mononuclear phagocytes in GvHD 
 
The role of MPs as APCs in GvHD is well established.  Antigen can be presented to 
donor T cells directly by host DCs (Shlomchik et al., 1999),!(Duffner et al., 2004), LCs 
(Merad et al., 2004) or non-haematopoietic cells (Koyama et al., 2012).  Donor APCs 
augment GvHD inflammation but are not required for its induction (Matte et al., 
2004).  Donor APCs can present exogenous host antigen on donor MHC class II to 
CD4 T cells or cross-present antigen via donor MHC class I to CD8 T cells.  
Alternatively, donor DC can “cross-dress” by acquiring intact membrane fragments 
from host cells including host MHC class I/ peptide complexes (Wakim and Bevan, 
2011).  In model settings, the contributions of cross-presentation and cross-dressing 
to antigen-specific T cell activation are variable (Wang et al., 2011),!(Markey et al., 
2014a).  The role of these mechanisms in GvHD induction is predicted to be 
important at later time points post-BMT, when host APCs are abolished. 
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A role for inflammatory monocytes and macrophages in the effector phase of GvHD 
inflammation has been described.  Macrophage production of IFNγ and TNFα can 
exacerbate tissue injury (Hill and Ferrara, 2000).  Limiting macrophage accumulation 
with dexamethasone palmitate limited GvHD severity in a murine acute GvHD model 
(Nishiwaki et al., 2014).  Targeting macrophages with CSF-1 antibody in an acute 
sclerodermatous GvHD model also reduced pathology (Alexander et al., 2014).  The 
selective S1P1 receptor agonist CYM-5442 limited monocyte extravasation into skin 
and reduced GvHD severity in a murine model (Cheng et al., 2015). 
 
Host macrophages may confer protection against GvHD by engulfing alloreactive 
donor T cells (Hashimoto et al., 2011), producing TGFβ and expanding Tregs 
(D'Aveni et al., 2015).  Pre-transplant CSF-1 therapy to expand host macrophages 
reduced subsequent GvHD (Hashimoto et al., 2011).  Immunoregulatory properties 
have also been ascribed to myeloid derived suppressor cells (MDSC) in GvHD 
(Wang et al., 2013).  For example, a donor CD34+ population with mature monocyte 
properties killed IFNγ-producing T cells using nitric oxide (D'Aveni et al., 2015). 
 
 
1.7 Experimental inflammation using lipopolysaccharide 
 
1.7.1 Toll like receptors  
 
Toll like receptors (TLRs) are a group of pattern recognition receptors that are 
evolutionarily conserved and recognize pathogen-specific epitopes.  TLRs1-9 are 
relevant in humans (Beutler, 2009).  TLRs1-2 and 4-6 are present in the plasma 
membrane and recognize bacterial, fungal and parasitic epitopes.  TLRs3 and 7-9 
are found within the endocytic compartment and recognize viral epitopes (Beutler, 
2009).  TLRs share common cell signaling pathways for activation of transcription 
factors such as NFkB and Interferon Regulatory Factors (IRFs).  Pro-inflammatory 
cytokines and type I interferon are produced as a result. 
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1.7.2 Lipopolysaccharide 
 
LPS is one of the most extensively characterized PAMPS.  It requires detailed 
introduction because it is important to this thesis as a factor in the pathogenesis of 
GvHD and as a trigger for experimental inflammation. 
 
LPS is a structural element in the outer membrane of Gram-negative bacteria.  The 
molecule comprises a lipid membrane anchor (lipid A), an oligosaccharide core and a 
polysaccharide tail exposed on the bacterial surface (O antigen).  Lipid A is the most 
immunogenic component (Lu et al., 2008).  The LPS signal is transduced across 
target cell membranes by TLR4 (Poltorak et al., 1998) in complex with CD14 and two 
soluble factors: lipopolysaccharide binding protein (LBP) and MD-2/LY-96 (Lu et al., 
2008).  When occupied by LPS, TLR4 oligomerizes and binds an adaptor protein: 
either MyD88 or TRIF.  The MyD88-dependent pathway culminates in activation of 
transcription factors IRF5, NF-κB and AP-1, resulting in pro-inflammatory cytokine 
gene transcription.  The MyD88-independent pathway (TRIF pathway) activates 
IRF3, NF-κB and AP-1 and most characteristically induces type I interferons (Lu et 
al., 2008). 
 
There is a sequential response to LPS in susceptible cells (Huang et al., 2012),!
(Raza et al., 2014).  Primary response genes are activated between 0.5 and 2 hours 
after exposure.  Genes include Tnf and Ifnb1 encoding TNFα and IFNβ (Medzhitov 
and Horng, 2009).  The transcription factors for these genes (NF-κB and IRFs) are 
poised for action in steady state and only require post-translation modifications such 
as phosphorylation and translocation to the nucleus (Medzhitov and Horng, 2009).  
Secondary response genes are activated between 2 and 8 hours after LPS exposure.  
The necessary transcription factors (ATF3, C/EBPδ) are induced as part of the 
primary response (Medzhitov and Horng, 2009).  Responses to LPS are dose 
dependent, but additional signals, most notably interferon-γ (IFN-γ) can increase LPS 
sensitivity (Schroder et al., 2006).  
 
Studies in animals with mutated TLR4, CD14 and signaling components have 
demonstrated the necessity of each for an inflammatory response to LPS (Poltorak et 
al., 1998), (Haziot et al., 1996), (Guha and Mackman, 2001).  The susceptibility of a 
given cell population to LPS might then be predicted to depend on TLR4 and CD14 
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expression.  While mRNA for TLR4 is present in most tissues, protein expression is 
restricted to haematopoietic tissues!(Ponten et al., 2008).  Amongst leukocytes, TLR4 
expression is limited to MPs but may be up-regulated on neutrophils by inflammatory 
stimuli (Muzio et al., 2000).  CD14 is primarily expressed on macrophages, 
monocytes and neutrophils but gradations of CD14 expression are seen on DCs, 
lymphocytes, basophils and non-leukocytes such as respiratory epithelial and 
endothelial cells (Jersmann, 2005).  Low-level expression of CD14 in LPS-exposed 
sites such as the airway may function to minimize exaggerated inflammatory 
responses (Jersmann, 2005).  CD14 lacks a transmembrane domain and can be 
cleaved from the surface of cells, yielding soluble CD14.  The soluble form 
participates in LPS signaling in CD14 negative cells (Guha and Mackman, 2001),!
(Verhasselt et al., 1997).  Thus, while CD14 and TLR4 expression are high in the 
well-studied LPS responsive cell types (monocytes and macrophages), the 
consequences of lower expression in other cell types are not fully understood. 
 
At an organismal level, the response to in vivo LPS is highly species specific.  
Humans develop fever and cytokine release with 250ng intravenous LPS while 
laboratory mice can tolerate 500µg.  Considering relative body weight, humans are 
approximately 105 fold more sensitive (Warren et al., 2010).  Serum proteins are 
thought to underpin this difference, as ex vivo macrophages from both species are 
similarly responsive to LPS (Warren et al., 2010).  LPS is capable of inducing a 
severe systemic inflammatory response even in the absence of pathogen (Taveira da 
Silva et al., 1993). 
 
1.7.3 Experimental inflammation using LPS 
 
LPS has been widely used in animal and human research to study mechanisms of 
acute inflammation.  In human studies, intravenous LPS has been used to model 
sepsis and intrapulmonary LPS to model acute lung injury, occupational lung disease 
and asthma.  Whether or not the models accurately reflect these diseases, they 
provide an opportunity to study early events in inflammation.  LPS is generally 
considered a trigger for neutrophil influx but many of the additional events have been 
poorly characterized. 
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1.7.4 Human LPS inhalation studies  
 
In human LPS inhalation models, doses of 20 to 100µg LPS have been delivered via 
nebulizer or inhalation chamber.  These doses were selected to represent 
environmental LPS exposure during cotton manufacture (Sandstrom et al., 1992).  
Direct instillation of 4ng/kg LPS via bronchoscope (the dose used in intravenous 
studies) has also been reported (O'Grady et al., 2001).  The administration method 
likely determines the tempo and character of the immune response.  Direct instillation 
or nebulization provides bolus exposure whereas inhalation chambers deliver a dose 
over 30-60 minutes.  All three methods may inoculate the bronchial mucosa rather 
than the alveolar space if improperly standardized and this is relevant as each 
compartment has a unique response (Moller et al., 2012).    
 
Immune sequelae of pulmonary LPS exposure have been measured in the peripheral 
circulation and in the airway by BAL/ induced sputum.  BAL is delivered to distal 
airways and samples the alveolar space while induced sputum samples the bronchial 
mucosa.  Neither method involves penetrating the tight junctions of the airway 
mucosa, therefore mucosal surface rather than intraepithelial or interstitial immune 
cells are sampled.  Induced sputum can be performed repeatedly without discomfort 
to the participant or precipitation of an inflammatory response.  BAL is a more 
invasive technique.  Transient leukocytosis and pyrexia are recognized 
consequences (Cohen and Batra, 1980).  Repeated sampling would therefore be 
poorly tolerated and may alter the course of inflammation.  
 
In the most comprehensive time-course of pulmonary LPS response, O’Grady et al. 
showed that neutrophil recruitment was maximal by 6 hours, while monocyte/ 
macrophage and lymphocyte recruitment occured between 6 and 12 hours (O'Grady 
et al., 2001).  Pro-inflammatory cytokines and chemokines peaked between 6 and 12 
hours.  Most studies have performed bronchoscopy at 6-8 hours.  As O’Grady et al. 
have demonstrated, this captures the neutrophilic phase of inflammation better than 
the mononuclear cell infiltrate.  
 
Existing data consistently find neutrophils scarce in steady state BAL (650 cells/ml in!
Brittan et al., 2012) but 100-fold more abundant 6 hours after LPS inhalation 
(Sandstrom et al., 1992),!(Maris et al., 2005),!(Brittan et al., 2012).  BAL lymphocytes 
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may be approximately doubled (Sandstrom et al., 1992), although some studies find 
no increment (Maris et al., 2005).  With the exception of Brittan et al, all studies have 
determined BAL composition by microscopy and differential cell count.  This makes 
for a crude assessment of MP repertoire.  Brittan et al used 5-parameter flow 
cytometry to distinguish AM and two populations of pulmonary monocyte-like cells in 
BAL!(Brittan et al., 2012).  Compared with saline inhalation, LPS inhalation resulted 
in 8 times more CD14+CD16- monocytes in BAL (Brittan et al., 2012).  CD14+CD16+ 
monocyte counts were consistent between LPS and saline and AM counts were not 
reported.  This led the authors to consider CD14+CD16- monocytes an ‘inducible’ 
population, possibly recruited from blood classical monocytes.  Airspace DCs have 
not been examined following LPS inhalation.  Alexis et al. proposed that airway 
monocytes differentiated into DCs following LPS inhalation though presented no 
convincing evidence in support of this (Alexis et al., 2005). 
 
 
1.8 Scope of the thesis  
 
This work examines inflammation relevant to acute GvHD in the skin and lung.  Only 
human tissue is used.  MPs are central to this investigation.  Tissue and blood MPs 
receive specific attention.  Bone marrow and lymphoid tissue counterparts will be 
considered but not examined.  The focus will therefore be on the diversity of MPs in 
inflamed skin and lung and their in situ functions, such as cytokine production and 
interactions with mature lymphocytes. 
 
Two contrasting approaches are employed to manage the logistic and scientific 
difficulties of studying GvHD in skin and lung.  In the skin, studying GvHD-affected 
tissues is tractable: tissue can be sampled shortly after presentation and before 
treatment, BMT recipients will volunteer control biopsies, and the incidence is high 
enough to yield necessary samples.  Furthermore, we understand the MPS of the 
human skin in steady state sufficiently to interpret our findings.   
 
In the lung, obtaining GvHD-affected material is difficult.  Our clinical protocols 
indicate bronchoscopy and BAL in suspected lung GvHD, but delays in sampling are 
common.  The clinical presentation may be insidious, multiple treatments may be 
attempted prior to sampling and patients may be too unwell for safe bronchoscopy.  
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Compounding these difficulties, the incidence of lung GvHD is relatively low.  The 
greatest barrier to studying MPs in lung GvHD, however, is an inadequate 
understanding of the MPS in human lung.  I have therefore focused attention on 
trying to bridge this knowledge gap by studying MPs in BAL during steady state, and 
following experimental acute inflammation produced by LPS inhalation.  LPS 
inhalation is not intended as a model for lung GvHD, but does provide a starting point 
for MP characterization in acute inflammation with a clearly timed and controllable 
inflammatory insult.  Insights from this model will inform more comprehensive studies 
of lung GvHD in the future. 
 
 
1.9 Hypotheses and aims 
 
1.9.1 Hypotheses 
 
1) The MP repertoire in inflamed tissues will be altered 
2) Inflammatory MPs derived from monocytes will be found in inflamed tissue 
3) Tissue MPs will perpetuate the damage mediated by T lymphocytes in GvHD   
 
1.9.2 General aims 
 
In the skin strand of this work, I aim to define the MP composition of GvHD lesional 
skin.  Through comparisons with steady state populations, I will characterize the 
inflammatory skin MP populations in terms of phenotype, gene expression and 
function.  I will gather evidence to support/ refute the hypothesis that inflammatory 
MPs are monocyte-derived. 
 
In the lung strand, I aim to define the MP composition of BAL in steady state and in 
response to LPS inhalation.  Again, steady state populations will be used as a 
platform for characterizing inflammatory MPs in terms of phenotype, gene expression 
and function.  BAL will be paired with serial blood samples to examine the temporal 
dynamics of blood MPs in response to tissue inflammation.   
 
Each of the following chapters has a specific and detailed research aim, which is 
informed by the results of preceding investigation. 
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Chapter 2: Materials and methods 
 
 
This chapter details general materials and methods used in multiple results chapters.  
Specific materials and methods tailored to each set of experimental aims are given in 
the results chapters.  With this organization, details of the samples, ethics, 
processing and analysis techniques are proximal to the data presented.  
 
2.1 General cell culture methods 
 
2.1.1 Cell counting 
 
Cells to be counted were re-suspended in a known volume of medium or phosphate 
buffered saline (PBS).  Ten microlitres of cell suspension and 10µl 0.4% Trypan Blue 
were thoroughly mixed in a plastic cuvette and 10µl was transferred to a 
haemocytometer.  Mean counts of live and dead cells were recorded from 5 squares 
(4 corners and centre).  The number of cells per ml was calculated by the formula: 
Cells/ ml= mean cell count x dilution factor x 104 
 
2.1.2 Freezing and thawing cells 
 
Cells to be cryopreserved were pelleted by centrifugation at 500g for 5 minutes.  All 
supernatant was completely aspirated.  The pellet was re-suspended in 1ml 4°C 
freezing solution (Table 2.3) per 107 cells and rapidly transferred to labelled 
cryopreservation tubes.  Tubes were wrapped in bubble plastic, stored at -80°C for 
24-48 hours, then removed from plastic and transferred to -140°C for long-term 
storage. 
  
In preparation for thawing, 15ml RF10 (Table 2.3) per sample were warmed to 37°C 
in polypropylene tubes.  Cryopreservation vials were taken from the freezer and 
placed on ice.  Samples were thawed by immersion in the water bath (37°C).  In a 
class II Safety Cabinet, the thawed samples were rapidly transferred into the warmed 
medium and the sample tube rinsed with medium to collect all residual cells.  
Samples were pelleted by centrifugation (5 minutes at 500g) and the supernatant 
was discarded. 
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2.2 Cell isolation 
 
2.2.1 Peripheral blood mononuclear cell (PBMC) isolation 
 
Blood was collected into tubes containing Ethylenediaminetetraacetic acid (EDTA) 
and diluted 1:1 with room temperature PBS before layering over 15ml LymphoprepTM.  
All centrifugation steps were performed at room temperature.  Centrifugation for 15 
minutes at 800g with half-maximal acceleration/ braking yielded a mononuclear cell 
layer.  The layer was gently aspirated with a Pasteur pipette and transferred to 
another tube for two washing steps.  In the first, the tube was filled with 4°C PBS and 
centrifuged at 500g for 5 minutes to remove residual LymphoprepTM.  In the second, 
the pellet was re-suspended, the tube filled with 4°C PBS and centrifuged at 300g for 
7 minutes to remove platelets.  Finally, the pellet was re-suspended in 1ml red blood 
cell (RBC) lysis buffer (Table 2.3) and incubated at room temperature for 10 minutes 
in the dark.  The remaining mononuclear cells were washed with 4°C PBS and 
centrifuged at 500g for 5 minutes. 
 
2.2.2 Magnetic bead isolation 
 
A CD14 positive-selection kit was used to isolate monocytes (Miltenyi, 130-050-201).  
The PBMC pellet was re-suspended in 400µl 4°C sort buffer, mixed with 100µl 
positive selection beads per 50 x106 cells, and incubated at 4°C for 20 minutes.  
Unbound antibody was removed by addition of 10ml sort buffer, centrifugation (500g 
for 5 minutes), and removal of the supernatant.  Cells were re-suspended in 500µl 
sort buffer and applied to an MS column within a magnet.  The column was washed 3 
times with 500µl sort buffer.  CD14+ cells remained adhered to the column.  
Following removal from the magnet, 1ml PBS was flushed through to the column to 
release monocytes.  Monocytes were cryopreserved, used in functional studies or 
differentiated in culture. 
 
2.2.3 Immuno-density negative selection 
 
Two immuno-density negative selection kits were used to isolate T lymphocytes 
(Human T cell enrichment cocktail, Stemcell 15021 and Human CD4+ T cell 
enrichment cocktail, Stemcell, 15022).  This method uses tetrameric antibodies to 
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cross-link unwanted leukocyte populations to red cells.  During density centrifugation, 
immune complexes are drawn into the red cell layer, leaving T cells at the interface.  
When performed on leukocyte cones, this was an economical method of isolating 
large numbers of un-stimulated T cells.  Aliquots from the same preparation could be 
cryopreserved to allow consistency across T cell stimulation assays.   
 
Leukocyte cones were obtained from the local NHS Blood and Transplant processing 
centre within 24 hours of collection.  Cones were diluted with 45ml PBS and 
incubated with 50µl enrichment cocktail per ml cone for 20 minutes at room 
temperature.  A further 1:4 dilution in PBS was used before density centrifugation.  
The T cell layer was removed and washed as described above.  Aliquots of 5x105 T 
cells were cryopreserved for functional studies.    
 
2.2.4 Fluorescence activated cell sorting  
 
Fluorescence activated cell sorting (FACS/ sorting) allowed the simultaneous 
isolation of up to 4 populations from preparations as small as 5x104 cells.  The use of 
up to 17 fluorescence parameters allowed fine control of the immunophenotype and 
purity of sorted populations.  This method was invaluable for isolating MP subsets 
from blood and tissue.   
 
Cells to be sorted were filtered through a sterile 100micron filter into a polypropylene 
FACS tube and washed in sort buffer (Table 2.3) (3ml 4°C sort buffer and 
centrifugation for 5 minutes and 500g).  Cell pellets with fewer than 1x106 cells were 
re-suspended in 100µl sort buffer.  Larger samples were re-suspended at 1x107 cells 
per 100µl sort buffer.  Non-specific antibody binding was reduced by pre-incubation 
with 3µl 10% mouse IgG at 4°C for 10 minutes.  Antibodies were added as per sort 
panels (detailed in results chapters), incubated at 4°C for 30 minutes and protected 
from light.  Samples were washed with 3ml 4°C sort buffer and centrifuged for 5 
minutes at 500g.  Cell pellets were re-suspended at approximately 1x107 cells per ml 
in sort buffer and kept on ice.  Large samples from tissue isolates were passed 
through a 100micron filter immediately prior to sorting. 
 
Sorting prior to June 2014 was performed on a 4-laser BD FACS Aria II.  After June 
2014, a 5-laser FACS Fusion running FACSDiva version 7 was used.  Quality control 
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was verified daily by core facility staff.  Sort panels were set up as detailed in section 
2.3.3. 
 
The 85micron nozzle was used for blood sorts and the 100micron nozzle used for all 
tissue sorts.  As standard, the 1.5 neutral density filter was used in front of the 
forward scatter detector.  With lung isolates the 2.0 filter was used in order to limit the 
intensity of scatter from alveolar macrophages.  Stream alignment into the collection 
tubes was verified.  Drop delay of the stream was set using Accudrop beads (BD, 
345249).  For 2-way sorts, a purity mask was selected for sort decisions and for 4-
way sorts a 0-32-0 mask was used.  
 
Cells were collected into 5ml polypropylene FACS tubes containing 3ml RF10.  The 
collection tube holder was cooled to 4°C.  The sort was paused and the drop delay 
reset if a deviation of more than 10 pixels occurred during sorting.  This ensured that 
accurate sort decisions could be made.   
 
 
2.3 Flow cytometry  
 
2.3.1 Sample preparation 
 
Cells for analysis were added to polystyrene FACS tubes, washed with 1-3ml flow 
buffer (Table 2.3) and centrifuged at 500g for 5 minutes.  All remaining supernatant 
was aspirated and the pellet vortexed to re-suspend the cells.  Non-specific antibody 
binding was blocked with mouse immunoglobulin for 10 minutes at 4°C.  Antibodies 
were added for 30 minutes at 4°C.  The sample was washed with flow buffer and re-
suspended in 150-500µl flow buffer.  DAPI was used for dead cell discrimination and 
was added at a 1in10 dilution shortly before data acquisition. 
 
2.3.2 Intracellular staining 
 
Intracellular staining was used to detect cytokines and the cytoplasmic molecule 
S100A8/9.  Cell pellets were re-suspended in 150µl fixation/ permeabilization buffer 
(BD 554714) and incubated for 30 minutes at 4°C.  Cells were washed with 1ml 4°C 
PermWash (BD 554714) and centrifuged at 500g for 5 min.  Cell pellets were stained 
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with relevant antibodies as above and washed again with 1ml 4°C PermWash.  Cells 
were re-suspended in 150-500µl PermWash for analysis. 
 
2.3.3 CFSE labelling 
 
T cell proliferation was quantified in mixed leukocyte reactions using the CFSE 
dilution method.  This fluorescent ester readily crosses cell membranes but is subject 
to activity of intracellular esterases.  Enzymatic activity cleaves the 
carboxyfluorescein molecule and prevents its egress from the cell.  Each time cell 
division occurs, the fluorescent molecules are split between daughter cells and the 
fluorescence intensity is halved. 
 
Cells were re-suspended in 50µl PBS and labelled with 1µM CFSE (Invitrogen) 
during a 10-minute incubation at 37°C.  Enzymatic activity was terminated by adding 
cold RF10.  CFSE-labelled cells were washed and recounted before use in functional 
studies.  
 
2.3.4 Antibody panel design and setup 
 
Where possible, antibodies were selected to maximize sensitivity.  In general, the 
most weakly expressed or rarest antigens were assigned a bright fluorochrome e.g. 
phycoerythrin (PE) or PE tandems.  Antibodies were selected to minimize spectral 
overlap into channels requiring high sensitivity (Maecker et al., 2004).  For example, 
when using allophycocyanin (APC) to detect a subtle change in activation status 
such as HLA-DR expression on T-cell, it would not be optimal to use CD3 Alexa 
Fluor® A700 as its spillover into APC is considerable. 
  
Voltages were decided using single-antibody stained cells.  The aim was to achieve 
adequate separation of positive and negative populations and minimize spectral 
overlap.  Next, positive and negative compensation beads labelled with each 
antibody were acquired.  The automatic compensation function of FACSDIVA was 
used to calculate a compensation matrix.  
 
Effort was made to keep panels consistent for similar samples throughout the thesis.  
Repeating setup and compensation was necessary at least once for each panel due 
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to upgrade and repair of instruments.  Panels were revised when interim analyses or 
insights from literature strongly suggested that revision would provide new 
information.   
 
2.3.5 Controls 
 
Specific antigen expression was assessed by comparison with isotype or 
fluorescence-minus-one (FMO) controls.  An FMO control contains every antibody in 
the panel except the one being controlled for.  Both FMO and isotype controls are 
accepted methods of defining what is positive staining (Roederer, 2011).  When 
isotype controls were used, the concentration of isotype was matched to the protein 
concentration of the test antibody. 
 
2.3.6 Instruments, quality control and analysis 
 
Data were acquired on 2 or 3-laser BD FACS Cantos, a 5-laser BD LSRII or 5-laser 
BD Fortessa X20, all running FACSDIVA version 7.  Quality control was verified daily 
by core facility staff.  Data analysis was performed with FlowJo version 9.5.2 
(TreeStar). 
 
 
2.4 Microscopy 
 
2.4.1 Cytospin slide preparation 
 
Cells in suspension were applied to slides by centrifugation (Cytospin) to view 
morphology or use in fluorescence microscopy experiments.  Slides were prepared 
from single cell suspensions using a Thermo CytospinTM 4 cytocentrifuge and 
ShandonTM coated slides (Thermo, 5991059).  Up to 5x104 cells were prepared in 
100-200µl RF10, added to a funnel and centrifuged for 10 minutes at 500g.  Slides 
were carefully removed, dried at room temperature, then fixed and stored as required 
for downstream application. 
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2.4.2 May-Grünwald Giemsa (Giemsa) staining  
 
Samples for morphological inspection were stained with Giemsa.  Cytospin slides 
were fixed with 100% methanol for 2 minutes.  Automated staining was performed on 
an Advia S60 Autoslide System using Hematek Wright-Giemsa stain packs (Sigma).  
Coverslips were mounted with a mixture of distyrene, plasticizer and xylene (DPX) 
prior to microscopy. 
 
2.4.3 Fluorescence in situ hybridization (FISH)  
 
Cytospin slides were stored at -20°C and processed in batches.  Slides were thawed 
at 4°C for 30 minutes, then fixed with 4°C 100% methanol for 2 minutes.  Slides were 
fixed a second time in Carnoy’s solution (3:1 methanol: acetic acid) for 5 minutes.  A 
fluorescent probe mixture was applied to the slide and the coverslip was sealed with 
rubber glue.  The sample and probe were denatured and hybridized on a 
ThermoBrite system (Abbott).  After removing the coverslip, slides were washed in 
0.4x saline sodium citrate for 2 minutes at 72°C, and rinsed in 2x saline sodium 
citrate with 0.1% NP-40 for 30 seconds at room temperature.  Slides were mounted 
with DAPI anti-fade at least 30 minutes prior to microscopy.  
 
Two FISH kits were used.  Abbott’s chromosome enumeration probes targeted X 
chromosome locus Xp11.1-q11.1 and Y chromosome locus Yq12.  Probes were 
conjugated to SpectrumOrange (X) and SpectrumGreen (Y) fluorophores (Abbott, 
07J22-050).  Cytocell’s dual labeled probe sets targeted the same regions and were 
conjugated to a green fluorophore (X) and a red fluorophore (Y) (Cytocell, LPE 
0XYq). 
 
2.4.4 Microscope 
 
Slides were visualized on a Zeiss Axioimager II using AxioVision software.   
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2.5 Detection of secreted cytokines 
 
Two methods for detecting cytokines in solution were used.  Cytokine bead array 
(CBA) was used to detect a small set of inflammatory cytokines.  Multiplexed 
enzyme-linked immunosorbant assay (ELISA) (Luminex®) provided a more 
streamlined workflow when a larger number of analytes were required.  Both 
techniques employ specific cytokine-directed antibodies conjugated to beads and use 
small volumes of sample (50µl).  In CBA, the capture beads are combined with 
detection beads to generate complexes with specific fluorescence properties.  A flow 
cytometer such as a BD FACS Canto II is used for data acquisition.  Position on a 2D 
flow cytometry plot determines the identity of the analyte and the fluorescence 
intensity is used to infer concentration.  A Luminex assay is similar, except that 
beads are magnetic and reactions are performed in a 96-well plate.  A set of 
biotinylated detection antibodies binds streptavidin PE.  A Luminex dual laser 
analyser is required to assess bead position and fluorescence intensity.  In both 
methods, analyte concentration is determined with reference to a standard curve. 
 
2.5.1 Cytokine bead array  
 
Concentrations of TNF, IL-1β, IL-6, IL-8, IL-10 and IL-12p70 were measured using 
the BD Human Inflammatory Cytokine CBA kit  (BD, cat. 551811).  Supernatants 
were thawed to room temperature and diluted 1in5 with assay buffer.  Dilutions of 
standards were prepared as per the manufacturers instructions.  FACS tubes 
containing well-mixed capture beads were prepared for each standard concentration 
and all unknowns.  Supernatants/ standards and then PE-detection reagent were 
added to all tubes.  The samples were incubated in the dark at room temperature for 
3 hours, and washed before acquisition.  Data were acquired on a BD FACS Canto, 
recording a minimum of 200 events per analyte.  Data were imported into BD 
FCAPArray software version 2 for analysis.  Standard curves and bead counts were 
inspected and concentrations derived from the standard curve were exported into 
Microscoft Excel.   
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2.5.2 Multiplexed ELISA (Luminex) 
 
A multiplexed ELISA was used to simultaneously assess 34 cytokines and 
chemokines within a single sample (ProcartaPlexTM 34-plex, EBioscience) (Table 
2.1).  Capture antibody-conjugated beads were applied to a 96 well plate.  A titration 
of standards was prepared according to the manufacturers instructions.  For tissue 
culture supernatants, standards were diluted in RF10.  For BAL fluid, standards were 
diluted in universal assay buffer.  Standards and samples were added to the plate in 
duplicate or as neat and 1in10 dilutions.  The plate was incubated at room 
temperature for 2 hours on a shaker (500rpm).  Biotinylated detection antibodies, 
then streptavidin PE were applied for 30 minutes each, with wash steps following 
each incubation.  Magnetic beads were re-suspended by shaking the plate for 5 
minutes at 500rpm.  Captured analytes were detected on a Qiagen Liquichip 200 
running Luminex 100 integrated system software version 2.3.  Procartaplex Analyst 
version 1.0 was used to define standard curves and interpolate analyte 
concentrations.  
 
 
 
 
 
 
 
 
Table 2.1.  Cytokines and chemokines detected with the EBioscience 
ProcartaPlex Immunoassay (34-plex)  
 
Cytokines Cytokines ctd. Chemokines/ growth factors 
IFNα IL9 IL8 
IFNγ IL10 Eotaxin 
TNFα IL12p70 GROα (CXCL1) 
TNFβ IL13 IP-10 (CXCL10) 
IL1α IL15 MCP-1 (CCL2) 
IL1β IL17A MIP-1α (CCL3) 
IL1RA IL18 MIP-1β (CCL4) 
IL2 IL21 RANTES (CCL5) 
IL4 IL22 SDF-1α (CXCL12) 
IL5 IL23 GM-CSF 
IL6 IL27  
IL7 IL31  !
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2.6 NanoString gene expression analysis 
 
Gene expression analysis has become commonplace in the study of MPs.  
Numerous groups have demonstrated that MP subsets have distinct gene expression 
signatures and that signatures are conserved between species (Vu Manh et al., 
2015).  The combination of surface phenotyping, analysis of signature-gene 
expression and functional characterization is considered the most robust approach to 
studying MPs!(Vu Manh et al., 2015).  Gene expression data for this work were 
generated by NanoString. 
 
2.6.1 Overview of the technology 
 
NanoString nCounter® technology detects a set of messenger ribonucleic acids 
(mRNAs) within a sample.  Analysis is multiplexed, allowing simultaneous detection 
of up to 800 mRNAs.  For each mRNA, 50-base capture and detection probes are 
designed.  Following hybridization, the capture probes allow the mRNAs to be 
immobilized on a cartridge.  The detection probes contain individual barcodes to 
identify the mRNA.  Barcodes are digitally imaged giving a direct count of mRNA 
molecules per sample.  
 
The technology was chosen for this work as it can generate gene expression data 
from a small amount of starting material (<100ng total RNA).  Measurements offer 
similar sensitivity to real-time polymerase chain reaction (PCR) and better sensitivity 
than microarray.  Unlike real-time PCR, measurements are direct and free from 
amplification bias!(Geiss et al., 2008).  A sufficient number of genes are included to 
make clustering techniques developed for microarray plausible (Green K, 
unpublished communication).  However the data sets are not so large that they 
require specialist programming knowledge to manipulate.  One limitation of 
NanoString is that mRNAs are user-selected.  Unlike RNA sequencing, which offers 
an unbiased snapshot of all gene transcripts, NanoString can only detect what the 
experimenter asks it to.  
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2.6.2 Panel composition  
 
Two panels were used in this work:  an off-the-shelf Human Immunology v 2 panel 
and a custom modification of this panel (“panel plus”). 
 
The Human Immunology v 2 panel contained 579 genes related to immunology.  The 
panel plus contained the same 579 genes and an additional 30 genes relevant to 
differentiating MP subsets (Table 2.2).  The 30 genes were selected based on 
microarray data published by our group (Haniffa et al., 2012).  Kile Green, Muzlifah 
Haniffa and Venetia Bigley determined the panel plus composition. 
 
Both panels incorporated controls:  8 negative controls, 6 positive controls spanning 
a range of concentrations and an additional 15 housekeeping genes.  
 
2.6.3 Sample preparation 
 
FACS sorted leukocytes were pelleted by centrifugation at 8000g for 4 minutes in 
1.5ml eppendorf tubes.  Buffer was completely aspirated and the pellet stored at -
80°C for up to 2 years.  RNA was released by thawing pellets, adding RNA lysis 
buffer, pipetting vigorously and vortexing for 30 seconds.  The quantity of RNA lysis 
buffer for each sample was adjusted to yield up to 1x104 cells in 5µl.   
 
2.6.4 Hybridization and detection  
 
Reactions were performed in 12-tube PCR strips.  First, 5µl of each sample was 
added.  Next, a master-mix containing detection probes and hybridization buffer was 
prepared and 20µl used for each reaction.  Finally, 5µl capture probe per tube was 
added.  Samples were mixed by inversion only and centrifuged at speeds lower than 
1000g to avoid shearing the probes.  PCR strips were added to a thermocycler set to 
65°C for 12 to 30 hours. 
 
After hybridization, 12 samples at a time were processed using the NanoString Prep 
Station.  Cartridges were read on a NanoString Digital Analyzer to yield a Reporter 
Code Count (RCC) data set. 
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2.6.5 Quality control and data normalization  
 
Raw data were imported into nSolver Analysis software version 2.0.  Background 
correction subtracted the mean of 8 negative controls from each probe count.  A 
positive control normalization factor was computed from the geometric mean of 6 
positive controls.  This controlled for differences in technical variables across the 
samples e.g. hybridization and binding efficiency, but not for differences in RNA 
input.  A housekeeping gene content normalization factor was computed from the 
geometric mean of 15 housekeeping genes.  This controlled for differences in RNA 
input between samples.  Samples outside the normalization factor ranges (0.3-3 for 
positive control and 0.1-10 for housekeeping gene content) were flagged for further 
examination.  Samples outside the positive control ranges were not encountered.  
Samples with high content normalization factors were seen when sample input was 
low.  Typically, samples with factors >10 were outliers in further analysis.  These 
were either excluded or re-normalized and analyzed with reference to other low-input 
samples only.  
 
 
2.7 Statistical methods 
 
2.7.1 Comparing means and distributions 
 
Normality of data distribution was verified using the D’Agostino-Pearson test.  For 
normal data, unless otherwise-stated, up to two means were compared with two-
tailed unpaired t-tests.  More than two means were compared with one-way ANOVA.  
Post-test comparison methods varied with the experimental design e.g. comparing 3 
different controls to GvHD used the Dunnett test, comparing everything with 
everything used the Tukey test.  Multiple comparison corrections are inbuilt with 
these methods. 
 
For data with a non-Gaussian distribution, Mann-Whitney test was used to compare 
the means of up to two ranks.  Non-parametric ANOVA used Dunn’s multiple 
comparisons test. 
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For categorical outcomes, event counts were entered into contingency tables.  The 
observed distribution was compared with the expected using Fisher’s exact test and 
a two-tail p-value. 
 
A p-value of less than 0.05 was deemed statistically significant, but significance was 
considered within the remit of each experiment.  These analyses were performed 
using GraphPad Prism version 6.0.     
 
2.7.2 Dimension-reduction and clustering 
 
Dimension-reduction techniques are useful both to check for outliers and to identify 
patterns in gene expression.  Two techniques were used in this work: Principal 
Components Analysis (PCA) and Hierarchical Clustering.  Both were performed 
using MultiExperiment Viewer software version 4.8 (Saeed et al., 2003).  Data sets 
were log2 transformed prior to analysis. 
 
2.7.3 Gene-set enrichment analysis  
 
Gene-set enrichment analysis is a means of testing whether a defined set of genes is 
better represented in one sample or another.  For this work, gene sets were 
generated with the GeneSign function of BubbleGUM (Spinelli L, BM Genomics 
2015).  The BubbleMap function was used to test relative enrichment between pairs 
of samples. 
 
2.7.4 Functional annotation 
 
Standard descriptions of gene functions have been created by the Gene Ontology 
Consortium.  A wide variety of tools are available for assigning these “GO terms” to a 
set of query genes.  GeneMania was selected for this work as it has an accessible 
web-based interface and a capacity to expand query genes with predicted pathway 
partners!(Mostafavi et al., 2008).  This is a useful feature with a NanoString data set 
as not all potentially relevant genes are sampled.  
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2.7.5 Comparing average gene expression 
 
Gene expression averages for populations/ conditions were performed in 
MultiExperiment Viewer using unpaired t-tests with alpha=0.05.  Multiple comparison 
correction with the standard Bonferroni method was considered for all analyses.  The 
correction was used where stated.   
 
2.8 Buffers, reagents and consumables 
 
 
Table 2.3 Custom buffers and media 
Medium/ Buffer Principal buffer/ medium 
 
Additional reagents 
 
RF10 RPMI 1640  100IU/ml Penicillin  
10µg/ml Streptomycin 
L-glutamine, 2mM 
10% heat inactivated fetal calf serum (FCS) 
RH10 RPMI 1640 100IU/ml Penicillin  
10µg/ml Streptomycin  
2mM L-glutamine  
10% heat inactivated human AB serum 
Flow buffer PBS  2% FCS 
2mM EDTA 
Sort buffer PBS 0.1% FCS 
2mM EDTA 
RNA lysis buffer  Buffer RLT 1% beta-mercaptoethanol 
Red cell lysis buffer (10x) Sterile water 1.5M Ammonium chloride 
100mM Potassium bicarbonate  
1.2mM EDTA  
Freezing solution FCS (heat inactivated) 10% DMSO !
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Table 2.4 Cytokines, growth factors and enzymes 
 
Product Manufacturer  Stock concentration/ diluent Working concentration 
Dispase Gibco  83mg/ml 0.83 mg/ml 
Collagenase type IV Worthington  160mg/ml 1.6 mg/ml 
Recombinant human 
GM-CSF 
R&D  10 µg/ml 50-100 µl/ml 
Recombinant human 
M-CSF 
R&D  5 µg/ml 100 ng/ml 
Recombinant human 
IL-4 
ImmunoTools 
 
5 µg/ml 50 ng/µl 
LPS from E.coli 026:B6 Sigma  1 mg/ml 100 ng/ml 
Recombinant human 
IFNγ 
R&D  1 µg/ml 5 ng/ml 
!
Table 2.5 Consumables 
 
Item Source Item Source 
Polypropylene tubes (15/50ml) Cellstar, Greiner Trypan blue Invitrogen 
FACS tubes BD LymphoprepTM Stemcell technologies 
Cryovials Nunclon DAPI Partec 
Tissue culture flasks Bio-one, Greiner  DPX Sigma 
Tissue culture plates Cellstar, Greiner DAPI mounting medium Vector 
Cell strainers  BD RPMI 1640 Lonza 
Cell filters  Partec PBS Sigma 
EDTA blood collection tubes BD Sterile water Sigma 
MS columns Miltenyi FCS Sera Lab 
Eppendorf tubes Bio-one, Greiner Buffer RLT Qiagen 
  Human AB serum Sigma 
  EDTA Invitrogen 
  DMSO (dimethyl sulphoxide) Kocklight Ltd 
  Penicillin and streptomycin Invitrogen 
  L-glutamine Invitrogen !
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Chapter 3.  Mononuclear phagocytes in skin Graft-versus Host 
Disease 
 
3.1 Introduction 
 
Skin is the most frequently affected organ in acute GvHD (Ferrara et al., 2009).  In 
some situations, the extent of skin involvement is limited and the inflammation 
resolves with topical steroids and a therapeutic dose of calcineurin inhibitor.  In other 
cases, skin involvement can be extensive, resistant to high-dose systemic steroids 
and fatal.  Alternatively, disease may responds to steroids but recur when they are 
withdrawn, leading to substantial immunosuppression related morbidity and mortality.  
The biological processes underpinning these divergent clinical situations are poorly 
understood.  The diagnostic methods for stratifying disease are insensitive and the 
treatments available are limited and globally immunosuppresive. 
 
As outlined in Chapter 1, the importance of alloreactive T lymphocytes in GvHD 
pathogenesis is incontrovertible and T cell depletion offers significant protection 
against GvHD (Kottaridis et al., 2000).  GvHD still occurs in around 20% of patients 
profoundly lympho-depleted with Alemtuzumab (Kottaridis et al., 2000),!(Perez-Simon 
et al., 2002).  It is possible that accessory cells and additional effector mechanisms 
contribute to GvHD inflammation in the lymphopenic patient; mechanisms that may 
not be apparent in lymphocyte-rich murine models of GvHD.   Combining 
lymphocyte-directed with accessory cell-directed approaches may permit progress in 
GvHD prevention and treatment. 
 
MPs are prime candidates as accessory cells in GvHD.  Their role in initiating GvHD 
through alloreactive T cell priming is recognized, and host DCs are specifically 
implicated (Shlomchik et al., 1999),!(Duffner et al., 2004).  However, there is little 
consensus as to the specific cells responsible in humans, how they can be depleted, 
and whether there is therapeutic utility in doing so (Yuksel et al., 2006),!(Kreutz et al., 
2012).  GvHD following BMT for GATA-2 deficiency, where recipients have profound 
DC immunodeficiency, suggests this may not be a tractable approach (Grossman et 
al., 2014).  Greater consideration of MPs in maintaining GvHD is warranted.  
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The skin contains a rich complement of MPs (see section 1.3.2).  There is growing 
appreciation that they function in peripheral regulation of inflammation as well as 
migrating to lymphoid tissue and interacting with naïve T cells (Bennett and 
Chakraverty, 2012).  Both DCs and macrophages can re-stimulate effector T cells 
and secrete pro-inflammatory cytokines (Haniffa et al., 2009).  Macrophages can also 
release directly damaging factors, including reactive oxygen species, proteases and 
TNFα (Takemura and Werb, 1984).  
 
The macrophage content of GvHD lesions has been shown to correlate with disease 
severity in several patient cohorts (Nishiwaki et al., 2009), (Terakura et al., 2015).  In 
murine models, macrophages are tractable to manipulation with a consequent 
reduction in GvHD (Alexander et al., 2014), (Nishiwaki et al., 2014).  However, to 
propose macrophages as therapeutic target in GvHD requires a greater depth of 
knowledge.  At present, we do not know whether macrophages in GvHD lesions are 
resident or recruited, how they relate to other inflammatory and steady state MPs and 
what their functions are. 
 
In the existing literature, interpretative difficulties arise when inflammatory MPs are 
studied in isolation, studied without consideration for steady-state MPs specific to 
that tissue, and defined in way that prevent a cross-compartment or system-wide 
appreciation.  At present, we define the heterogeneity of the MPS based on an 
accepted set of surface antigens.  There is growing concern that this biases our 
understanding of cell populations and disguises functionally distinct subsets 
(Reynolds and Haniffa, 2015).  Lability of surface antigens during inflammation and 
the need to resolve resident from recruited subsets adds additional stress to this 
fragile framework.  The skin strand of this work aims to create a global picture of the 
MPS in GvHD and test the utility of a priori definitions in acute inflammation.  Specific 
attention will be focused on macrophages within the dermal infiltrate.   
 
3.2 Skin strand hypotheses 
 
1) The MP repertoire in GvHD lesional skin will be altered 
2) Inflammatory MPs derived from monocytes will be found in GvHD skin 
3) Inflammatory MPs will promote T cell-mediated skin damage 
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3.3 Chapter Aims 
 
3.3.1 Skin strand Aim 1:  To characterize the mononuclear phagocyte 
composition of GvH lesional skin. 
 
Acute skin rashes in BMT recipients at our centre are biopsied for histological 
confirmation of GvHD and exclusion of other pathologies such as drug reaction, viral 
exanthem or cutaneous relapse of malignancy.  Care is taken to biopsy as soon as 
possible after presentation and before initiation of treatment.  As typical biopsies are 
a 10-15mm2 skin shaves, we have sufficient material to divide for diagnostic histology 
and MP analysis.  Recognizing that not all acute rashes may be GvHD, diagnostic 
histology will be referenced.  Taking all presentations of rash will permit analysis 
across a large cohort: up to 90 cases in 3 years can be predicted from our transplant 
activity and GvHD incidence (Jardine et al., 2015).  Heterogeneity within the cohort is 
likely and concurrent clinical information will be essential to identifying subgroups.  
To separate the effects of GvHD from the effects of BMT on skin MPs, a BMT control 
cohort will be recruited.  Further comparison with steady state is possible using 
normal skin (mammoplasty or abdominoplasty surplus).  Within Aim 1 I will: 
 
• Identify the MPs present in GvHD lesions using multi-parameter flow 
cytometry. 
• Quantitate MPs and look for global patterns in MP composition. 
• Correlate MP composition with clinical features, including concurrent and 
outcome measures of disease severity (clinical grade, chronic GvHD incidence 
and severity). 
 
 
3.4 Materials and Methods for Chapter 3 
 
3.4.1 Patient samples 
 
Consent for blood and up to 3 skin shave biopsies was sought prior to BMT under 
ethical approval from Newcastle and North Tyneside 1 Research Ethics Committee.  
From August 2012-December 2015 77 samples were collected from 73 individuals 
presenting with acute rash post-BMT.  Shave biopsies 5-15mm2 were obtained via 
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DermabladeTM and transported in serum-free medium (X-VIVOTM).  A central 1-2mm 
strip was fixed in formalin for histological diagnosis.   
 
Control biopsies were collected from 19 BMT recipients at day 28 or day 100 post-
BMT, coinciding with the predicted onsets of acute and immunosuppression-
withdrawal (ISW) GVHD.   
 
Additional controls were sourced from normal skin obtained from 26 patients 
undergoing breast reduction or abdominoplasty.  Skin shave biopsies from 3 patients 
with acute eczema and 1 patient with cutaneous sarcoidosis were used as non-BMT 
inflammatory dermatosis controls. 
 
3.4.2 BMT regimens 
 
Patients received a regimen of chemotherapy with or without total body irradiation 
and immunosuppressive treatment.  Regimen was tailored to the disease, 
performance status and donor stem cell source in each case.  Conditioning regimens 
were grouped into categories as shown in Table 3.1 
 
 
Table 3.1 Conditioning regimens for BMT 
 
Group Regimen 
Reduced intensity 
conditioning, T-cell 
depleted (RIC-TCD) 
 
Flu/Mel (Fludarabine 150mg/m2, Melphalan 140mg/m2, Campath 30mg or 60mg, Ciclosporin) 
Flu/Bu (Fludarabine 150mg/m2, Busulfan 8-10mg/kg, Campath 30mg or 60mg, Ciclosporin) 
Flu/Bu/ATG/MMF (Fludarabine 150mg/m2, Busulfan 9.6mg/kg, ATG Fresenius 30mg/kg, MMF, 
Ciclosporin) 
Reduced intensity 
conditioning, T-cell 
replete (RIC-TR) 
Flu/Mel/Mtx (Fludarabine 150mg/m2, Melphalan 140mg/m2, Methotrexate 15mg/m2, Ciclosporin) 
Flu/TBI (Fludarabine 90mg/m2, 200cGy TBI, Methotrexate, MMF, Ciclosporin) 
Pre-conditioned  
 
FLAMSA-Flu/Bu/ATG/MMF (Fludarabine 120mg/m2, Cytarabine 8g/m2, Amsacrine 400mg m2, 
Fludarabine 60mg/m2, Busulfan 9.6mg/kg, ATG rabbit 5mg/kg, MMF, Ciclosporin) 
FLAMSA-TBI/ATG/MMF (Fludarabine 120mg/m2, Cytarabine 8g/m2, Amsacrine 400mg m2, 4Gy 
TBI, ATG rabbit 5mg/kg, MMF, Ciclosporin) 
FLAMSA-TBI/Cy (Fludarabine 120mg/m2, Cytarabine 8g/m2, Amsacrine 400mg m2, 4Gy TBI, 
Cyclophosphamide 80mg/kg, Campath 30-60mg) 
Myeloablative 
 
Cy/TBI (12Gy TBI, Cyclophosphamide 120mg/kg, Campath 30-60mg, Ciclosporin) 
MAC Haplo (12Gy TBI, donor lymphocyte infusion, Cyclophosphamide 120mg/kg, Ciclosporin, 
MMF) 
Other 
 
RIC haplo (Fludarabine 150mg/m2, Cyclophosphamide 29mg/kg, 200cGy TBI, post-transplant 
Cyclophosphamide 100mg/kg, Tacrolimus, MMF) 
RIC cord (Cyclophosphamide 50mg/kg, Fludarabine 200mg/m2, TBI 200cGy, MMF, Ciclosporin) !
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3.4.3 Clinical data 
 
Patient, donor and transplant characteristics relevant to GvHD risk were collected 
from registry data (patient age, transplant indication, donor type, HLA match, gender 
match, conditioning regimen).  On receipt of biopsy, data were recorded on time 
post-transplant, current immunosuppression use and blood parameters (white cell 
count and differential, c-reactive protein (CRP), ciclosporin level).  GvHD skin stage 
and treatment were taken from medical records.  Skin stage, according to modified 
Glucksberg criteria (Table 1.2), was usually stated.  In some cases, stage had to be 
inferred from written descriptions using the rule of nines (e.g. rash on face and upper 
arms equates to 13.5% surface involvement and is skin stage 1).   
 
Outcome data were completed for 66 participants and 19 controls that reached 1 
year or died within the first year post-transplant.  Outcome data for 5 participants was 
recorded at 6 months, but 1 participant was transplanted too late in the study period 
for sufficient follow-up.  Outcome data included maximum severity of acute GvHD 
(modified Glucksberg grade), organs involved in acute GvHD, presence or absence 
of chronic GvHD, National Institutes of Health (NIH) cGvHD working group score 
(mild /moderate/ severe), date of death or follow-up and cause of death. 
 
Formalin fixed samples were examined by an independent consultant 
Histopathologist and graded according to Lerner’s criteria (Table 1.3).  Formal 
diagnostic reports were used to obtain categorical data on diagnosis and severity 
grading.   
 
3.4.4 Cohort characteristics 
 
The GvHD and BMT control cohorts were well matched in terms of patient, donor and 
transplant characteristics (Table 3.2).  White cell counts and differentials at the time 
of biopsy were not significantly different, though relatively increased lymphocyte, 
eosinophil and monocyte counts were seen in a small number of GVH participants 
(data not shown).  CRP was significantly higher in patients presenting with GVH than 
BMT controls (means 35mg/L and 10mg/L respectively). 
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Table 3.1 Cohort characteristics 
 
Categories highlighted in the same colour were grouped together for chi-
squared analysis in order to meet assumptions of the test.  
 
In the GvHD cohort, acute and ISW presentations were equally sampled, each 
representing 40% of cases (Figure 3.1).  Seventeen percent of cases occurred after 
DLI, and 3% were acute flares on a background of chronic GVHD.  The majority of 
specimens were taken from patients on no immunosuppression or ciclosporin 
monotherapy (92%).  The remaining samples were taken from patients presenting 
with rash through topical steroids or low dose oral prednisolone (<10mg).  There 
were no patients on combined immunosuppression at the time of biopsy.  Almost half 
of all patients presented with widespread rash equating to skin stage 3.  
Histologically, most rashes were graded at low severity (72% grade I and II).  There 
was little correlation between the clinical and histological severity of skin involvement.  
!
Table 3.2 Cohort characteristics 
 
 GVH BMT control p value 
Age; mean (SD) 54 (12)  52 (12) 0.53 
unpaired t test 
Disease; n (%) 
Acute leukemia 
Myelodysplasia 
Lymphoma 
Myeloma 
CLL 
Myeloproliferative 
neoplasms  
 
34 (44) 
13 (17) 
19 (25) 
5 (7) 
3 (4) 
3 (4) 
 
11 (58) 
1 (5) 
4 (21) 
1 (5) 
0 (0) 
2 (11) 
 
0.55 
Chi-square 
Donor type; n (%) 
MRD 
MUD 
Other 
 
19 (25) 
55 (71) 
3 (4) 
 
3 (16) 
16 (84) 
0 (0) 
 
0.41 
Chi-square 
 
Conditioning; n (%) 
RIC-TCD 
RIC-TR 
Pre-conditioned 
MAC 
Other 
 
61 (79) 
6 (8) 
6 (8) 
2 (3) 
2 (3) 
 
14 (74) 
1 (5) 
3 (16) 
1 (5) 
0 (0) 
 
 
0.39 
Chi-square  
Blood parameters 
*109/L; mean (SD) 
WCC  
Neutrophils  
Monocytes 
Lymphocytes 
Eosinophils 
 
CRP 
mg/L; mean (SD) 
 
Ciclosporin level; 
µg/L mean (SD) 
 
 
4.89 (3.86) 
2.91 (2.02) 
0.65 (0.43) 
0.10 (2.12) 
0.36 (0.71) 
 
 
35 (48) 
 
 
120 (146) 
 
 
3.61 (2.23) 
2.38 (1.52) 
0.54  (0.45) 
0.47 (0.49) 
0.20 (0.25) 
 
 
9.7 (8.9) 
 
 
159 (123) 
 
 
0.17 
0.30 
0.35 
0.29 
0.32 
 
 
0.03 
 
 
0.37 
Unpaired t test 
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Figure 3.1 GvHD cohort characteristics 
 
A) Time of onset of GvHD post-BMT.  Each participant is indicated by a 
dash.  Presentations are separated into acute, immunosuppression 
withdrawal (ISW), post- donor lymphocyte infusion (post DLI) and acute-on 
chronic presentations (chronic).   
B) Proportion of patients receiving immunosuppression at the time of 
biopsy.  Top steroid= topical steroid  (typically 0.1% betamethasone). 
C) Frequency of Glucksberg skin stage 1-4.   
D) Frequency of Lerner grades I-IV on diagnostic histology of skin 
biopsies.  Other diagnoses: C=chronic GvHD, D=drug reaction, 
E=eczema, R=relapsed disease, NS=no significant pathology. 
 
 
3.4.5 Diagnostic histology  
 
Samples were obtained and processed as soon as possible after presentation.  
Pathological confirmation of diagnosis took 2-3 days.  Fourteen biopsies (18%) were 
given non-GvHD diagnoses (1 relapsed lymphoma, 5 eczema, 6 drug reaction and 2 
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no significant pathology).  There was diagnostic uncertainty in several cases (Figure 
3.2).   
 
The diagnostic decision leaned towards “drug reaction” if eosinophils were present, 
even though this is an unreliable method for separating the conditions (Sharon et al., 
2012).  Four of the patients with a ‘drug reaction’ biopsy had clinical significant and 
persistent GvHD either at the time of biopsy or on subsequent immunosuppression 
withdrawal.   
 
The diagnostic decision leaned towards “eczema” if epidermal thickening 
(acanthosis) was present and intercellular oedema (spongiosis) was marked.  Most 
of the patients with eczema diagnoses had a single flare of inflammation responsive 
to topical steroid, but onset of the flare tended to correlate with immunosuppression 
withdrawal.    
 
 
 
Figure 3.2 Examples of non-GvHD diagnoses and diagnostic 
uncertainty in histology 
 
Full histology reports for 3 individuals where diagnosis was uncertain.  
Headings in bold are the diagnoses assigned for the purpose of this work.  
Key terms are highlighted. 
Figure 3.2 Examples of non-GvHD diagnoses and diagnostic uncertainty in histology  !
Drug reaction 
“Sections show skin with mild perivascular infiltrates in the upper dermis, containing lymphocytes, a lesser proportion of 
eosinophils and occasional mast cells. The epidermis is generally of normal thickness, with foci of spongiosis, including a 
spongiotic vesicle, acanthosis and exocytosis of lymphocytes. Occasional dyskeratotic cells are seen within this region, some 
above the basal layer. The inflammatory process also affects hair follicle epithelium, where dyskeratotic cells are also seen.   
The appearances are those of a combination of spongiotic and lichenoid changes associated with eosinophil-rich inflammation. 
While this could represent graft versus host disease, the presence of eosinophils is unusual, and more in keeping with a 
lichenoid drug eruption. Clinico-pathological correlation is suggested.” 
Eczema                
“Sections show a superficial biopsy of skin in which the epidermis exhibits parakeratosis, acanthosis and moderate to severe 
spongiosis. Occasional dyskeratotic cells are also present, but there is no clear evidence of hydropic degeneration of the basal 
layer. Spongiotic vesicle formation is present. The dermis appears oedematous, with a light lymphohistiocytic inflammatory 
infiltrate and scattered pigment incontinence. Eosinophils are not apparent, although there is little included dermis.  
The changes are primarily those of a moderately severe subacute spongiotic dermatitis, in keeping with an eczematous 
reaction. The presence of dyskeratosis may indicate a drug aetiology; in the absence of hydropic change, it is less likely to 
represent coexisting graft versus host disease.”    
GvHD  
“Sections show skin with epidermis and dermis. The epidermis appears acanthotic and spongiotic. There is exocytosis of 
lymphocytes with occasional dyskeratotic keratinocytes. Within the papillary dermis some oedema is noted, with mild 
perivascular chronic inflammation with moderate numbers of dermal eosinophils.   
The differential diagnosis includes eczematoid graft versus host disease and eczema, presence of eosinophils also raise 
possibility of allergic /drug aetiology.  Clinical correlation is recommended.” 
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As samples could not be reliably excluded based on pathological diagnosis, all were 
considered in primary analysis.  Non-GvHD diagnoses were classified GvHD grade 
0.   
 
3.4.6 Tissue processing  
 
Plastic surgery skin included reticular dermis to the depth of the fat layer.  The first 
step in processing was to prepare skin shaves comparable to the clinical biopsies.  
Skin was immobilized on a cork block covered with sterile silicon and approximately 
15mm2 skin shaves were performed using a DermaBlade®.  When a larger sample 
was required, the upper 200 microns of skin were harvested using a split skin graft 
knife.      
 
Skin shave biopsies were used whole or split into dermis and epidermis.  To release 
the epidermis, skin was cultured in X-VIVOTM (Lonza) with 830µg dispase for 60-90 
minutes at 37°C and 5%CO2 and then peeled under a dissection microscope.   At the 
beginning of the study period, fewer parameters were available on the flow 
cytometer/ sorter.  Dermis was therefore preferred as it removed LCs from analysis.  
Whole skin was used later in the study period, when parameters to identify LCs 
became available. 
 
Dermis or whole skin was digested in RF10 with 1.6mg/ml type IV collagenase for 
12-16 hours at 37°C and 5%CO2.  Shave biopsies were digested in 500µl RF10 in 
one well of a 24 well plate.  Larger plastic surgery preparations were digested in 1-2 
90mm2 petri dishes containing 30ml RF10 each.  Digest was passed repeatedly 
through a 1ml pipette (10ml for large plastic surgery skin preparations) until no visible 
material remained.  To yield a single cell suspension, digest was passed through a 
100-micron filter into a polypropylene sorting tube.  The well/ plate was washed twice 
using cold sort buffer without calcium or magnesium to collect residual and adherent 
cells.    
 
For some experiments, an enzyme-free preparation of leukocytes was required.  Skin 
was cultured as above but without collagenase.  After 48 hours, migratory leukocytes 
were harvested from the supernatant. 
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3.4.7 Sample preparation 
 
Dermal suspensions were processed immediately as yield was insufficient to recover 
after cryopreservation.  Single cell suspensions were prepared for flow cytometry/ 
flow sorting as outlined in section 2.3.1.  Antibody panels for sorting are detailed in 
Table 3.3.  Four different panels were used during the study period as experiments 
transitioned from flow analysis to flow sorting and instruments were updated.   While 
the core of the panel was conserved, fluorochrome choice was adapted to the 
specifications of each instrument. 
 
 
 
Table 3.3 Flow cytometry panels used for sorting/ analyzing biopsy 
digests 
 
Combinations of antibodies used to define populations in skin digests.  
Antibody supplier details are listed in Appendix B. PERCP= peridinin 
chlorophyll protein, Cy= Cyanine, BV= Brilliant violetTM, AF= Alexa FluorTM. 
 
 
 
 
 
 
Table 3.3 Flow cytometry panels used for sorting/ analysing biopsy digests 
 
Analysis panel 1- LSR II, 12.2012-04.2014  Sort panel 1- Aria, 05.2013-07.2013 
Antigen Fluorochrome    Antigen Fluorochrome 
CD3, 19, 20 56 FITC AF in FITC channel 
Test PE CD14 PE 
CD123 PERCPCY5.5 HLA-DR PERCPCY5.5 
CD1c  PECy7 CD1c PECy7 
HLA-DR V450   
CD45  V500 CD45  V500 
CD14  BV650   
CD141 APC CD11c APC 
CD11c AF700 CD1a AF700 
CD16 APCH7 CD16 APCH7 
DAPI  DAPI  
 
Sort panel 2- Aria 07.2013-12.2013 Analysis/ Sort panel 3- Fusion and X20 12.2014-12.2015 
Antigen Fluorochrome Antigen Fluorochrome 
AF in FITC channel AF ± CD3 FITC 
Test PE CD8 or 141 PE 
CD123 PERCPCY5.5 CD123 PERCPCY5.5 
CD1c  PECy7 CD1c  PECy7 
 V450 HLA-DR V450 
CD45 V500 CD45 V500 
CD14 BV650 CD14 BV650 
CD141 APC CD11b or 141  APC 
HLA-DR AF700   
CD11c APCH7 CD11c APCH7 
DAPI  DAPI  !
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3.5 Results for Chapter 3 
 
3.5.1. Analysis strategy for identifying skin mononuclear phagocytes by flow 
cytometry 
 
An analysis strategy was required that identified the 2 macrophage and 2 DC 
populations in normal dermis and could also be applied to inflamed skin without 
arbitrarily dividing inflammatory populations (Figure 3.3, panel A-B).   
 
First, live cells were gated as DAPI- events with forward scatter (FSC) >50,000.  
Events with lower FSC were debris such as erythrocytes and cell fragments.  They 
were numerous in analysis files as FSC thresholds were not used for FACS sorting.  
This was necessary to ensure that debris was not sorted into tubes. 
 
Doublets were excluded from the live cell gate by comparing side-scatter (SSC) 
height and SSC area.  Cells passing through the laser singly had equivalent height 
and area but cells passing through in pairs had a greater area.  While the height to 
area ratio for single lymphocytes was 1:1, the relationship for macrophages was <1.  
Stringency of the single cell discrimination gate was adjusted so that macrophages 
were not being removed from further analysis. 
 
Next, leukocytes were separated from other dermal populations such as fibroblasts, 
keratinocytes and endothelial cells by CD45 expression.  This was necessary as 
some CD45-negative cells expressed HLA-DR and would otherwise enter 
macrophage/ DC analysis. 
 
Leukocytes were split by HLA-DR and SSC into macrophages/ DCs and 
lymphocytes.  While a proportion of lymphocytes expressed HLA-DR in both normal 
and inflamed skin, consistent with an activated phenotype, expression was never so 
high as in macrophages/ DCs.  Lower SSC in lymphocytes helped refine this 
distinction. 
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Figure 3.3 Analysis strategy for identifying skin mononuclear 
phagocytes by flow cytometry 
 
Representative plots of digested dermis from normal skin (A) and GvHD 
lesion (B) are gated with the analysis strategy described in section 3.5.1.  
Alternative gating of macrophages using autofluorescence is shown for 
comparison.  Black polygons are intermediate gates in the hierarchy.  The 
gating process is depicted by arrows.  Coloured polygons are terminal 
gates that define populations.   
Macrophage populations identified in normal skin (C) and GvHD lesion (D) 
are compared in terms of scatter properties and autofluorescence.  
Lymphocytes are included for reference. 
FSC/ FSC-A= forward scatter (area), SSC-A= side scatter area, SSC-H= 
side scatter height, AF=autofluorescence 
 
Previous gating strategies have relied upon autofluorescence (AF) and SSC to 
separate HLA-DR+ cells into dermal macrophages and DCs/ CD14 MDM (Haniffa et 
al., 2009),!(Haniffa et al., 2012),!(McGovern et al., 2014).  This strategy did not work 
well in inflamed skin as cells with intermediate AF and SSC dominated the HLA-DR+ 
gate.  An alternative strategy was devised using CD14 and CD11c.  In normal skin, 
dermal macrophages could be identified as CD11c- CD14+ cells.  High AF and SSC 
were confirmed (Figure 3.3, panel C-D).  In inflammation, the CD11c- CD14+ 
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parameter space was sparsely populated because HLA-DR+ cells were 
predominantly CD11c+.  The few cells within the CD11c- CD14+ gate had equivalent 
AF and SSC to dermal macrophages.  In contrast, the CD11c+ CD14+ cells had 
lower AF and SSC than dermal macrophages.  The identity of the CD11c+ CD14+ 
cells in inflammation will be fully explored in later sections.  Regarding the scarcity of 
dermal macrophages in inflammation, it is possible that they enter the CD11c+ 
CD14+ parameter space by up-regulating CD11c.  Proliferation and cell division 
could also reduce SSC and AF.  Whole-mount microscopy of GvHD dermis does not 
identify CD11c on FXIIIa+ cells (Wang et al., 2014).   
 
In normal skin, the CD11c+ gate can be split by CD14 and CD1c expression into 
CD14 MDMs and CD1c+ myeloid DCs (cDC2).  Cells co-expressing CD14 and CD1c 
are frequently seen, but as they have not been adequately identified as DCs or 
macrophages to date, they are assigned a separate analysis gate.  
 
Within the CD14-CD11c- gate in normal skin, cDC1 are defined as CD141+ cells.  
They are known to have variable CD1c expression (Haniffa et al., 2012).  The 
CD141-CD1c+ population are consistent with the phenotype of Langerhans cells 
(Bigley et al., 2015).  In keeping with this, increased CD141-CD1c+ cells were 
present in specimens where the epidermis was difficult to remove or when whole skin 
was analyzed.   
 
3.5.2 Myeloid DC gates capture differences in steady state and inflammation 
 
Comparison between CD14 MDM in normal dermis and CD11c+CD14+ cells in 
GvHD is described in subsequent sections.  Comparison between myeloid DC 
populations in steady state and inflammation is not explored in such detail.  However, 
limited antigen analysis by FACS provides some insight (Figure 3.4). !
In inflamed skin, cells falling in the CD141+ parameter space were not consistent 
with cDC1.  They had lower expression of CD1c and CD141 and had scatter 
properties typical of lymphocytes (Figure 3.4, panel B).  CD141+ cells were back-
gated onto the HLA-DR versus SSC-A plot to see if analysis had unwittingly included 
lymphocytes.  CD141+ cells were distinct from the majority of lymphocytes due to 
higher HLA-DR expression.  Furthermore, the mean fluorescence intensity of CD141 
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in this population was >1000 fold higher than in lymphocytes (data not shown).  The 
possibility that these cells were pDC was considered.  While absent from steady-
state dermis, pDC are found in psoriasis-inflamed skin (Haniffa et al., 2015b).  There 
are no comprehensive descriptions of pDC surface phenotype in inflamed skin.  In 
blood, pDC have equivalent HLA-DR expression to myeloid DCs and higher CD123 
expression (Jardine et al., 2013).  CD141+ cells in GvHD skin did not fit this 
description.  Their lower expression of HLA-DR and lower SSC compared with total 
HLA-DR+ cells is reminiscent of blood monocytes simultaneously analyzed with 
dermal digest (McGovern et al., 2014).  CD141 expression on monocyte-derived cells 
is acknowledged (Haniffa et al., 2012).  However, these cells were definitely CD14 
negative, arguing against them being blood monocytes.  My impression is that 
CD141+ cells in inflammation may be cDC1 either recently recruited from blood or 
blocked from adopting a normal phenotype on recruitment due to the inflammatory 
milieu.  This hypothesis was not tested to due to the constraints of what is achievable 
with limited samples and the small numbers of these cells present.   To reflect this 
uncertainty, they will be referred to as CD11c-CD141+ cells, not cDC1, in subsequent 
sections. 
 
 
 
Figure 3.4 Myeloid DC gates capture differences in steady state and 
inflammation 
 
(A) Scatter properties and selected antigen expression of myeloid DC 
populations from normal dermis.  Populations are gated as in Figure 3.3 
and compared with dermal lymphocytes.  B) Populations from myeloid DC 
gates in GvHD dermis are compared with GvHD lymphocytes. 
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In inflamed skin, cells falling within the cDC2 parameter space were less obviously 
different from their steady state counterparts.  The sort panel including CD1a 
antibody, used on only 3 GvHD specimens, identified reduced frequency of CD1a+ 
cells.  The mean percentage of CD1a+ cells in the GvHD cDC2 gate was 45% (± 
standard deviation (SD) 7.2).  Only one normal skin sample was sorted with this 
panel, but in keeping with previous reports, cDC2 were >99% CD1a+ (Haniffa et al., 
2009).  As blood cDC2 are CD1a negative (Segura et al., 2013), this would also be 
consistent with recent recruitment/ impaired tissue differentiation of blood cDC2.  A 
full characterization of differences between steady state and inflamed skin cDC2 is 
warranted but has not been performed in this thesis.  Cells within the cDC2 gate in 
inflamed skin will be termed CD14-CD1c+ cells to reflect their incomplete 
characterization. 
 
3.5.3 Mononuclear phagocyte profile comparison between GvH lesion, BMT 
control, and inflammatory dermatoses 
 
Using the analysis strategy outlined in 3.5.1, the MP profile of a typical acute GvHD 
lesion was qualitatively compared with controls (Figure 3.5).  The GvHD biopsy was 
taken from a 43-year old female presenting with acute rash 22 days following a RIC-
TCD transplant for ALL from an unrelated donor.  The BMT control was from a 59-
year old female, 40 days following an equivalent transplant (same conditioning, 
indication and donor-type).  Cutaneous sarcoidosis and eczema were acute 
presentations at a tertiary referral dermatology clinic. 
 
Comparing GvHD to BMT control, the GvHD lesion was more leukocyte-rich (Figure 
3.5 A-B).  HLA-DR+ MPs outnumbered lymphocytes in both.  The lymphocyte: HLA-
DR+ ratios were similar  (30:60 in GVHD and 23:67 in BMT control) but GvHD 
lymphocytes had higher HLA-DR expression.  Amongst HLA-DR+ cells, 
CD11c+CD14+ were most prominent in GvHD and CD1c+ cells were relatively 
depleted.  The (CD11c+) CD14:CD1c ratio in GvHD was essentially reversed 
compared with BMT control (76:11 in GVHD and 20:60 in BMT). 
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Figure 3.5 FACS analysis of GvHD lesion, BMT control and 
inflammatory dermatoses 
 
FACS profile of digested material from A) acute GvHD lesion, B) BMT 
control, C) cutaneous sarcoid lesion and D) atopic dermatitis/ eczema 
lesion.  A and D are dermal digests; C and D are whole-skin digests.  The 
analysis strategy from Figure 3.3/ section 3.5.1 is used. 
 
Inflammatory dermatosis controls were used to examine whether the profile 
associated with GvHD was specific.  Eczema and sarcoidosis were selected as 
conditions associated with DC-rich and macrophage-rich inflammation respectively.  
The characteristic feature of cutaneous sarcoid lesions is the presence of non-
caseating granulomas.  Within sarcoid lesions, monocyte recruitment and IFNγ 
priming of macrophages by Th1 lymphocytes is recognized (Valeyre et al., 2014).  
Within eczematous lesions, myeloid DCs and pDCs have been described (Stary et 
al., 2005)!(Bieber et al., 2000),!(Wollenberg et al., 2002a),!(Wollenberg et al., 2002b).  
The sarcoid lesion had a prominent CD11c+CD14+ population (Figure 3.5, panel C).  
The CD14:CD1c ratio was higher than normal (54:28), but not as extreme as in 
GvHD.  The proportion of CD11c-CD14+ cells in eczema was greater than normal, 
but not so marked as in GvHD or sarcoidosis (Figure 3.5, panel D).  In the eczema 
example shown, the CD141+ gate appeared normal, with numerous cells and well-
Figure 3.5 FACS analysis of GvHD lesion, BMT control and inflammatory 
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distributed CD1c expression.  The sarcoid CD141+ gate had relatively few cells in 
proportion to the number of events, and as seen in GvHD, most cells were CD1c-. 
 
While heavily focused on representative examples, this analysis has highlighted that 
GvHD incurs a pattern of changes in MPs.  Some of these changes are shared with 
cutaneous sarcoidosis.  
 
3.5.4 Quantification of mononuclear phagocytes in GvHD lesions and controls 
 
The flow cytometry gating strategy detailed in 3.5.1 was used as a basis for 
quantitating MP subsets in GvHD lesions relative to BMT control and normal skin.  
Flow cytometry counted absolute events in the specimen (each event is a single cell) 
and percentage of cells as a proportion of the parent gate in the hierarchy.  The 
appropriate denominator for quantitation was considered at length.  The ideal 
quantitation would be MP subset number per area of affected skin.  Biopsy area was 
measured on graph paper prior to processing.  Mean area was 10 mm2 for both 
GvHD and BMT specimens.  This measure did not take into account thickness of the 
specimen, which varied substantially between patients and clinicians performing the 
biopsy.  Histologically, GvHD damage to the dermo-epidermal junction was not 
uniform (Appendix C), so biopsy area would not necessarily correlate with affected 
area.  It was decided that the measure least biased to sampling variability would be 
% of CD45+ cells.   
 
As detailed in section 3.4.5, diagnostic histology was ambiguous in a number of 
cases.  In this analysis, all samples that had been processed by digestion were 
included under the clinical descriptor “GvHD”.  By histology, this included 36 GvHD, 5 
drug reactions, 1 chronic GvHD, 3 eczema and 2 non-specific changes.  Controls 
included 20 BMT recipients with rash and 21 healthy skin donors. 
 
As shown in Figure 3.6, panel A, CD45+ leukocytes were a greater proportion of the 
dermal suspension in GvHD than in BMT or controls (mean ± SEM respectively 53.0 
± 3.5, 39.0 ± 4.3, 30.2 ± 2.8).   Lymphocytes were a similar percentage of CD45+ 
cells in GvHD and controls (data not shown).  Taking this information together, MP 
subsets occupying a higher proportion of CD45+ cells in GvHD are likely to be even 
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more enriched in absolute numbers.  MP subsets occupying a lower percentage of 
CD45+ cells may still be present at greater numbers than in controls.  
 
The only population significantly enriched in GvHD was CD11c+CD14+ (Figure 3.6, 
panel B).  Both CD11c-CD14+ and CD11c+CD1c+ populations were reduced in 
GvHD (Figure 3.6, panels C and E).  There was heterogeneity in the degree of 
enrichment/ depletion.  
 
 
 
Figure 3.6 MP quantification in GvHD lesions and controls 
 
Quantification of dermal leukocyte populations in digested GvHD dermis, 
BMT control skin and normal skin by flow cytometry.  A) Total leukocytes 
as a percentage of live cells.  B-F) MP populations as a percentage of total 
leukocytes.  Bars show mean ± SEM.  Comparison of means by 1-way 
ANOVA and post-tests * p<0.05, **p<0.01, ***p<0.005, ****p<0.001.  
Where no * is shown, comparison was not significant. 
 
 
3.5.5 Elevated CD14:CD1c ratio marks GvHD of greater severity 
 
Knowledge of the MP profile in GvHD was used to split the cohort in order to explore 
factors underlying the heterogeneity in population numbers. 
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As demonstrated in Figure 3.3 and 3.5, GvHD inflammation is typified by a reversal in 
the CD14:CD1c ratio compared with normal skin.  Mean ratios were 0.35 and 0.19 in 
BMT control and normal skin respectively.  In inflammatory dermatoses, the mean 
ratio was higher (2.1), but not so high as in GvHD (13.7).  The GvHD cohort (clinical 
descriptor) was divided into samples with a CD14:CD1c ratio greater than or less 
than 1 (Figure 3.7, panel B).  This cutoff was chosen because the sum of sensitivity 
and specificity at this point was maximal (sensitivity 80%, specificity 88%, area under 
the curve 0.88) when discriminating histologically confirmed GvHD from BMT control 
(Figure 3.7, panel A).  
 
 
 
Figure 3.7 Elevated CD14:CD1c ratio marks GvHD of greater severity 
 
A) ROC curve of CD14:CD1c ratio in histologically confirmed GvHD cases 
versus BMT controls.  Dashed line shows sensitivity and 100-specificity at 
ratio=1.  B) CD14:CD1c ratio in GvHD lesions and controls determined by 
FACS analysis.  Boxes indicate GvHD cohort division into ratio>1 (n=37 
and ratio <1 n=15).  C,D) GvHD presentation characteristics and E,F) 
GvHD outcome characteristics compared between cohort groups.  Colour-
coded categories, as stated in legends, include histology diagnosis, skin 
stage at presentation (Glucksberg criteria), maximum GvHD grade post 
BMT (Glucksberg criteria), and chronic GVHD severity (NIH score).  ‘IS’ 
denotes not scored as systemic immune suppression ongoing. 
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Fifteen out of 62 samples in the GvHD cohort (clinical descriptor) had a ratio <1 
(mean 0.45) and 47 out of 52 had a ratio >1 (mean 19.0 excluding the 3 samples 
where ratio could not be calculated as no CD1c+ cells were present).  Groups were 
termed “normal CD14:CD1c” and “high CD14:CD1c”.  More samples with a non-
GvHD diagnosis fell within the normal CD14:CD1c group (Figure 3.7, panel C).  
Considering only patients with a GvHD diagnosis, the normal CD14:CD1c group had 
less extensive rash at presentation (Figure 3.7, panel D).  During the entire follow-up 
period, patients in the normal CD14:CD1c group experienced a lower severity of 
GvHD (Figure 3.7, panel E) and a reduced burden of chronic GVHD (Figure 3.7, 
panel F).  Statistical analysis of these trends is shown in Table 3.4.  The sample size 
becomes too small for statistical comparison when considering chronic GvHD.  Few 
patients could be analyzed because a proportion died before the 1-year/ 6-month 
chronic GvHD assessment.  Mortality was 40% in the high CD14:CD1c ratio group 
and 20% in the normal CD14:CD1c ratio group (Fisher’s exact test p=0.11).  In both 
groups, 40% of patients could not be accurately assigned a chronic GvHD grade as 
systemic immune suppression was ongoing.  In keeping with the trend for a lower 
severity of GvHD in the normal CD14:CD1c ratio group, no patients in this group 
experienced moderate or severe chronic GvHD, while 20% of patients in the high 
CD14:CD1c ratio group did. 
 
 
Table 3.4 Contingency tests on GvHD severity measures split by CD14:CD1c ratio  
 
  Outcome A (n) Outcome B (n) Significance 
(Fisher’s exact test) 
Pathology diagnosis 
(all with clinical GvHD, 
n=62) 
 Histology did not confirm GvHD Histology confirmed GvHD  
Normal 14:1c 6 9 p=0.018 * 
High  
14:1c 
5 42 
Skin stage 
(all with clinical GvHD, 
n=62) 
 Stage 1 Stages 2-4  
Normal 14:1c 9 6 p=0.007 ** 
High  
14:1c 
13 34 
Skin stage 
(histologically confirmed 
GvHD, n=52) 
 Stage 1 Stages 2-4  
Normal 14:1c 5 4 p=0.099 ns 
High  
14:1c 
10 33 
Max. GvH grade 
(all with clinical GvHD, 
n=62) 
 Grade I Grades II-IV  
Normal 14:1c 9 6 p=0.026 * 
High  
14:1c 
12 35 
Max. GvH grade  
(histologically confirmed 
GvHD, n=52) 
 Grade I Grades II-IV  
Normal 14:1c 5 4 p=0.099 ns 
High  
14:1c 
10 33 
Chronic GvH  
(all with clinical GvHD alive 
at 12 months, n=24) 
 None/ mild Mod/ severe  
Normal 14:1c 7 0 p=0.146 ns 
High  
14:1c 
12 5 
Chronic GvH  
(all with histologically 
confirmed GvHD alive at 12 
months, n=19) 
 None/ mild Mod/ severe  
Normal 14:1c 4 0 p=0.530 ns 
High  
14:1c 
10 5 
 !
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3.5.6 Clinical features do not cluster by CD14:CD1c ratio groups 
 
Further consideration was given as to whether the 9 patients with a histological 
diagnosis of GvHD and a normal CD14:CD1c ratio had common features.   Clinical 
and transplant variables were compared between these patients and the 35 patients 
with histological GvHD and an elevated CD14:CD1c ratio.  Formal multivariate 
analysis such as binary logistic regression was not possible with the sample size.  To 
examine patterns in variables and associations with CD14:CD1c ratio a clinical 
variables matrix was constructed.  Variables were condensed into categories coded 
between 0 and 4.  The matrix was organized with each column representing a patient 
and each row representing a variable.  Hierarchical clustering was used to organize 
the matrix into groups with shared features (Figure 3.8).  Patients with a normal 
CD14:CD1c ratio were seen in all of the three broad clusters.  Six of the 9 patients 
with normal CD14:CD1c ratio presented before day+50, 5 had a monocyte count < 
0.5 x109/L and 5 had AML as their transplant indication.  Patients within the first two 
months post-transplant, particularly those who have received prior myelosuppressive 
treatment, still have recovering haematopoiesis.  It may be the case that macrophage 
infiltration into GvHD-affected tissue is limited when the capacity of the bone marrow 
produce monocyte is impaired.  Firm conclusions cannot be made from this analysis.  
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Figure 3.8 Clinical details do not cluster by CD14:CD1c ratio groups 
 
Cluster dendrogram of a clinical details matrix.  The matrix includes 10 
clinical measures divided into categorical variables on a scale from 0-4.  
Coding of variables is as follows: 
Stem cell source: 0= cord, 1= matched unrelated donor, 2= matched 
unrelated donor, 3= haploidentical 
HLA-match: 0= 12/12, 1= 11/12, 2= 10/12, 3= 9/12, 4= 6/12 
Conditioning: 0= other, 1= RIC-TCD, 2= RIC-TR, 3= preconditioned, 4= 
myeloablative 
Day of onset: 0= >day 200, 1= day 150-200, 2= day 50-150, 3= <day 50 
Presentation: 1= acute on chronic, 2= post-DLI, 3= ISW, 4= acute 
CRP: 1= >30, 2= 10-30, 3= <10 (mg/L) 
Immunosuppresion: 0= oral steroid, 1= topical steroid, 2= ciclosporin, 3= 
none 
Ciclosporin level: 1= >200, 2= 50-200, 3= <50 (µg/L) 
Transplant indication: 1= AML, 1.5= ALL, 2= MDS, 2.5= myeloproliferative 
neoplasm, 3= MM, 3.5= CLL, 4= lymphoma   
Monocyte count: 0= <0.2, 1= 0.2-0.5, 2= 0.5-0.8, 3= >0.8 (x109/L) 
X= the 9 patients with normal CD14:CD1c ratios. 
 
3.5.7 Dermal leukocytes migrated out of GvHD explants also had elevated 
CD14:CD1c ratio 
 
Many previous studies of human skin MPs have capitalized on their ability to migrate 
out of skin in culture.  This property allows isolation of a dermal leukocyte suspension 
without the need for enzymatic digestion.  Dermal macrophages do not migrate out of 
culture but CD14 MDM and dermal DCs do migrate (Klechevsky et al., 2008; Haniffa 
et al., 2009; Wang et al., 2014).  While enzyme-sensitive antigens are preserved with 
this method, cells are susceptible to changes in gene and surface antigen expression 
Figure 3.8 Clinical details do not cluster by CD14:CD1c ratio groups 
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(McGovern N, Immunity 2014).  Despite such changes, CD14+CD11c+ cells 
migrated from skin share more similarities in gene expression with CD14+CD11c+ 
digested from skin than they share with CD11c+CD1c+ cells migrated from skin 
(McGovern N, Immunity 2014).   
 
 
 
Figure 3.9.  Flow cytometry analysis of dermal leukocyte 
suspensions prepared by migration 
Flow cytometry analysis of leukocytes from normal skin (A) and from 2 
patients with acute GvHD (B and C).  Leukocytes were prepared by 
migration out of skin explants for 48 hours.  D) Comparison of CD14:CD1c 
ratio in GvHD and normal skin, gating on CD11c+ cells.  Normal skin 
samples n=6, GvHD specimens n=14.  Bars show mean ± SEM.  *** 
p=0.0002 by Mann-Whitney test. 
 
 
The FACS analysis strategy used for digested skin was applied to migrated skin 
preparations (Figure 3.9).  In normal skin, the CD11c-CD14+ gate was empty, in 
keeping with retention of dermal macrophages in the explant (Figure 3.9, panel A).  
CD141+ cells co-expressing CD1c were found in the CD11c-CD14- gate.  CD141-
CD1c+ cells, consistent with LCs, were also CD11c-CD14-.  CD11c+ cells could be 
divided into CD14+ and CD14-CD1c+ fractions in similar proportions to those seen in 
digested skin.  The flow cytometry profile of preparations migrated from GvHD skin 
mirrored that of GvHD digests (Figure 3.9, panels B, C).  CD141+ cells were few, and 
those that were present had minimal CD1c expression.  CD11c+CD14+ cells were 
Figure 3.9 Flow cytometry analysis of dermal leukocyte suspensions 
prepared by migration
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expanded compared with normal skin and CD14-CD1c+ cells tended to be fewer.  
The mean CD14:CD1c ratio was 0.34 in normal skin and 19.1 in GvHD (Figure 3.9, 
panel D). 
 
3.5.8 The CD14+CD1c- infiltrate precedes lymphocyte accumulation in GvHD 
 
Repeat biopsies were obtained from 3 individuals approximately 100 days following 
their presentation with GvHD.  Clinical symptoms had resolved in all three at follow-
up.  The most dynamic population shifts occurred in HLA-DR-SSClo lymphocytes and 
CD14+CD1c- cells: mean 3.5 fold increase and 5.2 fold decrease respectively  
(Figure 3.10).  This analysis suggests that biopsies are taken prior to peak 
lymphocyte accumulation in GvHD.  The CD11c+CD14+ infiltrate seen in GvHD 
specimens is therefore likely to be an early event.  On resolution of symptoms, the 
CD14:CD1c ratio is restored to normal. 
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Figure 3.10 Resolution of inflammation 
 
A) Flow cytometry analysis of skin biopsies from a patient at presentation 
with acute GvHD (i) and at follow-up 86 days later (ii).  Gates and 
quantified populations are shown.  Dermal macrophages were excluded 
by autofluorescence (AF) and side scatter in this analysis and CD11c 
staining was not performed.    
B) Changes in gated populations between GvHD presentation and follow-
up.  Positive axis shows fold change in populations increased over this 
time period, negative axis shows fold change in populations reduced.  
Bars indicate mean ± SEM from n=3 patients.!!
 
 
 
3.6 Summary of results for Chapter 3 
 
Using flow cytometry to dissect the MPs of GvHD dermis has demonstrated an 
expansion of cells in the CD14 MDM parameter space:  HLA-DR+, AFmid, CD14+, 
CD1c- cells.  When combined with a contracted population in the cDC2 parameter 
space, this is a characteristic profile of acute GvHD.  The CD14-rich, CD1c-poor 
profile is seen in three quarters of patients in the cohort.  Patients with this profile are 
more likely to receive a histological diagnosis of GvHD and to experience clinically 
significant disease. 
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Chapter 4.  Characterizing macrophages from cutaneous GvHD 
lesions 
 
4.1 Introduction 
 
Global analysis of MPs in clinical biopsies revealed that macrophage expansion is a 
common feature of GvHD lesions.  These macrophages (GVH14) have a similar 
immunophenotype to steady-state monocyte-derived macrophages (CD14 MDM) by 
initial analysis.  Clearly defining whether GVH14 are monocyte-derived or dermal 
macrophages will help understand their origins.  Whether these cells are donor and 
recently recruited or recipient and sessile will provide insight into their immune 
function and their susceptibility to modifying treatments.   
 
Valuable insights into the steady state MP diversity of human skin have been 
afforded by simple functional assays and comparative gene expression (Haniffa et 
al., 2009)!(Haniffa et al., 2012).  CD14 MDMs and myeloid DCs migrate out of 
cultured skin explants, but dermal macrophages remain in situ.  Myeloid DCs 
stimulate allogeneic T cell proliferation, but CD14 MDMs and dermal macrophages 
do not.  CD14 MDMs and macrophages share a monocyte-macrophage gene 
expression signature, but key genes are differentially expressed.  A similar approach 
will be applied to explore the relationship of GVH14 to other skin MPs.  Techniques 
will need to be scaled to accommodate the small number of cells available at biopsy. 
 
 
4.2 Chapter Aims 
 
4.2.1 Skin strand Aim 2:  To compare GVH14 with candidate steady state 
counterparts  
 
Comparison between GVH14 and CD14 MDM will include: 
 
• Detailing immunophenotype by flow cytometry 
• Testing ability to stimulate allogeneic T cells 
• Quantifiying chemokine and cytokine production in response to LPS stimulation 
• Assessing the chimerism of GVH14 and dependence on circulating monocytes 
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• Quantitating immune-relevant gene expression in GVH14 and steady-state 
subsets by NanoString.   
 
4.3 Materials and Methods for Chapter 4 
 
4.3.1 Patient samples 
 
Experiments for Chapter 4 were performed on sorted cells from GvHD skin shave 
biopsies and from normal skin surplus to mammoplasty/ abdominoplasty.  Ethics and 
cohort characteristics are described in section 3.3.  
 
In 10 GvHD patients undergoing skin biopsy, a simultaneous blood sample (4-8ml) 
was collected into EDTA. 
 
4.3.2 Sample processing and preparation 
 
Single cell suspensions of dermis or whole skin were prepared (see 3.4.6).  Sorted 
cells were used for cytospin, FISH or NanoString, as described in Chapter 2.  
Additional functional assays are detailed below. 
 
Blood samples were subjected to density centrifugation to yield a mononuclear cell 
preparation (see Chapter 2).  PBMC were cryopreserved and sorted/ analysed in 
batches. 
 
4.3.3 MP isolation by Fluoresence activated cell sorting (FACS) 
 
Individual MP populations were isolated from GvHD lesions and control skin by 
FACS.  The sorting strategy is outlined in Figure 4.1.  Further primary sorting data 
from normal skin is presented in Appendix B.  Four-way sorting was employed.  
CD11c-CD14+ macrophages, CD11c+CD14+CD1c- cells and CD11c+CD14-CD1c+ 
cells were always sorted from GvHD lesions.  The fourth population was 
CD11c+CD14+CD1c+ cells or lymphocytes depending on the downstream 
experiment.  7 MP populations were isolated from plastic surgery skin (section 4.3.)  
MP yield was between 200 and 20,000 cells depending on sample and subset.  
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Typically 4000 CD11c+CD14+CD1c- cells could be isolated.  These yields were 
insufficient for routine purity testing.   
  
 
 
Figure 4.1 MP isolation from GvHD lesions by FACS 
 
Strategy employed for flow cytometric sorting of MP populations from 
GvHD lesions.  Top row: debris and dead cells were excluded and CD45+ 
leukocytes selected.  Second row: single CD8+ T cells were isolated for 
experiments not included in this thesis.  Third row: HLA-DR+ MPs were 
divided into CD11c-CD14+ macrophages, CD11c+CD14+CD1c- cells and 
CD11c+CD14-CD1c+ cells.  Fourth row: each MP population was refined 
to single cells (only single 14 shown in this example). 
BD FACSDiva 8.0
Analysis Printed on: Tue Jul 7, 2015 10:50:08 BST
Figure 4.1 MP isolation from GvHD lesions by FACS  
cells P11 (viable cells)   P12 (CD45+)
P1
(HLA-DR+)
1c 
(CD11c+
CD14-
CD1c+)
14 (CD11c+CD14+
CD1c- or GVH14)
single 
14
mac (CD11c-CD14+)
Jardine L, 2016 
! 91!
4.3.4 Surface antigen profiling 
 
Surface antigens were tested on GVH14 cells and CD14 MDMs migrating out of 
culture (each n=5).  Cell preparations were divided between 5 tubes and stained as 
per Table 4.1.  Separate preparations were subjected to fixation/ permeabilization 
and stained with S100A8/9 antibody or isotype (n=3).  The staining protocol used 4µl 
of antibody in 50µl of flow buffer except where specified.  Within total migrated cells, 
GVH14/ CD14 MDMs were identified as DAPI-CD14+ cells. 
 
 
 
 
Table 4.1 Antibody panels for profiling surface antigens by flow 
cytometry 
Using DAPI and CD14 to identify live GVH14/ CD14 MDMs, expression of 
12 surface antigens was tested in 4 combinations (tubes 1-4).  The fifth 
tube included isotype controls. 
 
 
4.3.5 Fluorescence in situ hybridization (FISH) 
 
GVH14 and CD3+ T cells were sorted out of GvHD biopsies from participants with a 
gender-disparate BMT donor (n=5).  FISH was performed as described in section 
2.4.3.  All cells with identifiable probes were counted (min 3; max 130).  
 
The peripheral blood chimerism result most proximal to GvHD biopsy was taken from 
clinical records.  All clinical chimerism measurements were performed on CD15+ and 
CD3+ fractions of peripheral blood using short-tandem-repeat PCR method. 
 
 
 
 
 
Table 4.1- Antibody panels for profiling surface antigens by flow 
cytometry 
 
Tube PE APC FITC APCCy7 PECy7  
1 CD52 CD1c CD14 CD14 CD1c DAPI 
2 SIRPa (2ul) CD11c CD16 CD14 CD1c DAPI 
3 CD86 CD206 HLA-DR CD14 CD1c DAPI 
4 CD64 CD163 CD209 CD14 CD1c DAPI 
5 IgG1 IgG1 IgG1 CD14 CD1c DAPI !
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4.3.6 T cell proliferation and activation assay  
 
Bulk allogeneic T cells were prepared from whole blood by immunodensity negative 
selection.  Preparations from 3 donors were made, cryopreserved and stored at -
80°C.  Aliquots were thawed and labelled with CSFE (section 2.2.3). 
 
Three thousand sorted MPs and 750,000 T cells were re-suspended in 100µl RF10 in 
a 96-well v-bottomed plate.  cDC2s served as a positive control and T cells incubated 
alone served as a negative control.  Plates were incubated at 37°C and 5% CO2 for 
6-7 days. 
 
Cells were re-suspended in flow buffer, prepared for flow cytometry (section 2.3.1) 
and stained with the following cocktail of antibodies: CD3 V500, CD4 PE, CD8 
APCCY7, HLA-DR PERCPCY5.5 and CD69 PECY7.  A minimum of 20,000 events 
was acquired on a FACS Canto II running Diva version 7.    
 
Gates for proliferating T cells (CSFE-) and activated T cells (CD69+/HLA-DR+) were 
set using the negative control before applying to other samples as staining intensity 
for CSFE varied slightly between experiments. 
 
4.3.7 Stimulation and cytokine production 
 
GVH14 and CD14 MDM sorted from normal dermis were cultured for 10 hours with 
or without LPS:  5x104 cells in 50µl RF10 were added to a 96-well U-bottom plate ± 
100ng/ml LPS.  Supernatants were stored at -80°C and cytokine profiles analysed by 
Luminex assay (section 2.5.2).  Summary characteristics of the GVH14 donors are 
given in Table 4.2.  For multivariate analysis, cytokine concentrations were 
normalized as follows: 
Normalized sample_x cytokine_n= measured sample_x cytokine_n   + 1 
        Mean cytokine n(all samples) 
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4.3.8 Normal skin NanoString  
 
Control skin preparations (breast/ abdominoplasty surplus) were sorted to isolate 7 
skin MP populations (n=4).  The cDC2 subset was fractionated by CD5 expression 
for work not included in this thesis.  For the purposes of this chapter both CD5- and 
CD5+ cDC2 were considered replicates of cDC2.  Cell pellets were stored at -80°C 
and prepared in batches.  Samples were lysed in a volume buffer RLT + 1% beta-
mercaptoethanol to yield 20,000 cells per 5µl.  The Immunology v2 panel plus 
custom code set (see section 2.6.2) was used. 
 
4.3.9 GvHD skin NanoString 
 
GvHD samples were sort-analysed and if sufficient numbers of GVH14 were present, 
cell pellets were stored.  Four samples were selected based on having >3000 cells of 
CD14+CD1c- phenotype (Table 4.3).  All were sorted from dermal digests.  Lysates 
were prepared as above. 
 
 
 
Table 4.2 Summary characteristics of GVH14 donors for cytokine and chemokine production 
experiments 
 
Donor Experiment BMT type/  
indication 
Current 
immunosuppresion 
GvHD 
onset 
CD14: CD1c 
ratio by flow 
cytometry 
 
Histology 
Grade 
(Lerner) 
Max. clinical 
grade 
(Glucksberg) 
 
1  Stim and 
unstim 
RIC-TR for 
Myeloma 
Topical steroid ISW 
(day+58) 
3 2 III 
2  Stim only RIC-TCD for  
Follicular 
lymphoma 
Ciclosporin  
(41ng/ml) 
ISW  
(day+71) 
5 2 II 
3  Stim only RIC-TCD for  
Hodgkin 
lymphoma 
None post-DLI 
(day+ 
302) 
57 2 II 
!
Table 4.3 Characteristics of GVH14 donors used for NanoString 
 !
Donor Cell 
count 
BMT type/  
indication 
Current 
immunosuppresion 
GvHD 
onset 
CD14: 
CD1c ratio 
by flow 
cytometry 
 
Histology 
Grade 
(Lerner) 
Max. clinical 
grade 
(Glucksberg) 
 
1   4000 RIC-TCD 
for Follicular 
lymphoma 
Oral prednisolone ISW 
(day+495) 
30 2 II 
2   3000 RIC-TCD for 
AML 
Topical steroid Post-DLI 
(day+278) 
6 2 II 
3  3000 RIC-TCD for  
MDS 
Oral prednisolone  ISW 
(day+215) 
177 2 
(eczematoid) 
II 
4  12000 Preconditioned 
RIC for AML 
Ciclosporin (85mg/L) Acute 
(day+13) 
5 low 2 I 
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4.3.10 NanoString Quality Control and normalization 
 
Thirty-one samples were run.  All passed technical quality controls but 3 failed 
content normalization, indicating that there was insufficient RNA in these specimens.  
These samples were excluded and data were re-normalized.  PCA was performed to 
verify quality control.  Four subsets from one control skin sort were clear outliers and 
had low cell inputs/ high positive content normalization scores, so were excluded.  
The remaining 3 subsets from that sort had higher cell inputs and were retained.  
Data entering analysis included n=4 LCs, n=2 cDC1, n=6 cDC2, n=3 CD14+CD1c+, 
n=3 CD14 MDM, n=3 GVH14 and n=4 macrophages.     
 
4.3.11 NanoString analysis 
 
PCA was used to cluster samples, centering on the mean.  The data set was filtered 
using monocyte/ macrophage and DC gene signatures from McGovern et al., 2014.  
Nineteen of the 111 monocyte/ macrophage genes and 10 of the 99 DC genes were 
included on the NanoString panel.  With this 29-gene expression set hierarchical 
clustering was performed, with Pearson correlation as the distance metric. 
 
Differential gene expression was tested by t-test between GVH14 and CD14 MDMs, 
assuming equal variance between groups and setting alpha=0.05.  This 44-gene 
expression set was subjected to hierarchical clustering.  Functional annotation of the 
38 genes preferentially expressed in GVH14 (i.e. differentially expressed with highest 
expression in GVH14) was performed in GeneMania.   
 
 
4.4 Results for Chapter 4 
 
4.4.1 GVH14 have similar morphology and surface immunophenotype to steady 
state CD14+ MDM 
 
Comparisons between GVH14 and its putative steady state counterpart were made.   
GVH14 and CD11c-CD14+ cells (dermal macrophage equivalents) were sorted from 
GvHD lesional skin according to the gating strategy shown in Figure 4.1.  Morphology 
of these cells on cytospin preparations was compared with morphology of CD14 
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MDM and dermal macrophages from identically sorted normal skin.  GVH14, like 
CD14 MDM had a smaller cytoplasmic volume and fewer basophilic granules than 
dermal macrophages (Figure 4.2, panel A).   
 
To compare phenotype, GVH14 and CD14 MDM were migrated from explants.  This 
removed macrophages from the analysis and excluded the effect of collagenase on 
surface antigens.  Thirteen antigens were selected based on what is expressed by 
CD14 MDM and what might separate CD14 MDM from monocytes, as published in 
McGovern et al., 2014.  GVH14 and CD14 MDM had equivalent expression of CD14, 
CD1c, CD11c and CD209 (Figure 4.2, panel B).  HLA-DR and CD86, which are 
antigens associated with activation and tissue residence, were marginally lower on 
GVH14.  Monocyte associated antigens S100A8/9, CD52, SIRPα and CD64 were 
more abundantly expressed on GVH14 than CD14 MDM.  Macrophage-associated 
antigens CD163, CD16 and CD206 were also expressed at higher levels in GVH14.  
The overall immunophenotype of GVH14 was comparable to CD14 MDM but 
suggested differences in monocyte differentiation conditions.  Neither an M1 nor an 
M2 macrophage phenotype could be inferred from this data: GVH14 shared features 
of both classically activated M1 (HLA-DR, CD86, CD64) and alternatively activated 
M2 macrophages (CD163, CD206).  
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Figure 4.2 Comparison of GVH14 with steady state CD14 MDM 
 
A) Giemsa-stained cytopsin images of cells sorted from GvHD skin (i) and 
normal skin (ii).  B) Surface antigen expression by GVH14 (red line) and 
CD14 MDM (blue line) compared with isotype control (grey line).  This is a 
representative example of n=6.  
 
 
4.4.2 GVH14 are donor-derived and frequency correlates with monocyte 
availability 
 
To examine the hypothesis that GVH14, like CD14 MDM, depend on circulating 
classical monocytes, correlations between blood and skin were tested.  GVH14 were 
quantified as a proportion of CD45+ leukocytes in dermis by flow cytometry using the 
definition outlined in Figure 3.3 (HLA-DR+, CD11c+, CD14+, CD1c- cells).  Classical 
monocytes in paired blood samples were quantified as a proportion of CD45+ 
leukocytes by flow cytometry.  Monocytes were defined as lineage (CD3, CD19, 
CD20, CD56) negative, HLA-DR+, CD14+ CD16- cells (gated as per Figure 5.1).  
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There was a significant positive correlation between frequencies of these cell types 
(r2=0.58, p=0.011) (Figure 4.3, panel A). 
 
In 5 patients who had received transplants from a sex-disparate donor, GVH14 were 
sorted and subjected to XY FISH.  GVH14 were 99.6% donor (mean 99.6%; 
SEM=0.44).   This was similar to the chimerism of blood monocytes (mean 99.4%; 
SEM=0.6) (Figure 4.3, panels B-C). 
 
 
 
Figure 4.3 GVH14 chimerism and relationship to blood monocytes 
 
A) Correlation between blood classical monocytes and skin GVH14 
measured in paired samples by flow cytometry.  Bi) Example GVH14 and 
ii) skin T cells sorted from a GvHD biopsy and subjected to XY FISH.  
Example shows a female recipient of male donor stem cells.  C) 
Chimerism from M/F mismatched donor /recipient pairs.   nd=not done. 
 
 
4.4.3 GVH14 activate and recruit T cells and produce pro-inflammatory 
cytokines 
 
When considering the role of GVH14 within a developing GvHD lesion, three 
properties warranted close inspection.  Interactions of GVH14 with T lymphocytes 
were explored as donor T cells are critical to the pathogenesis of GvHD.  Ability to 
influence local inflammation through cytokine production was tested.  Additionally, 
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the contribution to inflammatory cell recruitment through chemokine production was 
measured. 
 
 
 
Figure 4.4 GVH14 induce proliferation and activation of T 
lymphocytes  
 
A) CCR7 expression on CD11c+CD14+CD1c- and CD11c+CD14-CD1c+ 
cells from control (blue) and GvHD dermis (red) compared with isotype 
control.  Representative staining from n=4.  B) Flow cytometry analysis of 
a T cell stimulation/ activation assay output.  Plots are gated on CD8 T 
cells in representative outputs from GVH 14 and CD14 MDM co-cultures 
with bulk T cells compared with T cells cultured alone (each co-culture 
minimum n=3).  C) Summary data of T cell stimulation/ activation assays 
for all conditions.  Bars present mean ± SEM; * p<0.05 by unpaired t-test. 
 
 
GVH14s expressed low levels of CCR7, suggesting that they were not capable of 
migrating to lymphoid tissue via a CCL19/21 gradient (Figure 4.4, panel A).  They 
may still interact with effector or memory T cells in situ.  Bulk CD3 cells from three 
allogeneic donors were used in co-cultures with MP subsets.  Both autologous and 
allogeneic interactions are possible in vivo: GVH14 are uniformly donor but skin T 
cells have mixed chimerism (Figure 4.4, panel B-C).  Autologous interactions (donor 
macrophage to donor T cell) might be considered more important for GvHD 
pathogenesis.  However, quiescent auto-reactive recipient memory T cells could 
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contribute to pathogenesis with appropriate stimulation or release from suppression.  
Autologous co-cultures were not performed as signal was predicted to be low and 
variable due to factors such as calcineurin inhibition.  MP subsets were isolated from 
GvHD lesions by flow sorting.  All subsets from GvHD lesions had enhanced ability to 
induce T cell proliferation and activation, with the exception of macrophages (Figure 
4.4, panel C).  The comparison to steady state populations was more marked for 
CD14+ cells than for CD1c+ cells.   For example, mean CD4 T cell proliferation was 
4.5-fold higher in GVH14 than CD14 MDM but only 1.9-fold higher in GVH CD1c+ 
cells than normal CD1c+ cells. 
 
 
 
Figure 4.5 GVH14 cytokine and chemokine quantification by Luminex  
 
A) Heat-map of cytokine and chemokine production by 5000 FACS-sorted 
macrophages during 10-hour stimulation with or without LPS.  Samples 
are normalized to the mean concentration of each protein.  Each column 
represents a specimen.  B) PCA plots of normalized protein 
concentrations showing CD14 MDM in blue, GVH14 in red and un-
stimulated samples with open circles.  C) Selected chemokine 
concentrations in stimulated CD14 MDM and GVH14. D) Selected 
cytokine concentrations in stimulated CD14 MDM and GVH14. * p<0.05, 
***p<0.0001 by unpaired t-test. 
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In response to a consistent stimulus (100ng/ml LPS), GVH14 samples produced a 
divergent chemokine and cytokine response from steady state CD14 MDM (Figure 
4.5, panels A-B).  The GVH14 response was heterogeneous.  As demonstrated in 
the heat-map (Figure 4.5, panel A), GVH14 sample 1 had elevated pro-inflammatory 
cytokines (e.g. IL-6, TNFα, IFNα and IL-8) and chemokines (e.g. CCL11 and CCL5); 
GVH14 sample 2 had elevated pro-inflammatory cytokines but a less marked 
chemokine response and GVH14 sample 3 had minimal pro-inflammatory cytokines 
but a marked chemokine response.  Solid conclusions about basal cytokine and 
chemokine production cannot be made as only 1 sample yielded sufficient cells for 
an un-stimulated control.  However, it appears that GVH14 and CD14 MDM produce 
a similar repertoire.  It may be the case that GVH14 are primed for an LPS response. 
 
4.4.4 GVH14 and CD14 MDM share a lineage-specific gene expression profile 
separated by an IFNγ signature 
 
Gene expression profiles of GVH14 and CD14 MDM were compared with those of all 
other MPs in steady state skin using a NanoString 638-gene panel.  PCA was used 
as a means of dimension reduction:  distilling the greatest variation in gene 
expression into a few key components.  The first two components accounted for 54% 
of the variation.  Component 1 divided macrophages from DCs (Figure 4.6, panel A).  
Component 2 split cDC1s/ LCs from cDC2s and CD14+CD1c+ cells from 
macrophages.  None of the components effectively split CD14 MDM from dermal 
macrophages.  GVH14 clustered with macrophages, overlaying CD14 MDM and 
dermal macrophages in PC1, 2 and 3.  Looking specifically at PRR genes, GVH14 
expressed a repertoire similar to CD14 MDM and CD14+CD1c+ cells (Figure 4.6, 
panel B).  The PRR gene profile included MRC1 (encoding mannose receptor 
CD206), TLR1-2, TLR-4 and TLR-8, intracellular receptors NOD1-2, CLEC4A, 
CLEC4E and CLEC5A, and CD209 (DC-SIGN).  Expression of receptors for 
response to growth factors CSF1 (M-CSF) and Flt-ligand divided the samples into 2 
groups (Figure 4.6, panel C).  GVH14, CD14 MDM, dermal macrophages and 
CD14+CD1c+ cells expressed CSFR1 but low levels of FLT-3.  The converse was 
true of myeloid DCs and LCs.  The data set was filtered to include 
monocyte/macrophage and DC “signature genes”, published in McGovern et al., 
2014.  Using unsupervised clustering, GVH14 grouped with macrophages (Figure 
4.6, panel D). 
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Figure 4.6 GVH14 have a macrophage-specific gene expression signature 
A) PCA plot of GVH14 and steady state MP gene expression.  B) Cluster 
dendrogram of PRR gene expression (mean expression values for each 
subset are shown).  C) Relative expression of growth factor receptors 
CSF1R and FLT3 across the populations (bars show mean± SEM).  D) 
Cluster dendrogram of monocyte/ macrophage and DC lineage gene 
expression.   
 
 
Gene expression differences between GVH14 and CD14 MDM were quantified by t-
tests.  Using stringent criteria (alpha=0.05 and multiple comparison correction) there 
were no significant differences.  Using less stringent criteria (alpha=0.05 only), 44 
genes (7%) were differentially expressed between the populations (Figure 4.6).  This 
analysis implied similar gene expression profiles.  
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Figure 4.7 Comparative gene expression between GVH14 and CD14 MDM 
 
A) Cluster dendrogram and heat-map of the 44 genes differentially 
expressed between GVH14 and CD14 MDM. B) Network plot of the 38 
genes preferentially expressed by GVH14.  Lines indicate co-expression. 
Nodes represent genes.  Node size is maximal in measured genes and is 
inversely proportional to the rank prediction value in predicted genes (i.e. 
larger nodes are more significant).  Measured genes are black and 
predicted genes are grey.  Genes involved in response to IFNγ are red: 
solid red nodes are measured genes and striped red nodes are predicted 
genes.    
 
 
Functional significance of the 38 genes preferentially expressed by GVH14 was 
explored using GeneMania.  The top 30 functions retrieved are distilled in Table 4.4. 
IFNγ response and signaling was most significant.  Antigen processing/ presentation 
and intracellular vesicle transport also featured prominently.  Capacity to cross-
present antigen was mentioned.  Positive regulation of lymphocyte/ leukocyte 
activation was the third most-retrieved functional annotation.  
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Table 4.4 Functional annotations of genes preferentially expressed in 
GVH14 over steady state CD14 MDM 
 
Top 30 functional annotations retrieved by GeneMania for the genes 
preferentially expressed by GVH14 relative to steady state CD14 MDM. 
Network genes are introduced by predicted co-expression.  Significance is 
ordered by false discovery rate (1= 2.9x10-24; 30=3.4x10-12). 
 
 
4.5 Summary of results for Chapter 4 
 
Functional, phenotypic and gene expression comparisons support the premise that 
CD14+ CD1c- cells expanded in GvHD lesions are the inflammatory counterpart of 
steady state CD14 MDMs.  Differential gene expression suggests that IFNγ may 
feature in the derivation of GVH14 from monocytes.  Functional assays have 
demonstrated that GVH14 can activate, expand and recruit T cells.  Functional 
annotation of differential gene expression proposes that GVH14 are primed for 
antigen presentation and may also be capable of cross-presenting antigen.  !
Table 4.4 Functional annotations of genes preferentially expressed in 
GVH14 over steady state CD14 MDM 
 
Function Significance Measured 
genes 
Network 
genes 
Interferon-gamma-
mediated response or 
signaling 
1,2,3 PML, JAK2, 
PTFAR, 
HLA-A,B,C 
 
STAT1, 
IRF1, 
TAPBP, 
B2M, HLA-
E,F,G, HLA-
DRA, DRB1, 
DPA, DPB1, 
DQB1 
Antigen processing and 
presentation 
4,9,11,12,13, 
15,22,24,27 
PSMB9, 
PYCARD, 
TAP1, HLA-
A,B,C, 
FCGRT, 
CD81, 
LILRA2 
TAPBP, 
B2M, HLA-
E,F,G, HLA-
DRA, DRB1, 
DPA, DPB1, 
DQB1, 
PSMB5 
Endocytosis & intracellular 
transport 
5,6,7,8,10,14,16, 
17,19 20,21, 29 
HLA-A,B,C, 
TAP1 
TAPBP, 
HLA-E,F,G,  
HLA-DRA, 
DRB1, DPA, 
DPB1, 
DQB1, B2M 
Regulation of T cell 
activation 
26,28 CD80, 
CCR7, 
CD247, 
PYCARD, 
HLA-A 
HLA-DRA, 
DRB1, DPA, 
DPB1, 
DQB1, HLA-
G, IRF1, 
CD3D 
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Chapter 5.  Modelling monocyte to macrophage differentiation in 
GvHD 
 
5.1 Introduction 
 
Evidence from Chapter 4 supports the premise that GvHD lesions are infiltrated with 
monocyte-derived macrophages.  Monocytes recruited to tissue may have pro-
inflammatory or immunomodulatory roles depending on the setting (Bain and Mowat, 
2014), (Grainger et al., 2013).  Gene expression and in vitro function assays suggest 
that GvHD skin monocyte-derived macrophages are pro-inflammatory and capable of 
stimulating T cells.  Accordingly, they could be a novel target for disease-modifying 
therapy. 
 
In this chapter, the activity of GVH14 in tissue is explored further.  Using in vitro 
GVH14 equivalents, interactions with keratinocytes and functions within whole skin 
are tested.  In order to generate GVH14 equivalents, the ‘nature and nurture’ of 
GvHD monocytes is considered.  Recent work on a murine Toxoplasma model has 
demonstrated that distinct transcriptional programmes are initiated in monocyte 
precursors in bone marrow as a consequence of remote tissue inflammation 
(Askenase et al., 2015).  This suggests that some attributes of monocyte-derived 
macrophages may be established before tissue recruitment and differentiation.  
Monocyte differentiation plasticity in response to cytokines, hormones and growth 
factors is well recognized.  Varying stimuli in vitro can give rise to a spectrum of 
macrophage activation (Xue et al., 2014).  Monocytes differentiating in vivo 
experience a more complicated milieu of stimuli and characterizing the tissue 
microenvironment may give additional insight into the activation and functional 
properties of inflammatory macrophages.  
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5.2 Chapter Aims 
 
5.2.1 Skin strand Aim 3:  To investigate the differentiation conditions and in 
situ functions of GvHD lesional macrophages. 
 
The differentiation conditions of GVH14 are considered from two perspectives: firstly 
whether peripheral blood monocytes in GvHD are different from monocytes in steady 
state, and secondly what signals they receive on recruitment to inflamed skin.  These 
results will be used to inform in vitro generation of GVH14 equivalents for use in a 
skin explant model of GvHD and a keratinocyte co-culture assay.  
 
 
5.3 Materials and Methods for Chapter 5 
 
5.3.1 Patient samples 
 
Patient and healthy donor blood samples (see sections 3.4.1 and 4.3.1) were used to 
generate NanoString data.  
 
Monocyte quantification from NHS full blood counts was recorded for GvHD patients, 
BMT controls and from healthy volunteers enrolled in the LPS inhalation study (see 
Chapter 7).  Post-BMT patients with neutropenia (neutrophils <1x109/L) were 
excluded.  GvHD counts taken >140 days post-transplant were excluded as there 
were no BMT controls to match later time points. 
 
Cryopreserved pairs of PBMC from pre-treatment recipients and their donors were 
used to establish mixed leukocyte reactions (MLRs).  Skin shave biopsies were 
obtained from 4 patients to set up skin explant experiments. 
 
Skin shave biopsies from 12 BMT recipients with suspected GvHD were used for 
whole-skin NanoString.  Rachel Dickinson collated this material as part of BloodWise 
grant 09031 “Conditioning the Host & Immune Activation.” 
 
 
 
Jardine L, 2016 
! 106!
5.3.2 Blood monocyte NanoString 
 
Monocytes were sorted from normal and GvHD blood PBMC preparations (Figure 5.1 
and Appendix B).  CD14 monocytes from n=6 GvHD donors with single-organ skin 
GvHD were selected (Table 5.1).  Cell pellets were stored at -80°C.  All three 
monocyte subsets from healthy donors were used for comparison.  Classical 
monocyte data had previously been generated by Gary Reynolds.  I added 
intermediate and non-classical monocyte data from an additional three donors.  
Samples were adjusted to concentration of 10,000 cells per 5µl in buffer RLT + 1 % 
beta-mercaptoethanol.   NanoString Immunology v2 panel plus custom code set was 
used. 
 
 
Table 5.1 Characteristics of patients for GVH blood NanoString experiment 
 
 BMT type/ 
indication 
Current 
immunosuppresion 
GvHD 
onset 
CD14: 
CD1c 
ratio by 
flow 
cytometry 
Histology 
Grade 
(Lerner) 
Max. clinical 
grade 
(Glucksberg) 
Monocyte 
count 
*109/L 
CRP 
mg/L 
A Preconditioned 
RIC for AML 
Ciclosporin 
(85 ng/ml) 
Acute 
(day+13) 
5   2 I 0.3 283 
B RIC-TCD for 
AML 
Ciclosporin 
(15 ng/ml) 
ISW 
(day+388) 
5   4 I 1.08 26 
C RIC-TCD for 
MDS 
Ciclosporin  
(12 ng/ml) 
ISW 
(day+102) 
2 Eczematoid 
(no grade 
given) 
III 0.74 12 
D RIC-TCD for  
Follicular 
lymphoma 
Ciclosporin  
(41ng/ml) 
ISW 
(day+71) 
5 2 II 0.69 28 
E RIC-TR for ALL None ISW 
(day+ 
376) 
1 1-2 II 1.03 22 
F RIC-TCD for  
Hodgkin 
lymphoma 
None post-DLI 
(day+ 
302) 
57 2 II 1.25 6 
!!
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Figure 5.1 Isolation of monocytes from PBMC by FACS 
Gating strategy for isolation of monocytes from PBMC illustrated by 
primary sorting data from a GvHD blood preparation.  Top row: viable 
leukocytes are selected.  Second row: lineage (CD3, 19, 20, 56) negative, 
HLA-DR positive cells are selected.  Third row: single CD14++CD16- 
classical monocytes are sorted.  Plots not discussed related to sorting not 
included in this thesis. 
BD FACSDiva 8.0
Analysis Printed on: Wed Jul 15, 2015 11:50:14 BST
Figure 5.1 Isolation of monocytes from PBMC by FACS
cells P2 (viable cells)    45+ (leukocytes)
  lin neg
 (lineage-
 HLA-DR+)
14 (CD14++
CD16- monocytes)
P9 (singles)
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5.3.3 Whole skin NanoString  
 
Rachel Dickinson processed skin for NanoString experiments.  Skin shave biopsies 
were diced with a scalpel and transferred into 350µl buffer RLT + 1% beta-
mercaptoethanol.  Material was passed 15 times through a 21-gauge needle, 
vortexed and stored at -80°C.  RNA was extracted from lysates so that a consistent 
amount could be used for NanoString.  Samples were thawed at 37°C for 20 minutes, 
passed 15 times through an 18-gauge needle and centrifuged for 3 minutes at 
17,000 x g.  The supernatant was used for RNA extraction with Qiagen RNeasy Mini 
Kit (cat. 74104).  RNA was eluted in 30µl water and quantified on a NanoDrop 
spectrophotometer.  Experiments used 150ng RNA per sample with the NanoString 
Immunology v2 panel.  All A260/280 ratios were >2. 
 
Kile Green did the initial data processing.  Quality control and normalization was 
performed in NSolver.  Samples were separated by pathology grade into 2 
categories: GvHD grade 0 and GvHD grade 2.  The “grade 0” category included n=3 
grade 0, n=2 grade 1 and n=1 borderline GvHD.  The “grade 2” category included 
n=5 grade 2 and n=1 grade 3.  Fold changes between gene expression in the 2 
categories were calculated.  I performed subsequent analyses. 
 
5.3.4 Chemokine/ chemokine receptor analysis 
 
Chemokine ligands on the Immunology v2 NanoString panel were filtered to include 
those with predicted impact on monocytes, T cells or both.  Predictions were made 
using Entrez Gene Summary, GeneCards Summary and UniProtKB/Swiss-Prot 
information from the GeneGards website. 
 
Chemokine receptor expression was inferred from GVH14 and GvHD monocyte 
NanoString data using the boxplot function of NSolver.  Populations were considered 
to express the transcript if the median log2 expression was >2 and the lower tail of 
the boxplot (1.5 x lower limit of the interquartile range) was >0. 
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5.3.5 Quantifying cytokines from GvHD lesions 
 
Skin conditioned media were prepared from n=12 GvHD biopsies and n=5 controls (1 
normal skin surplus and 4 BMT recipients at day+100 without rash).  A 3x1mm 
section of skin was cultured in 500µl RF10 for 48 hours.  Supernatants were stored at 
-80°C and batch analysed by Luminex.  The Procartaplex 45-plex panel was used 
(eBioscience).  Concentrations were calculated from a standard curve in 
Procartaplex Analyst. 
 
5.3.6 Monocyte-derived macrophage generation 
 
CD14+ monocytes were isolated from healthy donor peripheral blood by magnetic 
bead positive selection or FACS sorting (see section 2.2.2).  Five hundred thousand 
monocytes per well were cultured in 24-well plates in 500µl RF10 supplemented with 
100ng/ml GM-CSF for M1 polarization or 100ng/ml M-CSF for M2 polarization.  
Medium and non-adherent cells were completely removed on day 3 and replaced 
with 500µl fresh medium plus G-MCSF/ M-CSF.  Medium was removed again on day 
7 and replaced with 500µl fresh medium with or without 25ng/ml IFNγ and 100ng/ml 
LPS for un-stimulated and stimulated conditions.  To harvest cells, medium was 
removed, 500µl cold PBS without calcium or magnesium was added to each well and 
plates were kept on ice for 10 minutes to allow cells to detach.  Cells could then be 
dislodged by pipetting.  Surface antigen profile of cells was tested by flow cytometry, 
as detailed in 4.3.3.  Aliquots of 20,000 cells were harvested for NanoString.  The 
Immunology v2 panel plus was used. 
 
5.3.7 Mixed leukocyte reaction macrophage generation 
 
MLRs were established with cryopreserved PBMC from transplant donor recipient 
pairs.  Recipient PBMCs (isolated prior to conditioning) were used as stimulator cells 
and were irradiated (20Gy) to prevent expansion.  Donor PBMCs were added at a 
1:1 ratio in 1ml RH10 per million donor cells.  MLRs were incubated in vented T25 
culture flasks for 7 days at 37°C and 5% CO2.  Cells were harvested and prepared 
for flow cytometry. 
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To sort macrophages the following antibodies were used: CD3+19+20+56 FITC 
(lineage), HLA-DR V500, CD14 Qdot 655, CD16 APCH7, CD64 PE and CD206 APC.  
Sort gating and antibody details are given in Appendix B.  MLR macrophages were 
identified as DAPI-, HLA-DR+ cells co-expressing CD14 and CD16.  
 
5.3.8 Skin explant assay 
 
The skin explant assay, designed to test the effect of allogeneic cells in a donor-
recipient MLR (Dickinson et al., 1998), was modified to test the function of MLR-
macrophages.   
 
A donor-recipient MLR was initiated, as described above, with 10-30 million 
stimulator/ responder PBMC.  The yield and viability of harvested cells was assessed 
by counting with Trypan blue.  One million cells were reserved as a positive control 
and the remaining cells were prepared for flow sorting.  MLR macrophages were 
sorted as described above.  MLR T cells were identified as DAPI-, lineage+, SSClo 
cells.  Cells were re-suspended in 200µl RPMI containing penicillin, streptomycin, L-
glutamine and 20% heat-inactivated patient serum and added to individual wells of a 
96-well U-bottomed plate.   
 
A recipient skin shave biopsy was taken prior to the initiation of BMT conditioning.  
Equal 1-2mm squares were added to each well.  Test conditions were:  medium only 
(negative control), 1x106 PBMC (positive control), 3-4x105 T cells (sorting control) 
and 6-8x104 macrophages (test population).  Skin was cultured for 72 hours, 
harvested in to 10% buffered formalin and stained with haematoxylin and eosin.  
Histological changes consistent with GvHD were graded using the Lerner 
classification.  An experienced assessor without knowledge of the test conditions 
assigned grades (Xiao Nong Wang).  Four independent experiments were 
performed.  
 
5.3.9 Keratinocyte apoptosis assay 
 
HaCaT, a transformed keratinocyte cell line, was acquired from PromoCell.  HaCaT 
was cultured in T25 flasks in RF10.  Cells were split twice weekly by detaching, 
counting, and reseeding in a flask with fresh medium.  Cells were detached by 
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washing away culture medium with PBS, incubating with trypsin for 10 minutes at 
room temperature, re-suspending detached cells in fresh medium and spinning to 
pellet cells. 
 
HaCaT were seeded into a 24-well plate at a density of 10,000 cells per well 24 
hours prior to the assay, aiming to achieve approximately 80% confluence at time 
zero.  MLR macrophages were generated and isolated as described above.  
Macrophages were added to the wells at effector to target ratios 50:1, 25:1 and 10:1 
in RF10.  Co-cultures were maintained at 37°C and 5% CO2 for 5 hours. 
 
To harvest, wells were treated twice with 1ml trypsin as described above.  Adherent 
cells were detached by gentle pipetting.  Care was taken to treat all wells identically, 
recognizing that the detachment process may damage membrane integrity.  Cells 
were washed once in PBS and once in Annexin V binding buffer.  CD45 FITC, 
Annexin V PE and 7-AAD were added for 15 minutes at room temperature.  Data 
were acquired on a FACS Canto II.  HaCaT were identified as CD45- cells with high 
SSC.  Dead (annexin V+ 7AAD+) and early apoptotic (annexin V+ 7AAD-) cells were 
quantified in FlowJo. 
 
 
5.4 Results for Chapter 5 
 
5.4.1 Monocytes are expanded and DCs reduced in GvHD peripheral blood 
 
Absolute monocyte counts were recorded from NHS full blood counts in GvHD 
patients, BMT controls and healthy volunteers (Figure 5.2, panel A).  Mean counts (± 
SEM) were 0.66 ± 0.06, 0.61 ± 0.12 and 0.48 ± 0.02 respectively.  The mean count in 
GvHD differed significantly from healthy blood (p=0.012) but not from BMT control 
(p=0.645).  Twenty-eight percent of GvHD samples had a monocyte count higher 
than the normal range.  Considering the two BMT samples with markedly elevated 
monocyte counts, one had quiescent GvHD and the other had developed GvHD 
shortly afterwards.  This analysis demonstrates that while the expansion of 
monocytes in GvHD is subtle, it is absolute and not simply a proportional increase 
due to T cell depletion.  Monocyte and DC subsets were quantified by flow cytometry 
in PBMC preparations from blood taken at the time of GvHD biopsy and compared 
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with healthy donor blood (Figure 5.2, panel B-C).  As a proportion of leukocytes, 
classical monocytes were significantly expanded (mean ± SD 33% ± 17 in GvHD and 
14% ± 6 in normal).  Myeloid DCs were contracted in GvHD but pDCs were not 
significantly different.  Taking a global view, the monocyte: DC ratio was 4-fold higher 
in GvHD than in normal blood (Figure 5.2, panel D). 
 
 
 
Figure 5.2 Blood monocytes are expanded in GvHD 
A) Monocyte counts from NHS full blood counts in GvHD patients (n=47), 
BMT controls (n=15) and healthy volunteers in the LPS inhalation study 
(n=32).  Bars show mean ± SEM.  Dashed lines at y=0.2 and 0.8 
demarcate the normal range.   
B) Flow cytometry analysis of PBMC from healthy donor blood and GvHD 
blood.  Classical, intermediate and non-classical monocytes are HLA-DR+, 
CD14++CD16-, CD14++CD16+ and CD14+CD16++ respectively.  
Plasmacytoid DCs are CD123+CD11c-, cDC1 are CD11c+BTLA++ and 
cDC2 are CD11c+BTLAlo-mid.  Percentages indicate the population 
frequency relative to the parent gate.   
C) Frequency of each MP subset as a proportion of CD45+ cells in healthy 
blood (n=4) and GVH blood (n=10).  Bars show mean ± SEM.  D) Ratio of 
monocytes to DCs in healthy donors compared with GvHD.  *p<0.05 by 
unpaired t-test (C) and Mann-Whitney test (D).      
 
 
 
 
Figure 5.2 Blood monocytes are expanded in GVHD
40
30
20
10
0
14     1416  16    pDC cDC1  cDC2
%
 o
f P
B
M
C
0.8
0.6
0.4
0.2
0
CD3,19,20,56          CD16                   CD11c                CD11c 
H
LA
-D
R
C
D
14
C
D
12
3
B
TL
A
A B
C D
*
*
GVH     BMT     healthy
m
on
oc
yt
e 
co
un
t (
m
ill
io
n/
m
l)
80
60
40
20
0m
on
oc
yt
e:
 D
C
 ra
tio
heathy        GVH
*healthy
GVH
2.5
2.0
1.5
1.0
0.5
0
*
healthy
GVH
28% 79% 8%        27%                                                    7%
5%
56%                           91%
76%        66%  27%       12%      2%
6%
65%                           79%
Jardine L, 2016 
! 113!
5.4.2 GvHD monocytes carry an IFNγ gene signature 
 
In Chapter 4, differential gene expression was identified between monocyte-derived 
macrophages in GvHD relative to normal dermis.  To address whether these 
differences arose from recruitment to inflamed skin or whether the monocytes 
themselves were altered in GvHD, NanoString was performed on classical 
monocytes.  This monocyte subset was selected as it is the most likely precursor of a 
monocyte-derived macrophage.  Six GvHD donors with single-organ skin GvHD were 
used (see Table 5.1).   All 3 monocyte subsets were sorted from healthy donors for 
comparison. 
 
 
 
Figure 5.3 Distinct gene expression in classical monocytes from 
GvHD versus healthy donor blood 
 
A) PCA plot of NanoString gene expression data from GvHD classical 
monocytes (CD14 GVH) and healthy donor classical (CD14 SS), 
intermediate (CD1416) and non-classical monocytes (CD16).   
B) Cluster dendrogram and heat-map showing expression of the 25 genes 
differentially expressed between healthy donor classical monocytes and 
GvHD classical monocytes with p<0.05 and mean fold-difference>1.5.   
C) Network plot of genes preferentially expressed by GvHD relative to 
healthy donor classical monocytes. 
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On PCA, component 1 divided intermediate and non-classical monocytes from 
classical monocytes (Figure 5.3, panel A).  Component 2 separated normal blood 
from GvHD blood monocytes.  One hundred and one (16%) of genes were 
differentially expressed between GvHD and steady state classical monocytes.  
Genes preferentially expressed in GvHD were fewer then those preferentially 
expressed in steady state (20 versus 81).  Those with a fold difference >1.5 are 
displayed as a heat map (Figure 5.3, panel B). 
 
Preferentially expressed by GvHD monocytes were IFNγ response genes B2M, 
BST2, IFITM1 and GBP1 (Figure 5.3, panel C).  Genes involved in type I interferon 
response and antigen processing/ cross-presentation also featured.  Phagocytic 
receptor genes MRS1, MRC1 (CD206) and FCGR3A/B (CD16) were more highly 
expressed in GvHD monocytes.  Elevated CCR5 expression suggested heightened 
response to chemokine ligands CCL2-5.  Preferential expression of GNLY 
(granulysin)- a cytotoxic granule component typically seen in CD8 T cells and NK 
cells, and PPBP (CXCL7)- a platelet-derived chemokine was noted, but not obviously 
explained. 
 
GO annotations linked to genes preferentially expressed by steady state monocytes 
included “TLR-4 signalling pathway”, “positive regulation of innate immune response” 
and “positive regulation of cytokine production” (data not shown).  Modest but 
significant elevations of NOTCH1 and NOTCH2 were seen and reinforced by 
elevations of signalling pathway members.  As NOTCH proteins are critical in cell-
fate determination, it is possible that GvHD blood monocytes have altered propensity 
for further differentiation. 
 
5.4.3 GvHD skin microenvironment is poised to recruit and differentiate 
monocytes 
 
Next, the ability of the GvHD lesion to recruit, instruct and differentiate monocytes 
was examined.  Recruitment was predicted by chemokine receptor gene expression 
in the GvHD monocyte and skin GVH14 NanoString datasets.  Both datasets were 
considered as interaction with inflamed endothelium may be expected to alter 
chemokine sensitivity.  GvHD monocytes expressed genes for chemokine receptors 
CCR1, CCR2, CCR5, CX3CR1, CXCR2 and CXCR4.  The expression pattern in skin 
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GVH14 cells was similar, except CCR2 and CX3CR1 transcripts were undetectable 
and CCR7 was expressed.  Chemokine ligand transcripts were identified in the whole 
skin NanoString dataset (Rachel Dickinson & Kile Green).  Ten of the 13 ligands 
capable of recruiting GvHD monocytes were up-regulated in GvHD skin relative to 
BMT control (Figure 5.4, panel A). 
 
 
Figure 5.4 GvHD skin microenvironment is poised to recruit and 
differentiate monocytes 
 
Fold differences in selected gene expression by NanoString in GvHD 
relative to BMT control whole skin. A) Chemokine genes, organized by 
potential to attract monocytes (blue), T cells (red) or both monocytes and 
T cells (purple). Filled dot indicates the relevant chemokine receptor is 
expressed in skin GVH14 cells; open dot in GvHD blood monocytes. B) 
Growth factor, interferon and interleukin genes. C) IFNγ concentration in 
supernatant from GvHD biopsy culture. * p<0.05 by unpaired t-test. 
 
Expression patterns concerning interleukin, interferon and colony stimulating factor 
genes in whole skin were surveyed to gauge the environmental influences facing 
recruited monocytes.  Globally, GvHD skin was a Th1 environment, with elevated IL-
2, IL-12 and IFNγ and reduced IL-10 transcripts (Figure 5.4, panel B).  Genes for 
interleukins that maintain epithelial integrity (e.g. IL-20, IL-22) were over-expressed.  
IL-6 transcript was particularly elevated, but IL-8 suppressed, suggesting MP but not 
neutrophil innate immune activation.   
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According to simplified models of monocyte to macrophage transition, M-CSF, GM-
CSF, IL-4 and IFN γ/β instruct distinct differentiation and activation programs.  GM-
CSF and IFNγ induce a classically activated (M1) phenotype, while M-CSF and IL-4 
instruct an alternatively activated (M2) phenotype.  Elevated expression of M-CSF, 
IL-4 and IFN γ/β genes were seen in GvHD lesions.  Significantly higher levels of 
secreted IFNγ were detected in GvHD compared with control skin cultures (Figure 
5.4, panel C).  This suggests GVH14 macrophages are forged in an environment 
intermediate between the M1 and M2 paradigms. 
 
5.4.4 Monocytes differentiated in an MLR resemble GVH14  
 
A method of generating GVH14 equivalents in vitro was sought in order to perform 
more extensive tests on their function.  Based on the data presented above, it was 
predicted that M1 or M2 protocols would be insufficient and that Th1 cytokines may 
be required.  To provide a pathologically relevant context, MLRs were established 
from transplant donor and recipient PBMCs.  Cells with macrophage morphology 
were clearly identified in the MLR output (Figure 5.5, panel A).   Using flow cytometry 
to dissect the output, macrophages were identified as SSChi HLA-DR+ cells 
expressing CD14 and CD16 (Figure 5.5, panel B).  In common with GVH14, MLR 
macrophages expressed CD64 and CD206.  Macrophages varied from 3-24% of 
output cells.  They were significantly more abundant in related donor than in 
unrelated donor MLRs (macrophage: lymphocyte ratio 0.4 ± 0.2 and 0.09 ± 0.05 
respectively) (data not shown).  
 
Testing similarity of MLR macrophages to GVH14s was challenging.  MLR 
macrophages were significantly more autofluorescent, which made it difficult to 
compare surface antigen expression directly.  With gene expression profiles, major 
differences between cultured blood cells and ex vivo tissue cells were anticipated.  
Comparing cultured macrophages and GVH14 by PCA, the first principal component 
split stimulated from un-stimulated cells, with GVH14 falling mid-way (Figure 5.5, 
panel C).  The second principal component split cultured cells from GVH14.  On the 
third principal component, M1 macrophages were separated from M2 macrophages, 
with GVH14 and MLR macrophages falling mid-way.  GVH14 and macrophages 
shared similar expression of a number of GVH14-defining genes (Figure 5.4, panel 
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D).  While MLR macrophages could be said to resemble GVH14 it was difficult to 
establish that they were the optimal in vitro model. 
 
 
 
Figure 5.5 Monocytes differentiated in an HLA-matched MLR 
resemble GVH14.  
 
Ai) Cytopsin of an MLR output at day 7, Giemsa stained, imaged at 20x 
magnification.  Aii) Comparison of monocyte and MLR macrophage 
morphology at 40x magnification.   
Bi) Flow cytometry analysis of PBMCs, gating HLA-DR+ MPs, and 
assessing CD64/ CD206 expression on classical (red), intermediate (blue) 
and non-classical (green) monocytes.  Bii) Applying the same analysis to 
MLR output to identify CD14, CD16, CD64 and CD206 expression on MLR 
macrophages.   
C) PCA plots of NanoString gene expression in GVH14 and cultured 
macrophages (stim= LPS and IFNγ stimulation for 24 hours) 
D) Heat-map of selected gene expression in GVH14 and MLR 
macrophages. 
 
 
5.4.5 MLR macrophages mediate skin damage in an explant model of GvHD 
 
Functions of macrophages at the site of skin GvHD injury were tested using a skin 
explant model.  Using the total output from a donor-recipient MLR generated 
recipient skin damage consistent with Lerner grade 3, as has previously been 
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reported (Figure 5.6, panel B).  Introducing MLR macrophages in the absence of T 
cells could also induce recipient skin damage (median grade 2).  Features of skin 
damage included swelling of basal keratinocytes (white arrow) and oedema at the 
dermo-epidermal junction (black arrow) in grade 2 (Figure 5.6, panel A).  
Keratinocyte apoptosis (yellow arrow) and extensive cleft formation at the dermo-
epidermal junction (red arrow) occurred in grade 3.  
 
 
 
Figure 5.6 MLR macrophages induce tissue damage in a skin explant 
model of GvHD 
 
A) H&E stained images of recipient skin co-cultured with medium alone (i) 
imaged at 20x magnification or with MLR macrophages (ii, iii) imaged at 
40x magnification.  Coloured arrows representing features of tissue 
damage are discussed in the text.   
B) Median GvHD grade in explant skin co-cultured with the indicated cell 
type (summary of n=4).   
C) Detection of apoptotic HaCaT when cultured alone (i) or in the 
presence of macrophages (ii).  
D) Summary of keratinocyte apoptosis with 3 MLR macrophage lines.  
E) Candidate cytotoxic effector gene expression by NanoString. 
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To examine direct effects of macrophages on keratinocytes, MLR macrophages were 
co-cultured with a keratinocyte cell line.  Cells with established apoptosis were 
detected as Annexin V+ 7-AAD+ by flow cytometry (Figure 5.6, panel C).  Co-culture 
with macrophages induced marked keratinocyte apoptosis using two of the three 
MLR macrophage lines tested (Figure 5.6, panel D). 
 
Potential mediators of dermo-epidermal damage were considered.  Activated 
macrophages have high secretory activity (Takemura and Werb, 1984).  Potentially 
damaging products include proteinases such as collagenase, reactive oxygen 
species and cytolytic factors.  As keratinocyte apoptosis, and not simply disruption of 
extracellular matrix was seen in explants, attention was focused on cytolytic or pro-
apoptotic factors.  Analysing candidate gene expression by NanoString, genes for 
cytotoxic effectors perforin (PRF1), granzyme A (GZMA) and granulysin (GNLY) 
were up-regulated in MLR macrophages and similarly expressed in GVH14 (Figure 
5.6, panel E).  Apoptosis-inducing ligand TRAIL (TNFSF10) was expressed in MLR 
macrophages but little was present in GVH14.  Experiments are ongoing to confirm 
the cytotoxic potential and effector mechanisms of MLR macrophages.   
 
 
5.5 Summary of results for Chapter 5 
 
Analysis of gene expression by GvHD blood monocytes supports the concept that 
monocyte-derived macrophages have a subtly different precursor in inflammation.  
Whole skin NanoString indicates that GvHD inflamed skin is primed to recruit 
monocytes and that monocytes are differentiated under activation conditions that 
resemble neither M1 nor M2 paradigms.   Differentiating monocytes under Th1 
conditions in a MLR generated macrophages with similarity to GVH14 in terms of 
surface antigen and gene expression.  In a skin explant model, these MLR 
macrophages induced GvHD-like skin damage in the absence of T cells.  Potential 
cytolytic effectors were similarly expressed in MLR macrophages and GVH 
monocyte-derived macrophages. 
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Chapter 6.  Skin strand discussion 
 
6.1 Discussion point 1: Monocyte-derived macrophages accumulate in GvHD 
skin 
 
Studies of human cutaneous GvHD lesions have demonstrated that monocyte-
derived macrophages are the dominant MP.  Previous studies on inflamed skin have 
detected inflammatory MP populations but reached different conclusions about their 
identity.  The IDECs (inflammatory dendritic epidermal cells) described in the 
epidermis of eczema express CD1c and CD1a (Wollenberg et al., 1996), (Schuller et 
al., 2001), in contrast to the cells characterized here in GvHD.   FACS analysis in this 
thesis suggests that eczema has a distinct MP profile to GvHD, typified by 
dominance of CD1c-expressing cells.  It therefore seems likely that IDEC are 
different inflammatory population.  How they relate to the steady-state CD1c-
expressing DC population (cDC2) requires further clarification.   
 
The inflammatory populations described in psoriasis may overlap with what I have 
identified in GvHD.  The CD11c+HLA-DR+CD1c- inflammatory dermal DCs identified 
by Zaba et al had a similar immunophenotype and also expressed macrophage-
typical genes (Zaba et al., 2009), (Zaba et al., 2010).  A different conclusion was 
reached about their identity as they shared some gene-expression similarities with in 
vitro moDCs.  An ostensibly separate inflammatory population in psoriasis with 
greater expression of macrophage surface antigens (CD163 and FXIIIa) was 
described (Fuentes-Duculan et al., 2010).  In the absence of side-by-side comparison 
it is difficult to appreciate that this population is distinct from inflammatory dermal 
DCs.   
 
The inflammatory infiltrate accompanying cutaneous sarcoidosis has received less 
attention.  Lesions immuno-stain for CD11c and S100A8/9, but not CD68, consistent 
with what I describe in GvHD (von Bubnoff et al., 2011).  Though only performed in 
one sample, FACS analysis of cutaneous sarcoidosis revealed a similar MP profile to 
GvHD, with dominance of cells in the monocyte-derived macrophage parameter 
space. 
 
Jardine L, 2016 
! 121!
Accumulation of CD14+/CD163+/CD11c+ expressing-cells has been reported in 
other inflamed human tissues including the duodenum in Coeliac disease (Beitnes et 
al., 2011), the ileum in Crohn’s disease (Ogino et al., 2013),!(Tamoutounour et al., 
2012) and the colon in Ulcerative colitis (Bain et al., 2013).  Though not extensively 
characterized, these cells were compared with infiltrates detailed in parallel mouse 
studies (Tamoutounour et al., 2012), (Bain et al., 2013). 
 
Murine Ly6Chi monocytes are recruited to gut both in steady state and inflammation 
(Bain et al., 2013), (Tamoutounour et al., 2012), (Zigmond et al., 2012).  In steady 
state, they enter tissue as Ly6C+, MHC class II- cells.  They lose Ly6C and gain 
MHC class II, then sequentially acquire F4/80 and CX3CR1 (stages termed P1-4).  
Parabiosis experiments are in keeping with monocyte derivation of all these 
populations and adoptive transfer experiments support the sequential transition in 
phenotype.  In inflammation, P1 and 2 expand, but differentiation appears to be 
blocked, leaving pro-inflammatory cells with monocytic features.   
 
Similar analysis has been applied to mouse dermis in steady state and during contact 
hypersensitivity (Tamoutounour et al., 2013).  Successors of Ly6Chi monocytes at 
sequential stages of differentiation are seen in steady state, but in inflammation, the 
early derivatives of monocytes dominate.  Type I interferon and IFNγ-mediated 
signalling is implicated in this differentiation block.  In quiescent skin and gut, 
monocyte derivatives with DC features are described (Zigmond et al., 2012)!
(Tamoutounour et al., 2013), but in inflamed skin, these populations are diminished 
relative to cells with effector monocyte features (Tamoutounour et al., 2013).  While 
the Ly6Chi-MHC II waterfall plot used by Tamoutounour et al to identify monocyte-
differentiation into DCs (P1-3) has superficial similarity to the human CD14 CD1c plot 
used in this thesis, human CD1c+ cells are not currently thought to arise from 
monocytes.  Monocyte differentiation potential in both species needs further 
clarification, but the tendency of monocyte-derived effector cells to accumulate in 
inflamed tissue in both mouse and human can be agreed upon. 
 
 
 
 
Jardine L, 2016 
! 122!
6.2 Discussion point 2: Parallels to a murine model of macrophage infiltration 
in chronic GvHD. 
 
The closest murine parallel to my findings in human GvHD is the accumulation of 
macrophages in an IL-17 dependent sclerodermatous cGvHD model (Hill et al., 
2010), (Alexander et al., 2014).  The fact that this is a chronic GvHD model does not 
preclude comparison.  As this thesis studies a T cell depleted BMT cohort, the 
boundaries between typical acute and chronic GvHD can be expected to overlap 
(Pavletic and Fowler, 2012).     
 
In the cGvHD model, donor macrophages infiltrate the dermis from 7 days post 
transplant (Alexander et al., 2014).  Infiltration is not lichenoid:  macrophages are 
initially seen throughout the papillary (upper) dermis but become concentrated in the 
reticular (lower) dermis and subcutaneous fat by 3 weeks post-transplant and are 
implicated in the subsequent sclerosis of these tissues.  Data on the distribution of 
human macrophage infiltration not presented in this thesis can be seen in Appendix 
C.  Lichenoid infiltration was observed.  Involvement of the lower dermis could not be 
excluded as biopsies were superficial.  Sclerodermatous chronic GvHD did not 
develop in any patient, but all received some therapy to modify the course of their 
disease.  In summary, the pattern of macrophage infiltration is not a definite parallel. 
 
Infiltrating macrophages in the cGvHD model are said to have an M2 phenotype as 
they express CD206 but not iNOS by immunostaining (Alexander et al., 2014).  Using 
a broader range of antigens, an M1 or M2 phenotype could not be ascribed to human 
GVH14.  They do express CD206, but expression of MHC class II, CD86 and CD64 
and production of TNFα are features of classical macrophage activation.  The M1/M2 
paradigm is increasingly recognized as an unhelpfully simplified view of macrophage 
activation (Martinez and Gordon, 2014), (Xue et al., 2014). 
 
Macrophages in both the cGvHD model and human GvHD express the receptor for 
M-CSF (CSF1R)!(Alexander et al., 2014).  In the murine model, CSF1 dependence 
was demonstrated.  CSF1 administration increases macrophage accumulation.  Use 
of a CSF1 receptor knockout BMT donor or administration of a blocking CSF1 
receptor antibody reduces both macrophage accumulation and cutaneous pathology.   
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The precursor of cGvHD infiltrating macrophages is considered to be the Ly6Clo 
monocyte (Alexander et al., 2014).  Using CSF1r-/- foetal liver chimeras (FLC) on a 
B6 background, the authors reduced the proportion of peripheral blood Ly6Clo 
monocytes by approximately 50%.  Mice receiving BMT from a CSF1r-/- FLC had 
reduced skin macrophage infiltration, but that does not necessarily implicate Ly6Clo 
monocytes as the precursor.  Ly6Chi monocytes remain a likely candidate and may 
simply require CSF1 to differentiate into skin-infiltrating macrophages.  When 
characterising human GVH14, an assumption was made that classical monocytes 
(Ly6Chi-equivalent) were the most likely precursor.  This assumption was based on 
the striking similarity between GVH14 and steady state CD14 MDMs.  Connectivity 
map analysis (a gene set enrichment tool) aligns CD14 MDM with classical rather 
than intermediate or non-classical monocytes!(McGovern et al., 2014).  Murine 
models of inflammation demonstrate a precursor-product relationship between Ly6Chi 
monocytes and inflammatory macrophages (Bain et al., 2013), (Tamoutounour et al., 
2013).  As Ly6Chi monocytes are also the precursor of Ly6Clo monocytes (Yona et al., 
2013), it is not impossible that a Ly6Clo state directly precedes an inflammatory 
macrophage state.  However, a defined role for Ly6Clo monocytes as an endothelial 
macrophage is emerging, and retention of Ly6Clo monocytes in the intravascular 
space may be important for orchestration of the innate immune response (Carlin et 
al., 2013).  Perhaps a more detailed analysis of monocyte dynamics in murine 
cGvHD would be warranted. 
 
In summary, accumulation of macrophages in the murine cGvHD model has some 
parallels to findings described here in human acute GvHD.  Detailing the exact 
similarities in inflammatory macrophages between species is challenging.  This 
challenge should be addressed in future studies.  A murine model that faithfully 
represents a pathological process seen in patients would be invaluable for 
developing a more detailing understanding of the process and its response to 
therapy.  Cross species transcriptome profiling offers promise as a means of aligning 
findings in murine and human studies (Carpentier et al., 2016), (Haniffa et al., 2012), 
(Ingersoll et al., 2010), (McGovern et al., 2014). 
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6.3 Discussion point 3: GvHD monocyte-derived macrophages are pro-
inflammatory 
 
The monocyte-derived macrophages isolated from GvHD lesions secreted 
inflammatory cytokines (e.g. TNF, IL-8), produced little IL-10 and stimulated 
allogeneic T cells.  In vitro equivalents caused GvHD-like cutaneous damage.   
 
Experimental rigor must be considered for each of these observations.  As the 
number of cells isolated from GvHD lesions was insufficient for routine purity testing, 
it cannot be disproven that contamination by other cell types influenced results.  For 
example, DCs contaminating the GVH14/CD14 MDM gate would make the 
allostimulatory capacity of this population appear greater.  The likelihood of 
contamination was reduced by good sorting technique, encompassing both 
experimental design and conduct.  In sorting experiment design, single cell gates 
were used to avoid unwanted cells entering as doublets combined with cells of 
interest.  Gates were applied tightly to populations with as little overlap as possible.  
When conducting a sort, filtered single cell suspensions were used and a sufficiently 
large nozzle size selected to promote stream stability.  Sorts were monitored and the 
drop delay reset if deviation of more than 10 pixels occurred.  This ensured that sort 
decisions were applied to the droplet of interest (i.e. the droplet containing the 
specified cell), not the one above or below (which may contain any cell and would 
contaminate the specified sort population).  Even if a small number of DCs 
contaminated the GVH14 gate, this would be unlikely to occur without contaminating 
the CD14 MDM gate also.  GvHD and control samples were sorted within the same 
period of time, using the same sort template and sometimes on the same day.  The 
differences between GvHD and control are therefore more likely to arise from 
biological difference than inaccurate sorting. 
 
Monocytes entering inflamed tissue have been ascribed both pro-inflammatory and 
immunoregulatory roles depending on the context.  In a murine model of pathogen-
driven inflammation, pro-inflammatory monocyte activity benefited the host by aiding 
pathogen clearance (Serbina et al., 2008).  In models of inflammatory bowel disease, 
such activity is harmful and monocyte depletion can ameliorate pathology (Zigmond 
et al., 2012).  In an elegant study of gut Toxoplasma gondii infection, infiltrating 
monocytes were credited with maintaining mucosal integrity via prostaglandin E 
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production and inhibitory effects on neutrophils!(Grainger et al., 2013).  Despite 
systemic infection in this model and monocyte recruitment to multiple tissues, 
regulatory monocytes were only present in gut.   
 
Tissue-specific functions of recruitment monocytes require careful consideration in 
systemic diseases such as GvHD.  It is possible that while monocytes recruited to 
GvHD skin are pro-inflammatory, monocytes recruited to gut could function to limit 
the extent of pathology.  Without ruling out this possibility, attempts at therapeutic 
monocyte depletion may have undesirable consequences. 
 
 
6.4 Discussion point 4: Monocytes are recruited to GvHD skin before peak 
lymphocyte accumulation 
 
Follow-up biopsies after resolution of GvHD inflammation showed lymphocyte 
accumulation that was not apparent on presentation.  It therefore seems likely that 
monocyte recruitment is an early event and lymphocyte accumulation peaks later in 
this cohort.  It is worth reiterating that this is a cohort of older adults following T-cell 
depleted BMT.  Lymphopenia is expected to be more pronounced and more 
prolonged than in T-replete regimens, younger patients or mouse models of GvHD.  
Therefore innate cells may take on greater importance in inflammation. 
 
Is it possible that monocytes initiate the graft-versus-host reaction?  The prevailing 
view in immunology is that T lymphocytes are the sensors of histocompatibility.  
Challenging this, all metazoan organisms can recognize histoincompatibility but only 
vertebrates possess adaptive immune systems (De Tomaso et al., 2005).  In more 
primitive animals e.g. chordates, innate immune cells recognize and respond to the 
non-self products of polymorphic gene loci (De Tomaso et al., 2005).  In vertebrates, 
innate immune recognition of histoincompatibility has precedent in NK cells.  Rather 
than recognizing non-self MHC polymorphisms or peptides, NK cells respond to 
changes in the balance of activating and inhibitory signals received through 
interactions of MHC with various receptors (Kumar and McNerney, 2005).  In 
lymphocyte-deficient murine models, monocytes can recognize histoincompatibility 
(Zecher et al., 2009), (Liu et al., 2012), (Oberbarnscheidt et al., 2014) and this 
recognition is independent of MHC (Zecher et al., 2009).  For example, RAG(-/-) mice 
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given an intradermal injection of splenocytes have more florid inflammation 
(monocyte/ macrophage-rich) if the cells are allogeneic than if they are syngeneic!
(Zecher et al., 2009).  This response requires prior allo-immunization.  Monocytes 
retrieved from a sensitized animal can substitute a prior allo-immunization event.  In 
lymphocyte-replete settings, rapid recruitment of monocytes to xenogenic or 
allogeneic organ grafts is followed by T cell recruitment (Oberbarnscheidt et al., 
2014),!(Fox et al., 2001).  Reciprocal stimulation between monocyte-derived cells and 
T cells is noted, resulting in IFNγ, T cell proliferation and macrophage activation (Fox 
et al., 2001),!(Oberbarnscheidt et al., 2014).  Via phagocytosis, macrophages act as 
allogeneic effector cells (Liu et al., 2012).   
 
Whether donor monocytes themselves recognize histoincompatibility in human skin, 
or whether they are recruited following a T cell initiating event, their ability to act as 
antigen presenting cells warrants consideration.  GvHD monocyte-derived 
macrophages did not express CCR7 but were far superior to their steady state 
counterparts at stimulating allogeneic T cell proliferation and activation in vitro.  Thus, 
while interactions with naïve T cells in lymphoid tissue are unlikely, interactions with 
T cells in tissue are possible.  The ability of GvHD monocyte-derived macrophages to 
cross-present exogenous antigen was not tested, but was suggested from functional 
annotation of expressed genes.  Cross-presentation or cross-dressing would be 
required for these donor cells to display host peptides to donor CD8 T cells.  An 
additional possibility is that donor monocyte-derived macrophages interact with host 
T cells.  Resident memory T cells are present in abundance in human skin (Clark et 
al., 2006).   During Alemtuzumab treatment for cutaneous T cell lymphoma, skin T 
cells are protected from depletion because the necessary effectors of antibody-
mediated cytotoxicity cannot enter skin (Clark et al., 2012).  Data from this work and 
others has identified mixed T cell chimerism in skin following RIC BMT with 
Alemtuzumab-containing regimens (Collin M, unpublished communication).  The 
effector constituent of resident memory T cells is held in check by Langerhans cells 
and skin resident regulatory T cells (Seneschal et al., 2012).  It is plausible that BMT 
conditioning disturbs these regulatory mechanisms and allows effector function of 
residual host T cells upon stimulation by monocyte-derived macrophages.  Both 
antigen specific mechanisms (assuming that normal skin may harbour some auto-
reactive T cells), and antigen-independent mechanisms could be envisaged!(Iijima et 
al., 2011).  Finally, a more conventional view would be that donor monocyte-derived 
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macrophages presenting antigen contribute to the maintenance but not the initiation 
of GvHD (Matte et al., 2004). 
 
 
6.5 Discussion point 5: The MP balance is distorted in GvHD inflammation with 
an increase in CD14:CD1c ratio 
 
In the MP profile of GVHD, CD14+ cells were expanded and CD1c cells depleted 
relative to normal skin.  While CD14+ accumulation was seen in other inflammatory 
dermatoses, drastic reversal of the CD14:CD1c ratio was unique to GvHD.  This 
finding provokes three related questions. First, where are the myeloid DCs?  Second, 
how will they be replaced?  Third, is the absence of DCs and the abundance of 
monocytes-derived cells inter-linked?  
 
Myeloid DCs express CCR7, allowing them to respond to a CCL19/21 gradient and 
migrate to draining lymph nodes (Dieu et al., 1998).  It might be expected that skin 
DCs encountering danger signals mature and exit into lymphatics.  However the 
homeostatic mechanisms governing their replacement are not well characterized.  
DCs arising from monocytes have been described murine models of infection (Leon 
et al., 2007), (Nakano et al., 2009), sterile inflammation (Hammad et al., 2010), 
(Campbell et al., 2011), (Rivollier et al., 2012) and in steady state (Tamoutounour et 
al., 2013), (Jakubzick et al., 2013).  However the identifiers of DCs are not always 
watertight.  Expression of few DC-characteristic antigens does not constitute DC 
identity, as many antigens are labile during inflammation.  Transcriptional proximity to 
in vitro moDCs requires caution on two fronts.  Firstly, attention must be given to the 
homogeneity of the in vitro preparation.  Starting with an impure monocyte population 
or failing to remove undifferentiated cells will result in a mixed gene expression 
signature.  Secondly, the outcomes of gene-set enrichment analysis common to this 
field are dependent on the populations juxtaposed:  if important subsets are missing, 
a population may enrich with a signature that is not its closest match (Carpentier et 
al., 2016).  Concerning functional identifiers, detecting an inflammatory population in 
draining lymph node does not necessarily mean the population has migrated from 
inflamed tissue.  Monocyte-derived macrophages can be simultaneously recruited to 
regional lymph nodes but are not migratory (Tamoutounour et al., 2012).  Further, the 
ability to stimulate T cells requires careful interpretation of the system used.  
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Macrophages can stimulate extensive T cell proliferation with peptide antigens 
(Tamoutounour et al., 2013).  Despite the pitfalls in DC-identification, there is 
convincing evidence that monocyte-derived DCs exist in mouse, (Zigmond et al., 
2012).  In humans, it is difficult to reliably infer the origin of a cell, but single-cell 
technologies combined with trajectory algorithms could remedy this!(Bendall et al., 
2014).  
 
Myeloid DCs were also relatively depleted from blood in GvHD.  This depletion may 
arise from DC recruitment to lymph node or it may reflect reduced production in the 
bone marrow.  Leukocyte production is known to fluctuate according to remote 
signals in tissue!(Courties et al., 2015),!(Dutta et al., 2015), (Weber et al., 2015).  
Such “demand-adapted haematopoiesis” results in a bias towards myeloid over 
lymphoid production (Takizawa et al., 2012).  Whether inflammation biases the fate 
of common MP precursors is not known.  However, signalling in bone marrow (via 
IFNγ and G-CSF) can alter the functional characteristics of circulating monocytic 
progeny (Askenase et al., 2015), (D'Aveni et al., 2015).  Relevance to the 
development of subsequent GvHD has been demonstrated (D'Aveni et al., 2015). 
 
The increased CD14:CD1c ratio seen in GvHD suggests that DC replacement is not 
immediate.  The absence of DCs will have consequences for the balance of growth 
factor signals in tissue.  Under experimental conditions of extreme myeloid DC 
deficiency, monocytes accumulate in tissue and develop inflammatory effector 
phenotypes (Birnberg et al., 2008), (Sivakumaran et al., 2016).  Altered consumption 
of Flt-3 ligand and GM-CSF underpin these alterations.  It is possible that more 
subtle changes in these growth factors affect monocyte accumulation in inflamed 
tissue when myeloid DCs are reduced.  
 
 
6.6 Conclusions 
 
This work provides the first detailed characterization of monocyte-derived 
macrophages in human skin during inflammation.  Taking a broad view of the MPS 
has identified simultaneous changes in skin myeloid DCs and blood monocytes/ DCs.  
The inter-relationships of these populations and the tone of their haematopoietic 
precursors in inflammation are ripe for further investigation. 
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Chapter 7.  Lung mononuclear phagocytes in steady state and 
inflammation 
 
7.1 Introduction 
 
Lung pathology accounts for approximately 50% of non-relapse deaths following 
BMT.  Causative infections are found in only half of cases (Soubani and Pandya, 
2010).  Acute non-infective lung injuries are currently considered together as 
idiopathic pneumonia syndrome (IPS).  Treatment responses to IPS are limited and 
survival is poor (Panoskaltsis-Mortari et al., 2011).  Dissecting this syndrome and 
stratifying treatment accordingly may benefit patients with IPS.  
 
Animal models and clinical correlations implicate alloreactive T cells in IPS (Cooke et 
al., 1996), (Soubani and Pandya, 2010), (Nishie et al., 2016).  Dysregulated innate 
responses in the lung, for example in response to respiratory virus infection or LPS 
produced by translocated gut bacteria, have been identified as triggers for 
alloreactivity (Cooke et al., 1996), (Versluys et al., 2010).  MPs are predicted to be 
important as sensors of PAMPs, innate immune effectors and stimulators of 
alloreactive T cells. 
   
Patients with IPS are a difficult population to study.  In fulminant form, IPS is rare, 
patients are ill and even if broncho-alveolar lavage (BAL) is performed, patients are 
heavily pre-treated with anti-microbials, making infective and non-infective 
presentations difficult to separate.  As the normal immune composition of BAL fluid 
has been poorly detailed to date, interpreting inflammatory from resident cells would 
be challenging. 
 
In the lung strand of this work, a human experimental model of sterile inflammation is 
exploited to characterize the steady state and inflammatory populations in BAL.  This 
model offers a precise onset of inflammation, the ability to sample two compartments 
(blood and BAL), and the opportunity to test MP dynamics through serial samples.  
This work aims to provide a foundation for meaningful interpretation of IPS BAL fluid 
in future studies.   
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7.2 Lung strand hypotheses 
 
1) Steady state BAL contains monocyte-derived MPs, myeloid DCs and pDCs 
2) LPS inhalation will trigger inflammatory MP accumulation in BAL 
3) Inflammatory MPs will be derived from monocytes 
 
7.3 Chapter Aims 
 
7.3.1 Lung Strand Aim 1: To define the MPs present in BAL in steady-state and 
in response to LPS inhalation 
 
To test hypotheses 1 and 2, MPs of the lower airways will be sampled by BAL 
following standardized inhalation of LPS or saline.  Samples will be analysed by flow 
cytometry using a gating strategy applicable to blood, so that populations are defined 
with reference to circulating MPs.  Within Aim 1, the subsets of MPs present in BAL 
will be determined.  The differences between steady state and induced inflammation 
will be quantified. 
 
7.3.2 Lung Strand Aim 2: To understand how MPs transit from blood to lung 
following LPS inhalation 
 
Two research aims will gather evidence to test hypothesis 3.  Gene expression 
analysis will be used in next chapter.  In this chapter, parallels between blood and 
BAL fluid will be used.  Blood from experimental volunteers will be serially sampled to 
provide temporal information on MP dynamics.  The chemokine profile of BAL fluid 
will be compared with the chemokine receptor distribution on circulating MPs to 
understand specificity of recruitment.  Within Aim 2, blood MPs will be quantified 
using a flow cytometry TruCount method.  The chemokine and cytokine profile of 
BAL fluid will be tested by Luminex.  Repository data will be explored to examine 
differential chemokine receptor gene expression between MP subsets 
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7.4 Materials and Methods for Chapter 7 
 
7.4.1 Overview of the LPS inhalation study 
 
The LPS inhalation study was approved by Newcastle & North Tyneside 2 Research 
Ethics Committee (REC reference number 12/NE/0196) under the full title ‘A 
lipopolysaccharide (LPS) inhalation model to characterise divergent cellular innate 
immune responses and presence of alveolar leak early in the course of acute lung 
inflammation.’  The study was funded by the Joint Research Executive Scientific 
Committee of Newcastle upon Tyne Hospitals NHS Charity.  Professor John 
Simpson was the Principal Investigator.  Dr Sarah Wiscombe was the main co-
investigator and led the trial for 3 years.  I led the trial for the final year.  This role 
included recruiting and screening approximately 30 participants, scheduling study 
visits, administering study interventions, monitoring the participants, processing 
samples and following up participants.  An overview of the study groups and key 
assessments is shown in Figure 7.1.  Details of volunteer recruitment, inclusion and 
exclusion criteria and informed consent are given in Appendix A.    
 
 
 
 
 
cell pellet       
time (hrs)         0*            2*                 4*                  6*   7/8     24*  ! ! !!!!
Inhalation 
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60 µg (n=13)        
Inhalation 
saline (n=13) ! ! ! !!!!
!blood sampling*  ! !!!!
BAL  
150ml   ! !!!!
Figure 7.1 Overview of the LPS inhalation study 
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BAL  
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7.4.2 Group allocation 
 
The first 16 participants were randomly allocated to receive saline or LPS.  Allocation 
was made using sealed envelopes provided by a third party.  This process was 
abandoned for the final 10 participants to allow greater control over experiments.  
Participants were not made aware which intervention they had received. 
 
Samples from the first 7 participants were used to optimize protocols.  Data reported 
in this chapter are from the subsequent 9 participants receiving saline and 10 
participants receiving LPS.  The characteristics of participants were well matched 
between saline and LPS groups (Table 7.1). 
 
 
 
7.4.3 Study interventions  
 
All volunteers provided written, informed consent.  All were advised of the nature of 
bronchoscopy.  Intravenous sedation with midazolam was available, but all 
participants elected for a non-sedated procedure.  Participants received topical 
administration of 1% lignocaine spray to the mouth and pharynx.  When nasal 
intubation was used, 1% lignocaine spray was applied topically to the nose. 
 
An LPS solution for inhalation was prepared in sterile conditions immediately prior to 
use.  Two milligrams of LPS from E. coli 026:B6 (Sigma) were reconstituted in 1.8ml 
0.9% sodium chloride and mixed well.  At time=0 participants inhaled 60µg (54µL) 
LPS solution or sterile 0.9% saline.  Five controlled inhalations were performed using 
!
Table 7.1:  Participant characteristics 
 
 LPS Saline p value 
Age (years) 
Mean (SD) 
 
21 (1.83) 
 
21 (1.39) 
 
0.92 (unpaired t-test) 
Gender 
Male; n (%) 
Female; n (%)  
 
7 (70) 
3 (30) 
 
4 (44) 
5 (56) 
 
0.37 (Fisher’s exact test) 
Ethnicity 
Caucasian; n (%) 
Other; n (%) 
 
8 (80) 
2 (20) 
 
8 (89) 
1 (11) 
 
1.00 (Fisher’s exact test) 
Body surface area (m2) 
Mean (SD) 
 
1.90 (0.19) 
 
1.74 (0.16) 
 
0.06 (unpaired t-test) 
Forced vital capacity (L) 
Mean (SD) 
 
4.39 (0.73) 
 
3.93 (1.02) 
 
0.45 (unpaired t-test) 
Forced expiratory volume 
in 1 second (L) 
Mean (SD) 
 
 
4.39 (0.72) 
 
 
3.93 (1.02) 
 
 
0.22 (unpaired t-test) 
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an automatic inhalation-synchronized dosimeter nebulizer (Spira, Hameenlinna, 
Finland).  The test solution was released once the participant had inhaled 50ml air, to 
ensure that laminar flow was established.  Participants performed a 5 second breath 
hold at vital capacity to promote deposition of LPS in the lower respiratory tract 
(Darquenne et al., 2000). 
 
Venous blood sampling was performed at 0, 2, 4, 6 and 24 hours after inhalation.  At 
7 hours after inhalation, participants underwent bronchoscopy.  An experienced 
bronchoscopist (either Dr Sarah Wiscombe or Dr Ian Forrest) passed the flexible 
fibre-optic bronchoscope into a sub-segment of the medial segment of the right 
middle lobe and gently wedged the scope.  An initial 20ml sterile 0.9% saline was 
instilled, gently aspirated and discarded as a ‘bronchial sample’.  A further 150ml 
warmed saline was instilled in 50ml aliquots and retrieved by gentle suction.  
Typically 80-120ml was retrieved (see Table 7.2). 
 
 
 
7.4.4 BAL collection, handling and storage 
 
BAL fluid was passed through a 100micron filter and centrifuged at 500g for 7 
minutes to pellet cells.  Supernatant was stored in 1.5ml aliquots at -80°C.  The cell 
pellet was re-suspended in 1ml of PBS without calcium and magnesium and mixed 
thoroughly.  A 10µl sample was used for cell counting and viability assessment.  
Cells were either cryopreserved or prepared immediately for flow cytometry/sorting 
using antibody panels detailed in Table 7.3.  Recovery following cryopreservation 
was poor and immediate use of samples was preferred. 
 
 
Table 7.2  Sample characteristics 
 
 LPS Saline p value 
(unpaired t test) 
BAL volume (ml) 
Mean (SD) 
 
98 (20) 
 
93 (24) 
 
0.68  
Viable BAL leukocytes 
(*106) 
Mean (SD) 
 
 
16.4 (8.32) 
 
 
5.2 (2.49) 
 
 
0.001  
BAL red blood cells  
(*106) 
Mean (SD) 
 
 
33 (31) 
 
 
17 (28) 
 
 
0.04  
Blood neutrophil fold 
change (t=6/ t=0) 
Mean (SD) 
 
 
3.31 (1.01) 
 
 
1.17 (0.25) 
 
 
<0.001  
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7.4.5 Blood MP enumeration 
 
Blood samples were obtained from all 10 participants receiving LPS and 8 of the 9 
participants receiving saline.  Venous access could not be obtained in one participant 
that would satisfy repeated sampling.  At each time point, a full blood count (FBC) 
was performed on an automated haematology analyser (Sysmex XE-2100). 
 
Detailed MP enumeration used a BD TruCountTM method.  This employs flow 
cytometry to enumerate cells in whole blood by comparing event counts in a given 
volume to counts of polyfluorescent beads.   According to the manufacturers 
instructions, 50-100µl whole blood should be used, lysed in 450 or 900µl and 
acquired at a low event rate, taking 10-20 minutes per sample.  In previous 
experience, this method permitted enumeration of monocytes and DCs but event 
counts for DCs were low (Jardine et al., 2013).  An adapted method was devised to 
allow enumeration of MPs in 1ml blood with the same volume of reagents and time-
scale as the manufacturers protocol.  
 
1-2 ml blood was collected into EDTA.  1ml was transferred into a 15ml falcon tube 
and lysed with 2ml red cell lysis buffer for 10 minutes.  Leukocytes were washed and 
pelleted by centrifugation (5 minutes at 500g).  Care was taken to fully remove all 
supernatant.  Cells were re-suspended in their own volume (50µl) and transferred to 
Table 7.3 Antibodies used for LPS study BAL and blood flow cytometry/ sorting 
 
Antigen Fluorochrome 
conjugate 
Clone Manufacturer Catalogue 
Number 
Volume (µl)/ 1010 
cells in 100µl buffer 
CD45 V500 HI30 BD 560777 
 
4 
CD3, CD19, 
CD20, CD56 
FITC SK7 
4G7 
L27 
NCAM 16 
BD 345763 
345776 
345792 
345811 
4 each 
HLA-DR V450 G46-6 BD 561359 
 
4 
CD14 BV650 M5E2 Biolegend 301835 
 
2.5 
CD16 PE/ DazzleTM 594  3G8 Biolegend 302053 
 
3 
CD11c APCCy7 Bu15 Biolegend 337218 
 
3 
CD123 PERCPCy5.5 7G3 BD 558714 
 
4 
CD1c PECy7 L161 Biolegend 331516 
 
3 
CD11b APC ICRF44 Biolegend 301310 
 
4 
BTLA PE J168-540 BD 558485 
 
2 
dead cells DAPI  Partec 05-5005 1 in 10 dilution after 
final wash 
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a TruCount tube (BD), containing a standard number of beads.  Residual cells were 
re-suspended in 50µl flow buffer and added to the TruCount tube.  Antibodies were 
added (detailed in Table 7.3) for 20 minutes at 4°C.  The sample was re-suspended 
in 400µl red cell lysis buffer and acquired on a Fortessa X20.  No forward or side-
scatter thresholds were set so that all bead events were recorded.  A low CD45 
threshold was set so that red cell/ platelet debris could be excluded but CD45lo 
granulocytes included.  Samples were acquired slowly to ensure stable background 
subtraction by the cytometer. 
 
7.4.6 Chemokine/ cytokine analysis 
 
Chemokines and cytokines in BAL supernatant were quantified using the 
Procartaplex 34-plex luminex assay (see section 2.5.2).  Concentrations were 
inferred from standard curves in Procartaplex Analyst software.  
 
7.4.7 MP chemokine receptor gene analysis 
 
Normalized microarray repository data on blood monocyte and DC subsets were 
used (Haniffa et al., 2012).  Mean expression of 7 chemokine receptors capable of 
responding to the ligands present in LPS BAL fluid was calculated for each subset.  
Mean log2 expression data were imported into MeV software for heat-map 
generation. 
 
7.4.8 Alveolar macrophage NanoString 
 
Alveolar macrophages were sorted from saline and LPS BAL (each n=4) using the 
gating strategy shown in Figure 7.2 on a FACS Fusion cytometer.  Approximately 
1x105 cells were pelleted and stored at -80°C.  Cells were prepared and run on a 
NanoString Immunology v2 panel as described in section 2.6.2.  Lysis volumes were 
adjusted so that 20,000 cells from each population were used.  Normalization and 
QC were performed as described in 2.6.5.  One LPS sample failed positive content 
normalization (indicating that too little material was used) and was excluded.  
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7.4.9 Macrophage and CD14 stimulation assay 
 
Alveolar macrophages and CD14+ cells were sorted from LPS BAL (n=4 each) as 
above.  1x105 sorted cells were cultured in 96-well round bottom plates in 100µl 
RF10 containing 100ng/ml LPS.  After 10 hours, supernatants were harvested and 
stored at -80°C.  Supernatants were batch-analysed by cytometric bead array (see 
section 2.5.1).  Briefly, samples or standards were combined with antibody-coated 
bead mixes.  Antibodies to detect IL-10, IL1β, TNF, IL-6 and IL-8 were used in this 
experiment.  Bead populations were resolved using 2 fluorescence parameters on a 
FACS Canto II running FACSDIVA Version 7 and bead events were quantified (count 
and mean fluorescence intensity).  FCAP Array software version 3 was used to 
generate standard curves and calculate concentrations from flow cytometry data.  
 
 
7.5 Results Aim 1 
 
7.5.1 Flow cytometry identifies 7 MP populations in BAL 
 
MP populations in BAL fluid and blood were identified in parallel in order to simplify 
discussion about cross-compartment flux.  AM do not have a parallel in blood.  They 
were identified first within CD45+SSChi cells (Figure 7.2, panel A).  An additional 
CD45hiCD14+ gate removed neutrophils and identified a homogenous population of 
AM.  Further analysis demonstrated AM to be CD16+, CD11c+, autofluorescent and 
CD11b+.     
   
In BAL fluid, CD45+SSClo mononuclear cells could be compared with blood 
mononuclear cells.  It is well established that blood MPs are negative for T, B and NK 
lineage markers (CD3, 19, 20, 56) and positive for HLA-DR (Ziegler-Heitbrock et al., 
2010).  Use of a lineage cocktail is optimal to remove HLA-DR+ B cells and activated 
T cells from further analysis.  Without stringent removal of NK cells, CD16-expressing 
CD56dim NK cells appear in the non-classical monocyte parameter space.  Amongst 
lineage-HLA-DR+ cells, three subsets of monocytes are defined by expression of 
CD14 and CD16.  In order of abundance these are classical (CD14++CD16-), non-
classical (CD14+16++), and intermediate (CD14++CD16+) monocytes!(Ziegler-
Heitbrock et al., 2010).  In BAL, CD14++CD16- and CD14+CD16++ cells were 
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scarce.  CD14++CD16+ cells were relatively abundant (see Table 7.4).  While they 
overlap AM in terms of HLA-DR, CD11c, CD14 and CD16 expression, BAL 
CD14++CD16+ cells are small, non-autofluorescent and have uniformly high CD11b 
expression (Figure 7.2, panel C).  Subtle phenotypic distinctions can also be made 
from intermediate monocytes.      
 
 
 
Figure 7.2 Parallel identification of MPs in BAL fluid and blood 
 
Gating strategy used to identify MPs in steady state BAL (A) and blood (B) 
by flow cytometry.  Prior exclusion of dead cells and debris is not shown.  
Black rectangles show intermediate gates.  Red rectangles show MP 
populations 1-7.  The same gating is applied in A as in B.  C) Overlay plots 
of BAL monocyte/ macrophage populations compared with blood 
monocyte populations.  
 
 
Blood DCs are typically identified within the CD14-CD16- fraction of lineage-HLA-
DR+ cells!(Ziegler-Heitbrock et al., 2010).  There is negligible co-expression of CD14 
and cDC2 antigen CD1c in blood (Figure 7.2, panel B).  This was not the case in BAL 
fluid, where 10-15% of CD1c+ cells were CD14+ (Figure 7.2, panel A).  A gating 
strategy was chosen which allowed this fraction to be analysed separately from 
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CD14+ cells.   The CD14-CD1c+ gate could be refined to visualize CD11c+BTLAlo-mid 
cDC2.  cDC2 are approximately 2-fold more abundant in BAL fluid than blood.   
 
 
 
A broad CD1c negative gate was set on CD14- cells in order that all cDC1 would be 
identified (Figure 7.2, panel A).  Although blood cDC1 are CD1c-, skin cDC1 have 
variable CD1c expression and BAL fluid cDC1 characteristics were unknown.  Within 
the CD14-CD1c- gate, CD11c- cells expressing the IL-3 receptor alpha chain 
(CD123) were identified as pDC.  CD11c positive cells with high BTLA expression 
were identified as cDC1.  In common with cDC2, cDC1 were twice as abundant in 
BAL than in blood.  The converse was true of pDC.  
 
In summary, 7 distinct MP populations were identified in BAL.  AM were abundant 
and clearly distinguished.  Three MPs had parallel surface antigen expression to 
blood monocytes (CD14++CD16-, CD14++CD16+ and CD14+CD16++) although 
their relationship to circulating monocytes needs further exploration.  Two myeloid 
populations were enriched in BAL relative to their blood counterparts and pDCs were 
proportionally reduced. 
 
7.5.2 CD14+ and cDC2 populations expand following LPS inhalation 
 
The gating strategy described above was used to determine the MP composition of 
BAL fluid 8 hours after LPS inhalation.  MP frequency was compared with BAL fluid 8 
hours after saline inhalation (steady state) (Figure 7.3 panel A-B).  Differences were 
clearly evident from the first analysis plot:  CD45loSSCmid neutrophils and 
CD45+SSClo mononuclear populations were expanded.  On subsequent gates, 
expanded mononuclear cells were notable in the CD14++CD16- and the CD14-
CD1c+ parameter spaces (Figure 7.3, panel A). 
 
 
Table 7.4 MP frequency in BAL and blood 
 
Proportion of 
leukocytes (%) 
Mean (SD) 
AM CD14++ 
CD16- 
CD14++ 
CD16+ 
CD14+ 
CD16++ 
pDC cDC1 cDC2 
Whole blood  
0 
 
8.01 (2.04) 
 
0.47 (0.22) 
 
1.29 (0.85) 
 
0.23 (0.05) 
 
0.02 (0.01) 
 
0.30 (0.1) 
BAL fluid  
75.0 (9.8) 
 
0.17 (0.18) 
 
2.01 (0.99) 
 
0.14 (0.16) 
 
0.09 (0.06) 
 
0.05 (0.04) 
 
0.74 (0.45) 
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Figure 7.3 MP profile of BAL fluid following LPS inhalation 
 
A) MP populations in BAL fluid following LPS inhalation are gated as in 
Figure 7.2.  Black polygons are intermediate gates.  Dashed polygons 
overlying neutrophil and AM populations indicate that these are not 
terminal gates:  an additional CD45 versus CD14 plot (not shown) was 
used to resolve overlaps in these populations, as shown in Figure 7.2.  
Red rectangles denote MP populations. 
B) MP populations following saline inhalation (steady state) were used for 
comparison to A). 
Ci) The most abundant gated populations expressed as a mean proportion 
of CD45+ cells for LPS (n=10) and saline (n=9) samples.  “MP” 
encompasses the non-AM MPs.  Cii) The least abundant populations 
expressed as a mean proportion of “MP”.  The number within each pie 
illustrates the magnification that would be required if pies were scaled to 
MP % of 45.   
D) Quantification of neutrophils and MPs following LPS inhalation 
compared with saline inhalation.  The proportion of each MP relative to 
CD45+ cells on flow cytometry was combined with manual cell counts and 
measurements of BAL fluid volume to give absolute MP count/ml BAL 
fluid.  LPS and saline were compared by unpaired t test.  **** p<0.001, ** 
p<0.01, ns=not significant, PMN=neutrophil, AM=alveolar macrophage, 
14=CD14++CD16-, 1416=CD14++CD16+, 16=CD14+CD16++.    
   
 
The greatest MP expansion was in CD14++CD16- cells:  mean concentration per ml 
BAL fluid was increased 115 fold after LPS relative to saline inhalation (Figure 7.3, 
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panel C).  The significant increase in cDC2 concentration after LPS inhalation was 
smaller in magnitude (2-fold).  Juxtaposed with static numbers of pDC and cDC1, the 
selective expansion of cDC2 is intriguing and will be fully explored in subsequent 
sections.  A significant reduction in AM frequency was seen, and given that absolute 
counts were considered, this cannot be attributed to expansion of other leukocytes.  
Viability of CD45+SSChi cells was quantified by flow cytometry.  There was a non-
significant trend towards lower macrophage survival in LPS participants relative to 
saline controls (mean % viability ± SD was 60.6 ± 3.37 in LPS versus 68.0 ± 2.3 in 
controls; p=0.12).  Macrophage survival in vivo may have been impaired by LPS 
inhalation.  Alternatively, LPS inhalation may have induced changes in expression of 
molecules such as integrins, which mediate adherence to the alveolar epithelium.  
Either of these possibilities would result in lower AM retrieval in BAL fluid. 
 
 
7.6 Results Aim 2 
 
7.6.1 Dynamic changes in blood neutrophils, monocytes and myeloid DCs 
follow LPS inhalation 
 
The expansion of CD14+ and CD1c+ MPs in LPS BAL fluid could arise by movement 
of leukocytes across compartments in the lung (interstitial to airspace) or by 
recruitment of leukocytes from blood.  Blood leukocytes were serially quantified to 
look for evidence of direct recruitment.  It was anticipated that heavily enriched 
populations might decline in the blood at approximately 4-6 hours post inhalation, 
prior to their detected expansion in BAL fluid, and later be restored by a homeostatic 
response in bone marrow. 
 
Total white cell count began to rise in LPS relative to saline groups 2-4 hours post-
inhalation (Figure 7.4, panel A).  By 24 hours, the groups had converged as both 
were recovering from bronchoscopy.  Transient leukocytosis following BAL is well 
recognized (Cohen and Batra, 1980).  Examining the white cell differential counts, 
lymphocytes and eosinophils were static while neutrophils and monocytes accounted 
for the leukocyte expansion between 4 and 6 hours (Figure 7.4, panels B-E).  There 
was no decline in blood neutrophil count at any point between LPS inhalation and 
BAL.  Instead, neutrophil release/ production steadily increased.  A fractional decline 
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in blood monocytes was noted in the first 2 hours after LPS inhalation but this was 
not statistically significant. 
 
MP populations were quantified in more detail at 6 hours post-inhalation in 
participants receiving LPS.  MP concentration in whole blood was measured by flow 
cytometry at 6 hours relative to MP concentration at baseline.  This revealed further 
information on monocyte subsets and permitted quantification of DCs.  Classical 
monocyte expansion was accompanied by stasis in intermediate and non-classical 
monocytes (Figure 7.4, panel F).  Both myeloid DC populations significantly declined, 
while pDC counts remained constant.  cDC2 recruitment to the lung may account for 
this decline.  Alternatively, monocytes may be produced or released from the bone 
marrow at the expense of myeloid DCs.  This hypothesis cannot be tested in the 
current model, but the fact that both cDC1s and cDC2s decline in blood while only 
cDC2s are recruited favours altered haematopoiesis over recruitment. 
 
 
 
Figure 7.4 Peripheral blood leukocyte dynamics  
 
A) Total white cell count following LPS (red circles) or saline inhalation 
(blue squares).  Points indicate mean and error bars indicate SEM of LPS 
n=10 and saline n=8. B) Neutrophil count, C) monocyte count, D) 
eosinophil count, E) Lymphocyte count.  F) Mean fold change in blood MP 
count by flow cytometry at 6 hours relative to baseline in LPS participants 
only.  Bars show SEM.  
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* denotes p<0.05.  Panels A-E used unpaired t -test with Holm Sidak 
multiple comparison correction.  Panel F used two-sided paired t-test. 
 
 
7.6.2 AM contribute pro-inflammatory cytokines and chemokines following LPS 
inhalation  
 
The chemokine and cytokine profile of the LPS-exposed airspace was measured by 
Luminex assay to explore the selectivity of MP recruitment and understand the milieu 
in which recruited cells might mature, differentiate or function. 
 
Cytokines significantly enriched in LPS relative to saline BAL in order of magnitude 
were IL-6, IL1RA, IL-1β, TNFα, IL-2 and IL-4 (Figure 7.5, panel A).  CXC chemokines 
included CXCL8, which attracts neutrophils, CXCL10 (IFNγ-induced protein 10) and 
CXCL12 (stromal cell derived factor-1), which are best recognized for attracting 
lymphocytes via CXCR3 and CXCR4 respectively.  CC chemokines included CCL2 
(monocyte chemotactic factor 1, CCL3/4 (macrophage inflammatory protein 1a/b), 
CCL5 (regulated on activation normal T cell expressed and secreted; RANTES) and 
CCL11 (eotaxin).  CCL2 potently recruits monocytes via CCR2.  CCL3-5 and 11 act 
on CCR1, 3 and 5 on a number of cell types.  
 
The differential sensitivity of MP subsets to inflammatory chemokines is not well 
described.  Chemokine receptor gene expression was surveyed as a starting point, 
recognizing that gene expression and surface expression may differ and that surface 
expression may not necessarily confer a functional chemotactic response to ligand.  
A published Illumina microarray dataset was used, rather than the Nanostring data 
generated alongside this thesis as more of the genes in question were covered.  
Classical monocytes had higher expression of relevant chemokine receptors than 
intermediate and non-classical monocytes, specifically CCR2 and CCR5 (Figure 7.5, 
panel B).  The preferential recruitment of cDC2 over cDC1 correlates with higher 
expression of CCR1 and CXCR4 genes in cDC2.  Relevant chemokine genes are 
expressed at high levels in pDC, while they are not recruited.  Clearly chemokine 
gene expression is only one aspect of the propensity of cells to enter the LPS-
inflamed lung. 
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Figure 7.5 Recruitment of inflammatory cells following LPS inhalation 
 
A) Volcano plot of chemokines and cytokines in LPS relative to saline 
BAL.  Those significantly higher in LPS BAL are depicted in text (red text 
for chemokines; black text for cytokines). n=11 saline; n=12 LPS.   
B) Relative expression of chemokine receptor genes in steady state blood 
monocyte and DC subsets.  Microarray data from Haniffa et al 2012 is 
used.  Each column in the heat-map represents the mean of n=5 
replicates per subset.   
C) Expression of chemokine genes by AM from saline and LPS 
participants by NanoString.  Bars indicate mean ± SEM; * indicate p<0.01 
by unpaired t-test; n=4 saline and n=3 LPS.   
D) Inflammatory cytokine production by 14+ cells and AM isolated from 
LPS participants and stimulated with LPS ex vivo (each n=4)  
 
 
Finally, the cells responsible for inflammatory cytokine and chemokine production 
were considered.  LPS was delivered to the lower airways in this model.  Type I and 
II pneumocytes and AM cover the majority of this surface area.  LPS sensitivity has 
been reported in all three cell types (Wong and Johnson, 2013) but only AM could be 
isolated by BAL and tested further.  AM isolated after LPS inhalation expressed 
genes for all the detectable chemokines with the exception of CXCL12 (Figure 7.5, 
panel C).  Ex vivo AM stimulated with LPS produced high concentrations of TNF, IL-6 
and IL-8, detectable IL-1β and low level IL-10 (Figure 7.5, panel D).  However, a 
similar profile was seen in 14+ cells.  It is likely that resident cells, such as AM, are 
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important in establishing an inflammatory milieu and chemotactic gradient, but that 
recruited cells subsequently contribute. 
 
 
7.7 Summary of results for Chapter 7 
 
Flow cytometry analysis of BAL fluid in steady state revealed 7 distinct MP 
populations.  BAL fluid MPs expressing monocytic markers were proportionally less 
frequent than their counterparts in blood and BAL myeloid DCs were more frequent.  
Following LPS inhalation, the most dynamic changes occurred in neutrophils, CD14+ 
cells and CD1c+ cells.  While blood monocyte abundance rose steadily following LPS 
inhalation, a skew towards classical monocytes was apparent.  In contrast, blood 
myeloid DCs declined following LPS inhalation.  Putative chemokines for MP 
recruitment were enriched in LPS BAL fluid.  AM exposed to LPS in vivo were 
capable of elaborating many of these chemokines.  Inflammatory cytokine production 
was demonstrated in both resident (AM) and recruited (CD14+) cells.  
 
 !!
 !
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Chapter 8.  Heterogeneity of lung myeloid dendritic cells 
 
8.1 Introduction 
 
Analysis in Chapter 7 revealed that the cDC2 subset of myeloid DCs is expanded in 
BAL fluid within 8 hours of induced inflammation.  Enrichment of myeloid DCs in 
chronic inflammatory diseases of the skin and joints has been reported (Zaba et al., 
2009), (Segura et al., 2013).  In the most detailed characterizations, inflammatory 
DCs co-express monocyte/ macrophage antigens and have transcriptional similarity 
to in vitro monocyte-derived DCs (Segura et al., 2013).  However, none of these 
studies have had the perspective of an early time-point in acute inflammation.  It 
would be surprising if monocyte to DC differentiation, which takes 5 days in vitro 
(Sallusto and Lanzavecchia, 1994), occurred during the time-course of the LPS 
inhalation study.  Examining the inflammatory expansion of myeloid DCs may reveal 
novel detail about the relationship between blood and tissue DCs during 
inflammation. 
 
It has recently come to light that blood cDC2 comprises two distinct subsets 
(Reynolds, G., personal communication).  The subsets are separable by surface 
expression of B- and T- cell lymphocyte attenuator (BTLA).  BTLA negative cDC2 
have transcriptional similarity to monocytes while BTLA positive cDC2 have a more 
“DC-like” gene signature (Reynolds, G., personal communication).  The subsets have 
contrasting effects on T cell polarization and have distinct differentiation potentials.  
While BTLA+ cDC2 induce regulatory T cell generation and IL-4 production from T-
helper cells, BTLA- cDC2 induce Th1 cytokine production.  BTLA+ cDC2 more 
readily adopt characteristics of Langerhans cells in vitro while BTLA- cDC2 
preferentially undergo osteoclast differentiation (Reynolds, G., personal 
communication).  Separating the contributions of the two cDC2 subsets in humans 
and unpicking the heterogeneity of the analogous CD11b population in mouse has 
the potential to transform our understanding of myeloid DC immunology.  
 
In chronic joint inflammation, BTLA- cDC2 are enriched (Reynolds, G., personal 
communication).  However, the fate of BTLA positive cDC2 in acute inflammation is 
unknown and the stability of the functional differences outside blood have not been 
tested. 
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8.2 Chapter Aims 
 
8.2.1 Lung Strand Aim 3:  To examine heterogeneity within the cDC2 expansion 
in the inflamed airspace 
 
The inflammatory expansion of cDC2 will be dissected further using flow cytometry.  
FACS-sorted populations will be subjected to in vitro functional assays or gene-
expression analysis to address the questions: 
• Are cDC2 most likely derived from monocytes or blood cDC2? 
• Is there heterogeneity in the inflammatory-expansion of cDC2? 
• Is there evidence for differential recruitment of BTLA+ or BTLA- cDC2? 
• Are functional differences between BTLA+ and BTLA– cDC2 conserved on 
entry to inflamed tissue? 
• How do cDC2 differ across compartments in steady state and inflammation? 
 
 
8.4 Materials and Methods for Chapter 8 
 
8.4.1 Testing surface antigens by flow cytometry 
 
Candidate antigens that may separate blood from inflammatory or tissue cDC2 
populations were selected from Segura et al., 2013, McGovern et al., 2014 and 
Desch et al., 2015.  Antibodies used were CD1a AF700, FcER1 PE, CD11b APC, 
CD206 PE, Axl APC, CD86 PE and BTLA PE and CD1c PECy7 (details in Appendix 
B).  Expression was assessed relative to FMO or isotype control. 
 
8.4.2 T cell proliferation assay 
 
The ability of MP populations isolated from BAL to stimulate allogeneic T cells was 
tested in a mixed leukocyte reaction.  The T cell proliferation and activation assay 
described in Chapter 4 (section 4.3.5) was used.  Briefly, this comprised a 6-7 day 
co-culture of 3000 sorted MPs with 75,000 CSFE-labelled bulk allogeneic peripheral 
blood T cells.  The output was analysed by flow cytometry and T cell proliferation was 
quantified by CSFE dilution.  Three experiments were performed on populations 
sorted from LPS BAL. 
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8.4.3 T cell cytokine production assay 
 
CD4 T cells were isolated from peripheral blood of healthy donors by immunodensity 
negative selection (see section 2.2.3), and aliquots were cryopreserved at -80°C. 
 
3x104 FACS-sorted DC populations were added to 96-well round-bottom plates in 
200µl RF10.  1x105 CD4 T cells were added to DCs or incubated alone.  Following a 
6-day incubation at 37°C and 5% CO2, medium was replenished with RF10 with 
10U/ml IL-2.  At day 10, cells were stimulated with phorbol 12-myristate 13-acetate 
(PMA, 10ng/ml) and ionomycin (1µg/ml) for 4 hours to elicit cytokine production.  
Brefeldin A (10µg/ml) was added to cultures after 1 hour to concentrate cytokines 
within the endoplasmic reticulum.  Dead cells were stained with a fixable viability dye 
(Zombie Aqua) prior to fixation and permeabilization (see section 2.3.2).  Antibodies 
to IFNγ, IL-17, and IL-4 were used to identify T-cell cytokines.  Antibody details are 
provided in Appendix B.  Data were acquired on a Fortessa X20. 
 
8.4.4 Monocyte-derived DC, LPS-stimulated cDC2 and blood DC/monocytes for 
NanoString 
 
Gary Reynolds prepared moDC for NanoString.  Classical monocytes were isolated 
from healthy donor PBMC by FACS sorting.  5x105 monocytes were cultured in 500µl 
RF10 in 24-well plates for 5 days at 37°C and 5%CO2.  Medium contained 50ng/ml 
GM-CSF and 50ng/ml IL-4.  Medium and cytokines were refreshed on day 3.  Cells 
were harvested and FACS-sorted on day 5, to exclude undifferentiated CD14+ 
monocytes and include only CD1a+ moDC.   
 
I isolated blood cDC2 from healthy donor PBMC by FACS-sorting.  3x104 cDC2 were 
cultured in 96-well round-bottom plates containing 200µl RF10 and 100ng/ml LPS 
from E. coli 0.26:B6 (Sigma).  Cells were harvested at 6 hours.  
 
Gary Reynolds isolated monocytes, BTLA+ and BTLA- cDC2 from healthy donor 
PBMC by FACS-sorting.   
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Cell pellets for all preparations were stored at -80°C and lysed to a concentration of 
1x104 cells per 5µl RNA lysis buffer prior to NanoString. 
 
8.4.5 BAL samples for NanoString 
 
Cells from BAL fluid were FACS-sorted according to the gating analysis shown in 
Figure 7.2.   In LPS BAL, cDC2 were either fractionated into BTLA+ and BTLA- 
subsets or resident cDC2 (CD1chi±Axl+) and recruited cDC2 (CD1clo±Axl-) subsets.  
Samples were selected for NanoString if more than 4000 cells were sorted.  Cell 
pellets for all preparations were stored at -80°C and lysed to a concentration of 1-
2x104 cells/ 5µl RNA lysis buffer prior to NanoString 
 
8.4.6 NanoString data acquisition, normalization and QC 
 
Immune relevant gene expression in samples isolated from BAL fluid was tested with 
the Immunology v2 panel.  All other samples were tested on the Immunology v2 
panel plus custom code-set (see section 2.6.2) to align with experiments not included 
in this thesis.  Data from both panels could be combined for QC and normalization 
without producing a “batch” or “panel” effect.  Only expression of the 579 genes 
common to both panels could be considered. 
 
Normalization and QC was performed as described in section 2.6.5.  Samples with a 
positive content normalization score>10 were excluded and data were re-normalized.  
Principal component analysis was used to screen for outliers.   One normal blood 
donor, 1 saline BAL cDC2 sample and 1 resident/ recruited LPS BAL cDC2 pair were 
excluded.  Samples entering analysis included triplicates of blood monocytes, blood 
BTLA- cDC2, blood BTLA+ cDC2, saline BAL cDC2, LPS BAL cDC2, resident LPS 
BAL cDC2 and recruited LPS BAL cDC2 and duplicates of moDC and LPS-
stimulated cDC2. 
 
8.4.7 BTLA+/- Gene expression analysis 
 
Samples from n=3 BTLA+/- blood and n=3 BTLA+/- LPS BAL samples were pooled 
and normalized.  One LPS BAL pair failed positive content normalization and was 
excluded.  The BTLA+/- differentially expressed gene (DEG) set was created by 
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unpaired t-test of blood BTLA+ and BTLA- samples using alpha=0.05 and omitting 
multiple comparison correction.  With standard Bonferroni correction only 1 gene 
(ZEB1) was significant.  Using the DEG set, gene-expression similarity between 
samples was tested by hierarchial clustering using Pearson correlation as the 
distance metric and average linkage clustering.   
 
8.4.8 Gene expression analysis 
 
Clustering was tested by PCA in MeV software, centering on the mean.  The first 3 
components accounted for 66% of variation in gene expression.  Gene-set 
enrichment was performed in Bubble GUM software.  Gene signatures were 
generated in GeneSign using a one versus all comparison of mean(test)/mean(ref), a 
minimal linear fold-change of 2, and Benjamini-Hochberg false discovery correction 
limit of 0.05.  Gene-set enrichment was tested using BubbleMap.  Differential gene 
expression between blood, saline-BAL and LPS-BAL was assessed in MeV using an 
unpaired t-test with alpha=0.05. 
 
 
8.5 Results Aim 3 
 
8.5.1 cDC2 in BAL fluid are heterogeneous following LPS inhalation 
 
BAL fluid from participants obtained 6 hours following LPS inhalation was re-visited 
using the gating strategy introduced in Figure 7.2.  Mononuclear cells that were 
lineage-HLA-DR+CD16- were visualized on a two-dimensional plot of CD14 versus 
CD1c expression.  From this plot, it was apparent that cDC2s present after LPS 
inhalation differed from the cDC2s seen in after saline inhalation (steady state) 
(Figure 8.1, panel Ai).  In steady state, cDC2 were CD1chi CD14mid.  After LPS 
inhalation, most cDC2s had lower expression of both CD14 and CD1c, but a small 
population of CD1chi CD14mid cDC2 could also be seen.  A similar image could be 
created by superimposing equivalent plots from saline BAL and blood (Figure 8.1, 
panel Aiii).  This analysis was consistent with the hypothesis that CD1chi CD14mid 
cells are airway resident and CD1cmidCD14- cells are recruited from blood.   
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Figure 8.1 The inflammatory expansion of cDC2 following LPS 
inhalation is heterogeneous. 
 
A) CD14 versus CD1c analysis plots displaying lineage-HLA-DR+CD16- 
mononuclear cells from i) BAL fluid following LPS inhalation and ii) BAL 
fluid following saline inhalation.  Panel iii shows an overlay plot of panel ii 
(blue dots) plus steady state blood lineage-HLA-DR+CD16- cells (red 
dots). 
B) Expression of selected surface antigens on cDC2.  cDC2 were gated as 
lineage-HLA-DR+CD16-CD14lo-midCD1cmid-high cells.  Representative 
histograms from saline BAL (n=2), LPS BAL (n=2) and blood (n=3) are 
shown.  Antibody expression (coloured lines) is shown relative to isotype 
or FMO control (grey lines).  Numbers indicate publication antigen was 
selected from: 1=Desch et al, 2=Segura et al, 3=McGovern et al. 
 
 
Surface antigen expression was tested between saline BAL, LPS BAL and blood to 
explore this hypothesis further.  Eight antigens were selected based on their ability to 
distinguish blood and tissue cDC2 in three publications: Desch et al (blood and 
digested lung tissue cDC2 analysed by microarray), Segura et al (blood and 
inflammatory fluid cDC2 analysed by flow cytometry) and McGovern et al (blood and 
steady state skin DC analysed by flow cyometry) (Desch et al., 2016),!(Segura et al., 
2013), (McGovern et al., 2014).   
 
Saline BAL cDC2 expressed CD1a, CD14, CD206, CD11b and FcER1, in common 
with Segura’s inflammatory fluid DC, perhaps suggesting that they are markers of 
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tissue-residence rather than inflammation per se (Figure 8.1, panel B).  LPS BAL 
cDC2 expression was heterogeneous.  However the majority of cells had lower 
CD1a, CD14, CD206 and FcER1 expression, in keeping with more recent derivation 
from blood cDC2.     
 
Consistent with gene expression data from Desch et al, saline BAL cDC2 expressed 
receptor tyrosine kinase Axl.  Axl is not expressed by blood cDC2.  The 2-
dimensional plot of CD1c versus Axl was best at distinguishing resident from 
recruited cDC2 in LPS BAL samples. 
 
In summary, BAL cDC2 expressed a range of tissue-associated antigens in steady 
state.  In inflammation BAL cDC2 antigen expression was more similar to blood. 
 
8.5.2 Both subsets of blood cDC2 are recruited to the airspace in inflammation  
 
In blood, BTLA expression splits the cDC2 population approximately 50:50 (Figure 
8.2, panel A-B).  In saline BAL cDC2, the ratio of BTLA+ to BTLA– is 20:80 but in 
LPS BAL the ratio is 50:50.  This is consistent with recruitment of both BTLA+ and 
BTLA– cDC2 from blood.   
 
Before analyzing specific properties of cDC2 subsets, functional verification of cDC2 
identity was sought.  cDC2 were isolated from LPS BAL and their T cell stimulation 
capacity was compared with two other MP subsets.  Unlike AM and CD14++CD16- 
cells, cDC2 induced proliferation of allogeneic T cells (Figure 8.2, panel C).  
Experiments were not repeated in BAL following saline inhalation as fewer cells were 
isolated in this context. 
 
The first specific property of cDC2 subsets tested was the ability to skew T cell 
cytokine production.  BTLA+ and BTLA– cDC2 from saline and LPS BAL were co-
cultured with T cells.  Bulk T cells isolated from the peripheral blood of allogeneic 
donors were used.  As adult peripheral blood contains only 50% naïve T cells 
(Hannet et al., 1992), this cannot precisely be called a polarization experiment.  Bulk 
T cells were favoured because BAL fluid lymphocytes are predominantly memory 
cells (Jardine L, unpublished data) and this thesis is concerned with MP activity in 
tissues.  Both cDC2 subsets isolated from BAL fluid favoured Th1 cytokine 
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production (Figure 8.2, panel D).  This was true of steady state (saline inhalation) and 
inflammation (LPS  
 
 
Figure 8.2 Both subsets of cDC2 are recruited in inflammation 
 
A) Flow cytometry analysis of cDC2 in blood, saline BAL and LPS BAL.  
Plots show lineage-HLA-DR+CD16-CD14-CD1c+ cells.  Frequency of 
BTLA+ and BTLA- subsets in representative examples are shown. 
B) Ratio of BTLA+ to BTLA- cDC2 in blood (n=4), saline BAL (n=5) and 
LPS BAL (n=4).  Bars indicated mean ± SEM, * p<0.05 and ** p<0.01 from 
1-way ANOVA with Tukey’s multiple-comparison adjusted post-test.   
C) Proliferation of allogeneic T cells in MLRs established with alveolar 
macrophages (AM), CD14++CD16- cells (14) and cDC2 isolated from LPS 
BAL as stimulators.  % T cell proliferation was quantified by CSFE dilution 
on flow cytometry.  ** p<0.01 with 1-way ANOVA and post-test as above. 
D) Mean T-cell cytokine production following co-culture with BTLA+ or 
BTLA- cDC2 from saline or LPS BAL (each n=2).  Cytokine production 
was quantified by flow cytometry.  Each cytokine is expressed as a 
proportion of total cytokine produced.  There was no dual production of 
cytokines.       
E) Hierarchical clustering of gene expression data in BTLA+ and BTLA- 
cDC2 from LPS BAL and blood.  Clustering was performed on the 93 gene 
BTLA+/- DEG set. 
E) Fold differences in gene expression between BTLA+ and BTLA- cDC2 
from blood and BAL using the BTLA +/- DEG set.  Each bar represents 
mean expression of a gene in BTLA+ divided by mean expression in 
BTLA-.  Positive bars are therefore “BTLA+ genes” and negative bars are 
“BTLA- genes”.    
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inhalation).  In contrast to blood BTLA+ cDC2, BAL fluid BTLA+ cDC2 did not induce 
significant IL-4 production.  This suggests functional convergence of cDC2 subsets 
on entering the lung. 
 
Next, cDC2 subset gene expression signatures were probed.  NanoString data were 
used to test whether distinct gene expression signatures seen in blood subsets were 
conserved in tissue subsets.  Only cDC2 from LPS BAL fluid were used in this 
analysis and insufficient BTLA+ cDC2 were present in saline BAL fluid to use for 
NanoString.  Ninety-three genes (16%) were differentially expressed between blood 
BTLA+ and BTLA– cDC2.  This gene-set clustered BAL fluid BTLA+ cDC2 separately 
from BAL fluid BTLA- cDC2, indicating some conserved differential gene expression 
(Figure 8.2, panel E).  As evidenced by the height of cluster-connecting lines in the 
dendrogram and the fold-difference plots from blood and BAL (Figure 8.3 panel E-F), 
BAL cDC2 subsets were more similar to each other than blood cDC2 subsets.  This 
supports the concept of subset convergence upon entry to inflamed tissue.    
 
8.5.3 Comparison of cDC2 across compartments in steady state and 
inflammation  
 
Data presented above support the recruitment of blood cDC2 to BAL fluid in 
inflammation and identify convergence of blood cDC2 subsets on entering the lung.  
Gene expression data were explored further to detail differences between cDC2 in 
the intravascular and airspace compartments and to contrast the resident and 
recruited cDC2 populations seen inflammation. 
 
For this analysis, cDC2 were isolated from BAL fluid following saline inhalation 
(steady state) and LPS inhalation (inflammation).  LPS BAL cDC2 were isolated 
either as total cDC2, i.e. lineage-HLA-DR+CD16- cells that were CD14lo-mid and 
CD1cmid-hi, or as resident and recruited populations.  Resident populations were 
sorted as CD1chiCD14mid or as CD1chiAxl- cells.  Recruited populations were sorted 
as CD1cmidCD14- or as CD1cmidAxl+ cells.  Gene expression was consistent between 
samples despite the use of two sorting strategies (Figure 8.3, panel A).  Blood cDC2, 
blood classical monocytes and two in vitro manipulated MPs were used for 
comparison: moDCs generated from classical monocytes and blood cDC2 stimulated 
ex-vivo with LPS. 
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Figure 8.3 Comparison of cDC2 across compartments in steady state 
and inflammation 
 
A) PCA plot of BAL and blood cDC2, blood monocytes, moDC and blood 
cDC2 simulated ex-vivo with LPS.  
B) Bubblemap showing pairwise gene-set enrichment with monocyte, 
moDC, blood cDC2 and LPS-stimulated blood cDC2 gene signatures.  
Columns represent gene signatures.  Red circles indicate that the 
signature is enriched in the test population written in red relative to the 
population written in blue.  Larger, more intensely coloured circles indicate 
more significant enrichment.  sal= saline BAL cDC2, bld= blood cDC2, 
lps=total LPS BAL cDC2, res= resident LPS BAL cDC2, rec= recruited 
LPS BAL cDC2, NES= normalized enrichment score, FDR= false 
discovery rate. 
C) Venn diagram showing numbers of differentially expressed genes in 
blood, saline and total LPS BAL cDC2.   
 
 
By PCA, the most defining point of cDC2 identity was whether it was blood-derived 
(positive axis of PC1) or BAL-derived (negative axis of PC1).  Saline BAL cDC2 were 
readily distinguished from LPS BAL cDC2 on PC1 and PC2.  Resident and recruited 
LPS BAL cDC2 formed distinct, but proximal clusters.  If resident cDC2 were once 
equivalent to saline BAL cDC2, and recruited cDC2 were once equivalent to blood 
cDC2, they underwent significant gene expression convergence on LPS exposure/ 
inflammatory recruitment.  The third principal component (13% of variation; not 
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shown) separated out ex-vivo manipulated cells (moDC and LPS-stimulated cDC2) 
and offered little additional information on BAL subsets. 
 
Gene-set enrichment analysis was used to probe for specific gene signatures in 
inflamed BAL cDC2.  Neither total, resident, nor recruited cDC2 in LPS BAL enriched 
with a moDC signature (Figure 8.3, panel B).  The blood monocyte signature was 
more enriched in saline BAL cDC2 and blood cDC2 than LPS BAL.  When the 
recruited and resident subsets of LPS BAL were compared, the blood monocyte 
signature enriched most with recruited cells.  This type of analysis cannot prove or 
disprove whether a particular MP is monocyte-derived.  However the results are in 
keeping with cDC2 in inflammation not arising from monocytes. 
 
While LPS BAL cDC2 had surface antigen similarity to blood cDC2 (Figure 8.1), they 
did not have a blood cDC2 gene expression signature.  An LPS-activated cDC2 
signature was enriched in LPS BAL subsets (total, resident and recruited).   Saline 
BAL had more of an LPS-activated cDC2 signature than blood, perhaps reflecting the 
heightened activation state of tissue DCs.  When comparing resident to recruited 
LPS BAL cDC2, the resident subset has a stronger LPS-activation signature, 
supporting the concept that it was present in the airspace when LPS was 
administered. 
 
Forty-six percent of genes (268) tested by NanoString were differentially expressed 
between blood and steady state BAL cDC2 (Figure 8.3, panel C).  Genes 
preferentially expressed by saline BAL cDC2 were associated with mature DC 
function: T cell co-stimulation (CD40, CD80) migration to lymph node (CCR7); 
complement-mediated immunity (CQ1A/B, C2, C8B); anti-viral response (TLR7); and 
chemokine production (CCL18, CCL19, CCL22, CXCL10, CXCL11).  Thirty-six 
percent (208) of these differentially expressed genes were also different between 
blood and LPS BAL cDC2.  While forty-three percent of genes (251) were 
differentially expressed between saline and LPS BAL, the magnitude of these 
differences were smaller.  Genes preferentially expressed in saline BAL cDC2 
encoded complement components, scavenger receptors (CD163, MSR1, MARCO), 
and pathogen detection molecules (CLEC6A, TLR5, TLR8, NOD1) consistent with a 
role in airway immune defense.  Fewer genes were preferentially expressed by LPS 
BAL cDC2 (18 with fold change>1.5 compared with 54 for saline BAL cDC2). 
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8.6 Summary or results for Chapter 8 
 
Analyses in this chapter have demonstrated that the inflammatory expansion of cDC2 
in BAL is heterogeneous.  LPS BAL cDC2 comprise a major recruited and a minor 
resident fraction.  The recruited cDC2 have surface antigen similarity to blood cDC2.  
Both BTLA+ and BTLA- blood cDC2 appear to be recruited to the airspace in 
inflammation, but their functions and gene expression signatures converge.  There is 
no evidence for monocyte derivation of recruited cDC2.  Compartment of residence is 
the most important defining feature in cDC2 identity.  Differentially expressed genes 
between blood and BAL DC support a specialized role for airspace cDC2 in pathogen 
detection and clearance and support of complement-mediated immunity.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jardine L, 2016 
! 157!
Chapter 9.  Lung strand Discussion 
 
9.1 Discussion point 1: BAL fluid contains 7 distinct MP populations 
 
Using multi-parameter flow cytometry, 7 distinct MP populations were identified in 
steady state BAL fluid.  These were identified with a parallel gating strategy in blood, 
in order to facilitate comparison across compartments. 
 
Accurate characterization of human lung tissue MPs has been difficult as lung is a 
vascular organ.  Without adequate perfusion of vessels prior to digestion- a 
procedure difficult to achieve without an intact lung- overlay of blood MP populations 
can confound analysis (Desch et al., 2016).  Lung MPs with negligible blood 
contamination have been characterized in this thesis.  Around 20 million erythrocytes 
were detected in BAL specimens.  Given that the normal circulating red blood cell 
count is around 5x1012/L, this suggests a whole-blood leak into the airspace 
equivalent to 4µl.  With a blood myeloid DC concentration of around 15 cells/µl 
(Jardine et al., 2013) and around 40,000 myeloid DCs detected in a saline BAL, 
blood contamination can be assumed to be minimal (<0.01%).  Enrichment of certain 
DC populations in BAL, differences in surface phenotype and differential gene 
expression between blood and BAL populations all support the assertion that a 
distinct compartment has been sampled. 
 
In the most comprehensive description of human lung tissue MPs to date, Desch et 
al carefully excluded blood contamination and concluded that 5 MPs subsets were 
resident in lung.  Three of these were variations of myeloid DCs, one was described 
as a tissue monocyte, and the last was the AM (Desch et al., 2016).  Plasmacytoid 
DCs and cDC1 were declared absent.  In this thesis, pDCs and cDC1 were clearly 
identifiable in BAL fluid.  As has been described previously, pDCs were CD11c-
negative (Dzionek et al., 2000).  It is probable that Desch et al excluded their pDCs 
prior to analysis as CD11c-enrichment was performed before flow cytometry.  The 
BAL cDC1 identified in this thesis had modest expression of CD1c and CD206.  They 
probably occupied the territory between gates in the definitions used by Desch et al  
(Figure 9.1).  cDC1s are rare and difficult to identify in tissue preparations unless 
multiple parameters are used (Haniffa et al., 2012).  The tissue monocyte described 
by Desch et al was CD14+CD16+, consistent with the “resident pulmonary-
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monocyte-like” cell described previously (Brittan et al., 2012) and the CD14++CD16+ 
cell identified in this thesis.  The rare CD14++CD16- cells identified in steady state in 
this thesis expressed a full spectrum of CD206.  Some will have been captured in the 
tissue monocyte gate of Desch et al. and the others will have been excluded.  The 
three myeloid DC variations described by Desch et al. were separated by CD206 and 
CD1a expression.  Based on absence of dendritic morphology, the CD206 subsets 
were designated “monocyte-derived.”  Expression differences across a selected set 
of genes were presented, but overall, the evidence to support 3 distinct subsets of 
myeloid DCs is unconvincing.   
 
 
 
Figure 9.1 Location of Jardine MP subsets in Desch et al analysis  
The strategy used by Desch et al. to analyse lung MPs is depicted (Desch 
et al., 2016).  Gates 1, 2 and 4 in the second analysis plot encompass 4 of 
the 5 MPs described in that publication (moDC are divided into CD1a+ 
and CD1a- subsets, AM are the additional population).  Pink labels display 
the MP populations described in this thesis.  White arrows indicate their 
probable location in this analysis strategy. 
 
 
In summary, this thesis reliably concludes that 7 subsets of MPs are present in BAL 
fluid and that no subset is present as a result of blood contamination.  Insufficient 
understanding of how BAL samples pulmonary MPs and how the MP composition 
across lung compartments might vary prevents a complete understanding of the 
pulmonary MPS.  
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 9.2 Discussion point 2: LPS inhalation is associated with accumulation of 
monocytes and cDC2 myeloid DCs in BAL 
 
LPS inhalation recreated the influx of CD14+CD16- monocytes into 6-hour BAL fluid 
described previously (Brittan et al., 2012) and identified an accumulation of CD1c-
expressing DCs. 
 
CD1c accumulation in murine lung has been described following a range of 
inflammatory stimuli including viral infection (GeurtsvanKessel et al., 2008), TLR 
agonist application (Hammad et al., 2009) and asthma (Hammad et al., 2010).  
These cells were presumed to originate from monocytes (Lambrecht and Hammad, 
2012).  When time-course is considered, accumulation of DCs between 4 and 8 
hours can be seen in both humans and animal models, (McWilliam et al., 1994).  In 
vitro, the induction of CD1 molecules on human monocytes takes 5 days (Assier et 
al., 2007).  It is therefore unlikely that monocytes could differentiate into the recruited 
DC population identified in this thesis.  Uniformly low expression of monocyte 
markers CD14 and CD11b on recruited DCs supports this assertion.  As concluded 
by the authors of the allergen challenge-recruited DCs, rapid accumulation of DCs in 
this thesis is consistent with cDC2 recruitment from blood (Jahnsen et al., 2001). 
 
 
9.3 Discussion point 3: Convergence and the importance of tissue identity 
 
Both of the recently identified blood cDC2 subsets were present in the LPS-recruited 
DC population.  On entering lung, convergence was seen in both gene expression 
and functional interaction with T cells.  Considering inflamed and steady state blood 
and BAL together, the most important defining feature of cDC2 was their tissue of 
residence. 
 
The concept of convergence occurs repeatedly in MP biology and is most hotly 
debated with regard to macrophages (Epelman et al., 2014b).  Macrophages with 
distinctly different ontogeny (fetal/ yolk sac precursor versus adult monocyte) coexist 
in certain tissues such as the heart (Epelman et al., 2014a).  It remains unknown 
whether ontogeny is relevant to the function of these cells (Epelman et al., 2014b).  
Certainly tissue exerts a major influence on macrophage identity!(Amit et al., 2015).  
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The publication of data regarding two distinct origins of human cDC2 will bring a 
similar debate to DCs.  Though the differences in ontogeny are not so stark as with 
macrophages, it will be important to understand whether mature tissue DCs arising 
from BTLA+ and BTLA- blood DCs always converge or under what conditions 
subset-specific properties persist.  
 
When considering gene expression data sets derived from analogous populations in 
multiple tissues, anatomical site is recognized as the major source of variation 
(Satpathy et al., 2012b), (Elpek et al., 2011), (Miller et al., 2012), (Gautier et al., 
2012).  This variation can be explored to provide meaningful insight into tissue-
specific immunity.  For example, Eplek et al. examined CD4 and CD8 DC subsets 
from murine lymphoid tissue and found greater similarity between subsets from the 
same tissue than they found between subsets from different tissues (Elpek et al., 
2011).  Both CD4 and CD8 DCs from mesenteric lymph nodes expressed Aldh1a2 
gene and its product aldehyde dehydrogenase 2, while neither subset from spleen 
expressed Aldh1a2.  As the product of this enzyme (retinoic acid) is implicated in 
imprinting primed T cells with a gut-homing signature, a mesenteric lymph node-
specific function was proposed.  
 
Often, with the goal of overlaying analogous populations from different tissues or 
species on a PCA plot, tissue-specific gene signatures are removed (Robbins et al., 
2008), (Ingersoll et al., 2010), (Haniffa et al., 2012).  There is no doubt that this 
approach has rationalized our understanding of DC subsets and harmonized efforts 
between murine and human immunologists, but I would argue these signatures 
harbour useful information. The validity of removing tissue-specific signatures from 
datasets with a smaller number of user-selected genes, such as with NanoString, 
remains to be proven. 
 
Both gene expression and surface antigen data generated from BAL cDC2 have 
identified characteristics not seen in blood cDC2.  Surface expression of CD206 and 
Axl, expression of PRR, complement component and chemokine genes needs further 
interrogation to understand the functions and interactions of pulmonary cDC2. 
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9.4 Discussion point 4: Benefits and limitations of experimental inflammation 
for understanding lung GvHD  
 
A significant focus in performing the LPS inhalation study was to understand the MP 
content of normal (saline) BAL.   This important foundation for examining BAL in BMT 
patients with respiratory compromise was previously absent.  
 
An additional focus was to use LPS as a well-tolerated, reproducible inflammatory 
stimulus to see how the MPS was perturbed.  Heightened sensitivity to LPS derived 
from gut bacteria has been implicated in the pathogenesis of IPS and alloimmune 
lung injury (Cooke et al., 1996), (Cooke et al., 2000), (Garantziotis et al., 2007), 
(Martinu et al., 2014).  Mice without GvHD following BMT can be induced to develop 
lymphocytic bronchiolar infiltrates and epithelial injury following LPS inhalation 
(Garantziotis et al., 2007). 
 
Critics of LPS-exposure studies argue that inter-supplier and inter-batch variability in 
LPS preparations make it difficult to ascertain exactly what immune responses are 
being stimulated (Mathiak et al., 2003).  This study used LPS from Escherichia coli.  
The relative TLR4 versus TLR2 ligation is not of great importance to this work, but 
with enteric bacterial LPS, TLR4 is the predominant ligand!(Takeda and Akira, 2005). 
 
The LPS inhalation study afforded the unique perspective of an early time point in 
inflammation.  From these data, it is possible to generate new hypotheses about the 
role of LPS in the initiation of alloreactive lung disease and test these in animal 
models.  For example, the influx of cDC2 may be important in stimulating alloreactive 
T cells.  The limitation is that LPS inhalation gives rise to short-lived, self-resolving 
inflammation.  It is not clear whether the BAL 6-hours following LPS inhalation 
represents what we would see in evolving sterile inflammation or how generic the 
features of early inflammation actually are.  Furthermore, we will never be able to 
sample BMT recipients at such an early time point in the acquisition of lung injury.  
The cellular profile of LPS-exposed BAL is therefore of limited use as a comparison 
for BAL in BMT recipients. 
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9.5 Conclusions 
 
This work provides a comprehensive analysis of MPs in the human airspace that 
challenges data recently published.  It provides a benchmark for investigating BAL in 
disease.  Study of BAL following LPS inhalation has focused on the novel finding that 
cDC2 are recruited.  Data support the conclusion that cDC2 arise from blood DCs 
and not monocytes in this setting.  The gene expression data set of steady state and 
inflammatory populations can be exploited further to learn more about the immune 
functions and tissue-specialization of airway MPs. 
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Chapter 10.  General discussion and future work 
 
Key insights from the data presented in this thesis have been discussed in Chapters 
6 and 9.  Here, findings will be reviewed against the hypotheses made in Chapter 1 
(section 1.9).  Unresolved issues will be detailed and future avenues of investigation 
discussed. 
 
10.1 GvHD skin: review of hypotheses 
 
In GvHD skin, the MP repertoire was altered.  Myeloid DCs were reduced and 
macrophages were expanded.  Monocyte-derived MPs were found in tissue.  Several 
lines of evidence supported the derivation of inflammatory “GVH14” macrophages 
from classical monocytes.  The possibility that monocyte-derived DCs were present 
in GvHD lesional skin was not addressed.  In murine skin, “P3” monocyte-derived 
DCs can be identified in steady state and are modestly expanded in inflammation 
(Tamoutounour et al., 2013).  Counterparts of P3 and of the murine tissue monocytes 
“P1/P2” have not been identified in human skin to date.  Evidence indirectly 
presented in this thesis suggests that CD14+CD1c+ may be the human P3.  
CD14+CD1c+ cells from steady state dermis expressed a monocyte/ macrophage 
gene signature (Figure 4.5A,D) but were capable of stimulating proliferation and 
activation of T cells (Figure 4.3C).  The mean proportion of CD14+CD1c+ cells in 
GvHD lesional skin was not significantly higher than in controls (Figure 3.6D), but 
some specimens did have CD14+CD1c+ enrichment.  Flow cytometry data from 
atopic dermatitis lesions suggested that CD14+CD1c+ cells may be expanded under 
alternative inflammatory conditions (Figure 3.5D).  Detailed characterisation and 
cross-species comparison of these cells is warranted.  
 
The hypothesis that inflammatory MPs perpetuate T cell-mediated skin damage has 
not been rigorously tested.  This was largely due to the constraints of working with 
small amounts of infrequently available human material.  GVH14 elaborated pro-
inflammatory cytokines and chemokines capable of recruiting activated T cells to 
lesions (RANTES and CXCL10).  GVH14 were capable of stimulating T cell 
proliferation and activation in an allogeneic in vitro setting.  This evidence is in 
keeping with a role for GVH14 in supporting T lymphocyte activity, but several 
important questions remain unanswered.  It needs to be established whether GVH14-
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T cell interactions are antigen specific.  If so, what are the mechanisms of antigen 
presentation?  For donor macrophages to present host antigens to donor T cells, 
cross-presentation to CD8 T cells, indirect presentation to CD4 T cells and cross-
dressing need to be considered.  Development of an assay testing in vitro cross-
presentation of minor antigen HY has been unsuccessful during the course of this 
work.  These mechanisms would be better dissected in murine models. 
 
 
10.2 BAL: review of hypotheses 
 
Studies on BAL fluid required an evaluation of steady state MPs before inflammatory 
MPs could be considered.  All 6 of the MP subsets present in human blood could be 
detected in BAL.  Alveolar macrophages (AM) constituted a 7th subset.  These 
findings are discordant with a recent description of MPs in human lung tissue (Desch 
et al., 2016).  A consensus definition of pulmonary MPs would facilitate human 
immunology and the investigation of clinical states.  The definitions used in this thesis 
were purposefully based on accepted definitions in human blood (Haniffa et al., 
2015a) and nomenclature agreed between human and murine MPS immunologists 
(Guilliams et al., 2014).  The definitions used here in BAL fluid have also been tested 
in lung tissue surplus to lung cancer resections.  Data were not presented in this 
thesis because confounding by blood MP subsets has not been adequately resolved.  
Whole lung donations unsuitable for transplant would be the optimal material for 
resolving MP subsets in specific compartments (blood, bronchoalveolar, interstitial). 
 
As in GvHD-inflamed skin, the MP repertoire of LPS-inflamed BAL fluid was altered.  
The predominant inflammatory MP was a CD14++CD16- cell, which shared 
phenotypic similarity to a classical blood monocyte.  This inflammatory MP has 
already been reported and partially characterized (Brittan et al., 2012), (Brittan et al., 
2014).  Efforts were therefore directed at the novel finding of cDC2 expansion in 
inflamed BAL fluid.  Evidence presented in this thesis supported cDC2 derivation 
from blood DCs rather than monocytes.  Using material I have collected from the LPS 
inhalation study, the trajectories of monocytes in inflamed BAL fluid are currently 
being scrutinized by single cell RNA sequencing and associated computational 
techniques. 
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The role for inflammatory MP in lung GvHD has not been investigated in this thesis.  
Now the MP composition of steady state BAL fluid has been characterized, it will be 
possible to identify inflammatory perturbations in BAL fluid from patients with lung 
GvHD.  Careful consideration will be required as to how patients can be identified 
early in the evolution of lung inflammation and with minimal confounding from 
infection.  Insights from human studies can be used to inform mechanistic studies in 
animal models.  Understanding the pathogenesis of lung injury will be an important 
step in rationalizing the diagnosis and treatment of non-infective lung injury post-
BMT. 
 
 
10.3 Unresolved issues in MPS biology 
 
The boundaries between MPs, their inter-relationships and differentiation potentials 
are continually being revised.  The discovery of two cDC2 subsets will bring a 
substantial change to our understanding of the MPS.  Data presented in this thesis 
demonstrated that steady state BAL had a BTLA- cDC2 bias, but acute inflammation 
recruited both BTLA+ and BTLA- cDC2 from blood.  Unfortunately, BTLA is labile in 
culture and destroyed by enzymatic digestion of skin, so the subset composition of 
skin cDC2 could not be addressed.  BTLA- cDC2s expressed monocyte-associated 
genes.  It will be important to identify proximal precursors of both BTLA+ and BTLA- 
cDC2s and to clearly define the relationships between BTLA- cDC2 precursors and 
monocytes.  It is possible that some previous descriptions of monocyte-derived DCs 
have actually characterized BTLA- cDCs.  The DC repertoire in inflammation will 
need to be revisited. 
 
Both GvHD skin and blood demonstrated an augmented dominance of monocytes/ 
monocyte-derived cells over classical DCs compared with steady state.  The 
mechanisms and consequences of this dominance need to be addressed.  Proximal 
precursors of human DCs have been reported (Breton et al., 2015), (Lee et al., 2015) 
but a comprehensive description of steady state monocyte and DC production has 
not yet been achieved.  Once the steady state has been deconvoluted, the acute and 
chronic effects of inflammation on MP haematopoiesis can be explored.  It may be 
the case that inflammation biases haematopoiesis towards monocyte production.  If 
so, what would be the consequences for tissue DC turnover in chronic inflammation 
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and how would that impact upon the individual’s response to subsequent immune 
challenge?  If tissue DCs were replaced by monocyte-derived cells, would they be a 
faithful replicate?  The concepts of monocyte plasticity and convergence have been 
discussed in this thesis, but would convergence be so absolute that tolerance to 
commensals and immunity to pathogens is conserved? 
 
 
10.4 Unresolved issues in GvHD 
 
In analysing the MP repertoire of GvHD lesional skin, the dermal macrophage was 
difficult to identify.  As shown in Figure 3.6C, the dermal macrophage was a 
significantly lower proportion of leukocytes in GvHD skin than in control skin.  Efforts 
are continuing to quantify absolute numbers of dermal macrophages in GvHD skin by 
microscopy.  The activity of dermal macrophages in skin GvHD warrants 
consideration.  As dermal macrophages are the longest surviving host MP in human 
skin following BMT (Haniffa et al., 2009), they may continue to present host antigen 
to donor T cells.  Some murine models have demonstrated that host macrophages 
protect against GvHD in the early post-BMT period by engulfing alloreactive T cells 
(Hashimoto et al., 2011).  Detailing whether dermal macrophages survive skin GvHD 
will help inform the relevance of these potential functions.  
 
Classical monocytes in the blood of patients with skin GvHD showed transcriptional 
differences compared with healthy volunteers.  Comparisons with well-matched BMT 
controls have not yet been made, but these will be important.  It has been 
established in a murine model that remote tissue signals can prime monocytes 
developing in bone marrow (Askenase et al., 2015).  Isolated skin GvHD cannot 
strictly be considered a remote tissue signal as sub-clinical systemic inflammation is 
likely.  However, the extent of monocyte priming is of academic interest, and may be 
a predictor of disease severity. 
 
 
10.5 Ongoing challenges to studying the human MPS in inflammation 
 
This work was approached with the assumption that inflammatory populations should 
be studied with reference to steady state populations.  This was considered important 
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for two reasons.  The first was that inflammation represents a shift in a 
homeostatically maintained system.  Inflammatory populations are therefore more 
likely to have a steady state counterpart than to be a completely foreign entity.  
Secondly, tissues have a resident leukocyte population.  If this is not adequately 
identified, incorrect conclusions can be made about recruited inflammatory cells.  
Parsing resident from recruited cells was difficult, especially in the context of skin 
GvHD.  Few surface antigens adequately distinguish dermal macrophages from 
CD14+ monocyte-derived macrophages.  In steady state, physical parameters (side-
scatter and autofluorescence) provided adequate separation, but this was not the 
case in inflammation.  Absence of CD11c expression was the best method to identify 
dermal macrophages in the GvHD flow cyometry data, but this is clearly not an 
optimal strategy.  Work is in progress to apply dimensionality reduction algorithms to 
the flow cytometry data to see if subtle differences in fluorescence across the 10-12 
channels might afford better resolution of resident from inflammatory cells.  
 
 
10.6 Opportunities arising from new technologies 
 
Ultimately, the goal will be to analyse GvHD skin using high-dimensional single cell 
techniques, such as mass cytometry or RNA sequencing.  Testing 50 or more 
surface antigens with CyTOF, for example, should identify better antigens for 
discriminating dermal macrophages from inflammatory monocyte-derived 
macrophages. 
 
The expansion of single-cell techniques offers the potential to enter new territory in 
human immunology.  It can reveal previously unseen heterogeneity.  It can validate 
the antigens we currently use for a priori definition of populations or can highlight 
better alternatives.  It can provide reams of information from small samples of human 
tissue.  Computational techniques can be applied to RNA sequencing data to 
understand functions, interactions and developmental relationships between cells.  
Using the knowledge acquired from lower dimensional analysis, such as in this 
thesis, new techniques can be targeted to the biological questions unanswered in 
disease and weaknesses in our knowledge of the immune system.  For example, it 
could be possible to distinguish whether there is a developmental trajectory from 
monocytes to DCs in inflamed human tissue.  
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In addition to single-cell techniques, methods for analysing small populations of 
human material are now tangible.  It is possible to laser micro-dissect material from 
slides of FFPE-preserved tissue and generate gene-expression data by NanoString.  
This will allow retrospective analysis of GvHD biopsies, incorporating material from 
across centres and stratifying variables to give greater statistical power to analysis 
than was possible with the prospective cohort study performed in this thesis.  
 
As methods are evolving in research, techniques are entering clinical practice which 
provide new diagnostic information.  Next generation sequencing can assist 
pathogen detection (Naccache et al., 2015).  This may be particularly revealing in 
BMT recipients with lung injury, and may help distinguish infective from alloreactive 
aetiology. 
 
 
10.7 Future directions  
 
Studying inflammatory perturbations of the human MPS has potential to yield 
important insights into the pathogenesis of transplantation-associated, autoimmune 
and pathogen-driven inflammation.  Greater appreciation of the MPS is required to 
direct therapeutic manipulation with monoclonal antibodies and inform vaccine 
strategies.  As a clinician scientist working with BMT recipients, I have found the 
timely diagnosis and effective management of post-BMT lung injury a pressing unmet 
need.  Using research insights to bring clarity to the spectrum of lung injuries 
following BMT will be an important extension of this thesis.   
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Appendix A 
 
A.1 Conduct of the LPS inhalation study 
 
A.1.1 Volunteer recruitment and screening 
 
The study was advertised to medical, dental and biomedical science students at 
Newcastle University by email, in accordance with the study’s ethical approval.  
Potential recruits were invited to a screening interview to assess their suitability for 
participation.  Written consent to screen was documented.  The interview comprised: 
• short medical interview 
• cardio-respiratory examination 
• bedside observations (heart rate, blood pressure, oxygen saturation, 
temperature) 
• blood tests (full blood count, urea, creatinine, electrolytes and liver function 
tests) 
• pregnancy test (urinary b-HCG) 
• spirometry (forced expiratory volume in 1 second (FEV1) and forced vital 
capacity (FVC) 
• practice inhalation using the nebulizer dosimeter (to check ease of following 
instructions and co-ordinating breathing).   
 
A.1.2 Inclusion and exclusion criteria 
 
Inclusion criteria were:  
• healthy adult volunteers aged 18 to 40 
• able to give informed consent. 
 
Exclusion criteria based were: 
• age <18 or >40 years 
• history of chronic respiratory disease, diabetes, heart disease, renal disease 
or recurrent infections 
• current respiratory tract infection 
• taking prescription medication (except oral contraceptives) 
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• current smoking or history of smoking 20 cigarettes per day for more than 2 
years or any smoking in the past year 
• alcohol intake of more than 21 units per week 
• pregnancy or lactation 
• abnormal examination findings:  temperature >37.3 °C; oxygen saturation 
<95% breathing room air 
• abnormal blood results: haemoglobin concentration, total white cell count or 
neutrophil count outside the gender-specific laboratory reference ranges; 
platelet count <100 x109/L; serum sodium, potassium, creatinine or alanine 
aminotransferase outside laboratory reference ranges; serum urea >10mg/dL; 
serum bilirubin >30µmol/L 
• Abnormal spirometry: FEV1 or FVC <80% predicted or FEV1:FVC ratio <70%.  
 
When volunteers were found to be ineligible, permission was sought to inform their 
general practitioner with the reason and results of screening tests.   
 
A.1.3 Informed consent and confidential data storage 
 
Eligible volunteers were given verbal and written information about the study and at 
least 24 hours to consider their participation before signing a consent form.  All 
primary research documents were anonymised and participant details kept 
confidentially in accordance with Caldicott guidelines. 
 
A.1.4 Participant safety 
 
To ensure safety of participants, the study was conducted in a fully staffed clinical 
research facility and clinical bronchoscopy suite.  History, bedside observations, 
cardio-respiratory examination and spirometry were performed immediately before 
LPS/ saline inhalation.  Bedside observations were repeated hourly and spirometry 
repeated at 6 hours after inhalation.  If FEV1 fell by 10% from baseline, 
bronchoscopy was cancelled.  Prior to bronchoscopy, participants were fasted for 4 
hours.  There was constant monitoring of oxygen saturations and electrocardiogram 
during bronchoscopy.  Patients were observed for 30-60 minutes after bronchoscopy 
and allowed to leave if beside observations and cardio-respiratory examinations were 
normal.  Written and verbal advice was given to avoid eating and drinking within two 
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hours of local anaesthetic administered to the mouth and pharynx.  Participants were 
informed that LPS inhalation and bronchoscopy may result in temperature, mild 
headache, shivering, dry cough, and upper airway discomfort.  Advice was to try 
paracetamol in the first instance and to contact the clinical research fellow if 
symptoms were severe or persistent.   
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A.2 Ethical approval for the LPS inhalation study (most recent amendment) 
 
 
 
A Research Ethics Committee established by the Health Research Authority 
 
 
North East - Newcastle & North Tyneside 2 Research Ethics Committee 
Room 001 
Jarrow Business Centre 
Rolling Mill Road 
Jarrow 
NE32 3DT 
 
Tel: 0191 428 3476 
21 September 2015 
 
Professor John Simpson 
Professor of Respiratory Medicine 
Newcastle University and Newcastle Hospitals NHS Foundation Trust 
Institute of Cellular Medicine 
Medical School 
Newcastle University 
Framlington Place 
Newcastle upon Tyne 
NE2 4HH 
 
Dear Professor Simpson 
 
Study title: A lipopolysaccharide (LPS) inhalation model to 
characterise divergent cellular innate immune responses 
and presence of alveolar leak early in the course of acute 
lung inflammation 
REC reference: 12/NE/0196 
Amendment number: Substantial Amendment 2, 12/08/2015 
Amendment date: 04 September 2015 
IRAS project ID: 99089 
 
The above amendment was reviewed by the Sub-Committee in correspondence.  
 
Summary of Amendment 
 
This amendment was submitted to reflect changes to the protocol, participant information 
sheet and consent form. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document   Version   Date   
Covering letter on headed paper [Covering letter for 
REC 07-09-2015 v1.2]  
v1.2  07 September 2015  
Notice of Substantial Amendment (non-CTIMP)  Substantial Amendment 
2, 12/08/2015  
04 September 2015  
Jardine L, 2016 
! v!
 
 
 
 
 
 
 
 
 
A Research Ethics Committee established by the Health Research Authority 
 
Other [Summary of changes to the LPS inhalation 
study Final]  
v1.1  10 August 2015  
Other [Timeline Group 4AB, v2.1 Final]  v2.1  03 August 2015  
Other [Timeline Group 4CDE, v2.2 Final]  v2.2  03 August 2015  
Participant consent form [Group 4 (6hr BAL +- d-
glucose) Consent Form v2.1 03-08-15 Final]  
v2.1  03 August 2015  
Participant information sheet (PIS) [Group 4 (6hr BAL 
+-d-glucose) PIS v2.1 03-08-15 Final]  
v2.1  03 August 2015  
Research protocol or project proposal [LPS Study 
Protocol v1.7 03-08-15 Final]  
v1.7  03 August 2015  
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff  at  our  NRES  committee  members’  
training days – see details at http://www.hra.nhs.uk/hra-training/  
 
12/NE/0196:  Please quote this number on all correspondence 
 
Yours sincerely 
Pp 
 
Dr Alasdair MacSween 
Chair 
 
E-mail: nrescommittee.northeast-newcastleandnorthtyneside2@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to: Miss Jillian Peacock, RVI, Newcastle 
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A.3 Ethical approval for GvHD studies in BMT recipients (most recent 
amendment) 
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Appendix B.  Sort gates and antibody details 
 
 
B.1 MLR macrophage sort gates 
 
 
 
Legend 
Viable cells were split into HLA-DR+SSChi MPs and HLA-DRlo-midSSClo lymphocytes.  
Lymphocytes expressing lineage markers CD3/19/20/56 were sorted.  MPs 
expressing CD14 and CD16 were sorted.  Black arrows show gating strategy.  Bold 
black boxes show sorted populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BD FACSDiva 8.0
Global Sheet2 Printed on: Thu Mar 31, 2016 04:49:57 BST
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B.2 Dermal digest sort gates 
 
 
Dermal digest sort gates 
Viable leukocytes were gated as DAPI-CD45+.  HLA-DR+ MPs were separated into 
autofluorescent (AF+) and AF- populations.  AF+ cells were CD14+ dermal 
macrophages.  From AF- cells, CD14+CD1c- CD14 MDM and CD14+CD1c+ 
populations were sorted.  CD14-CD1c+ cells were split into CD141+ cDC1 and 2 
populations of CD11c+ cDC2.  Black arrows show gating strategy.  Bold black or 
white boxes show sorted populations. 
 
 
 
 
 
 
 
 
 
 
 
BD FACSDiva 8.0
Analysis Printed on: Tue Feb 24, 2015 12:14:33 GMT
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B.3 Epidermal digest sort gates 
 
 
Epidermal digest sort gates 
Viable leukocytes were gated as DAPI-CD45+.  LCs were identified as AF-
CD1c+CD11cloCD1a+ cells.  Black arrows show gating strategy.  Bold black box 
shows sorted populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BD FACSDiva 8.0
Analysis Printed on: Tue Feb 24, 2015 12:55:36 GMT
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B.4 Blood sort gates 
 
 
 
B4 Blood sort gates 
Viable MPs were identified as DAPI-CD45+lineage-HLA-DR+ cells.  Classical 
monocytes were sorted as CD14++CD16- cells.  Intermediate monocytes were 
sorted as CD14++CD16+ cells.  Non-classical monocytes were sorted as 
CD14+CD16++ cells.  cDC2 were identified as CD11c+CD1c+ cells expressing low 
to intermediate levels of BTLA.  SSC versus area plots were used to confirm sorting 
of single cells.  Black arrows show gating strategy.  Bold black boxes show sorted 
populations. 
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B.5 Details of antibodies used in flow cytometry experiments 
 
Antigen Fluorochrome conjugate Supplier  Catalogue number 
7-AAD n/a BD 51-66121E 
Annexin V PE BD 51-65875X 
Axl APC R&D FAB154A 
BTLA PE BD 558485 
CD11b APC BioLegend 301309 
CD11c APC BD 559877 
CD11c AF700 BD 561352 
CD11c APCCy7 BioLegend 337218 
CD123 PERCPCy5.5 BD 558714 
CD14 FITC BD 555397 
CD14 APCCy7 BD 557831 
CD14 BV650 BD 301835 
CD14 PE BD 555398 
CD14  Q.655 Invitrogen Q10056 
CD141 APC Miltenyi 130-090-907 
CD141 PE BD 559781 
CD16 APCH7 BD 560195 
CD16 FITC BD 335035 
CD16 PE/DazzleTM 594 BioLegend 302054 
CD163 APC R&D FAB1607A 
CD1a AF700 BioLegend 300120 
CD1c APC BD 559775 
CD1c PECy7 BioLegend 331506 
CD20 FITC BD 345792 
CD206  APC BD 550889 
CD206  PE BD 555954 
CD209 FITC BD 551264 
CD3  V500  BD 561416 
CD3  FITC BD 345763 
CD4 PE BD 555347 
CD45 FITC BD 345808 
CD45 V500 BE 560777 
CD52 PE Serotec SFL1642PE 
CD56 FITC BD 345811 
CD64 PE BioLegend 305007 
CD69  PECy7 BD 557745 
CD8 APCCy7 BD 557834 
CD8 PE BD 345773 
CD86 PE BD 555658 
CD9 FITC BD 345776 
FcER1 PE eBioscience 12-5899-42 
HLA-DR PERCPCy5.5 BD 339126 
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Antigen Fluorochrome conjugate Supplier  Catalogue number 
HLA-DR V500 BD 561224 
HLA-DR FITC BD 556643 
HLA-DR V450 BD 642276 
HLA-DR PERCPCy5.5 BD 339216 
HLA-DR AF700 BD 560743 
HLA-DR BV786 BioLegend 307642 
IFNγ  PE/DazzleTM 594 BioLegend 505845 
IL-17  AF647 BioLegend 512309 
IL-4 PECy7 Biolegend 500823 
SIRPa PE BioLegend 323805 
zombie aqua n/a BioLegend 423101 !
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Appendix C.  GvHD immunohistochemistry 
 
C.1 Immunohistochemistry methods 
 
Formalin-fixed and paraffin-embedded skin shave biopsies surplus to diagnostic 
requirements were used.   Anna Long and Stacey Newton performed sectioning and 
staining (Immunocytochemistry Department, Newcastle upon Tyne Hospitals NHS 
Foundation Trust).  Maharani Paramitha (MRes student under my supervision) 
imaged the specimens.    
 
4µm sections were made.  Antigen retrieval and staining were performed using the 
BenchMark autostainer (Ventana).  CD163 and Ki67 primary antibodies and the 
‘ultraview’ detection kit were used.  CD163 was conjugated to a red chromagen and 
Ki67 to a brown chromagen. 
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C.2 Inflammatory macrophage distribution in GvHD skin 
!
Inflammatory macrophage distribution in GvHD skin 
Three GvHD specimens stained with CD163 (red) and Ki67 (brown) are shown.  
Imaged at 20x magnification, distribution of CD163+ macrophages along the dermo-
epidermal junction can be appreciated.  This is a lichenoid pattern.  Reticular dermis 
was limited in these specimens due to the biopsy method. !!!!
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Appendix D.  Gene Lists 
 
D.1 Genes differentially expressed between BTLA+ and BTLA- cDC2  
 
Gene 
name fold change in blood fold change in BAL  
   cDC2 (BTLA+/-) cDC2 (BTLA+/-) 
BTLA 43.19 10.14 
HLA-DQA1 24.00 12.37 
HLA-DQB1 12.16 7.49 
KIT 11.97 -1.3 
IDO1 6.94 -1.26 
IL18RAP 6.71 -1.67 
ZEB1 6.70 1.38 
DPP4 6.31 1.2 
CD5 5.81 6.42 
PIGR 5.23 -1.42 
CD40LG 5.21 2.26 
CD22 4.83 1.89 
CXCR3 4.19 -1.69 
CAMP 4.14 -1.36 
CCL4 4.09 -2.67 
CD45RA 4.05 2.59 
SLAMF7 4.01 1.04 
CD79A 3.85 -1.82 
XCL1 3.85 -1.59 
HLA-DOB 3.84 1.43 
IL18R1 3.75 2.24 
CCBP2 3.45 -1.03 
LTA 3.45 -3.04 
IL7 3.40 -1.3 
ITLN1 3.32 -1.3 
SLC2A1 3.24 2.19 
TLR3 3.09 1.53 
EBI3 3.06 -1.17 
LAG3 3.04 2.01 
LILRA5 -3.25 2.28 
CMKLR1 -3.26 -5.08 
LILRA3 -3.35 -5.75 
CD9 -3.36 -2.91 
CCL24 -3.39 -1.36 
KLRC4 -3.41 -1.3 
IKBKE -3.53 1.22 
ITGAM -3.65 -1.47 
FCGR2B -3.74 -3.93 !!
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! ! !Gene 
name fold change in blood fold change in BAL  
  cDC2 (BTLA+/BTLA-) cDC2 (BTLA+/BTLA-) 
BST1 -3.84 -2.81 
CD163 -4.24 -1.08 
CCR1 -4.58 -1.52 
LAIR1 -5.16 -1.02 
S100A9 -5.30 -1.13 
LILRA6 -8.25 -2.63 
LILRA6 -8.25 -2.63 
S100A8 -11.14 -1.25 
CLEC4E -14.38 -2.91 
CLEC4E -14.38 -2.91 
MRC1 -46.26 -1.44 
CD14 -57.46 -1.9 !
Gene list associated with Figure 8.2. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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D.2 Genes differentially expressed between GVH14 and CD14 MDM 
 
Gene 
name Fold change GVH14/CD14 MDM 
SELPLG 2.18 
PYCARD 2.13 
SPP1 1.91 
CD82 1.61 
CD247 1.59 
C2 1.57 
CCL24 1.54 
HAVCR2 1.54 
LILRA2 1.53 
TLR8 1.51 
CLEC4E 1.45 
TAP1 1.33 
STAT5B 1.32 
CCRL2 1.32 
MAFF 1.31 
PTAFR 1.29 
CD80 1.28 
TNFSF13B 1.26 
GGT5 1.23 
RAF1 1.22 
HLA-A 1.20 
IKBKG 1.20 
PSMB9 1.19 
HLA-C 1.19 
GPI 1.17 
TBK1 1.16 
MAPK1 1.15 
CXCR4 1.15 
CD81 1.14 
HLA-B 1.14 
TRAF3 1.13 
FCGRT 1.13 
PML 1.12 
FCER1G 1.11 
LCP2 1.11 
CCR7 1.10 
NFKBIZ 1.09 
JAK1 1.07 
IL10 -1.16 
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Gene 
name 
Fold change GVH14/CD14 
MDM 
IL10 -1.16 
TFRC -1.22 
KCNJ2 -1.56 
NFIL3 -1.72 
MAP4K1 -2.25 
TNFSF8 -2.58 
 
 
Gene list associated with Figure 4.6. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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D.3 Macrophage and DC signature genes  !
Macrophage 
genes DC genes 
CD14 FLT3 
IRAK3 BTLA 
FCGR2A CIITA 
CEBPB BATF3 
CD163 CD86 
TLR4 CCR6 
MERTK GCSAM 
TLR2 CXCR3 
FCER1G KIT 
CCL13 TYK2 
F13A1 
 MAF 
 KCNJ2 
 LILRA5 
 NOTCH1 
 LAIR1 
 CD53 
 ATG7 
 C1QA 
 !
 
Gene lists associated with Figure 4.5 
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D.4 Gene signatures used in Figure 8.3 Gene Set Enrichment Analysis 
 
 
moDC% !! !! mono%(classical)% !! !!
ABL1! CLEC4A! MAP4K1! ARHGDIB! ITGAL! TNFRSF8! FCGR2A!
AIRE! CLEC7A! MAP4K2! ATG7! ITGB2! TNFSF10! TNFRSF14!
APP! CMKLR1! MAPK1! BCL10! LILRA1! TNFSF12! TYK2!
ATG5! CSF1R! MBP! BST1! LILRA2! TNFSF8! CD44!
B2M! CSF2RB! MIF! BTK! LILRA3! TRAF6! CD1D!
BATF3! CTSC! MR1! CASP8! LILRA5! ZBTB16! LEF1!
BAX! CXCL13! MRC1! CCND3! LILRA6! ATG12! TGFBR2!
BCAP31! CXCR1! NFATC2! CD14! LILRB2! CASP2! TLR1!
BCL2L11! CXCR2! NFATC3! CD244! LILRB3! CD163! TNFRSF1B!
BCL6! EGR2! NFIL3! CD28! LTB4R! CD99! CTSG!
BLNK! FCER1A! NOD1! CD36! LTBR! CMKLR1! CARD9!
C1QA! GPI! PDCD1LG2! CD48! MAPK14! EGR1! NFATC1!
C1QB! HLABDMB! PECAM1! CD97! NCF4! FADD! HFE!
C2! HLABDPA1! PLA2G2E! CFD! NOD2! ITGA4! PSMB8!
C4BPA! HLABDRA! PLAU! CFP! NOTCH1! MBP! CUL9!
CARD9! HLABDRB1! PSMB5! CHUK! NOTCH2! MYD88! IL15!
CASP10! HLABDRB3! PSMB8! CLEC4E! PDCD2! PECAM1! LTF!
CASP2! HRAS! PSMC2! CLEC6A! POU2F2! STAT2! MAPK1!
CASP3! IFI16! PTPN2! CLEC7A! PRKCD! TGFBI! JAK2!
CCL13! IFNGR1! RUNX1! CR1! PSMB10! C5! LY96!
CCL23! IGF2R! SELPLG! CSF3R! PTAFR! CD45RB! LAIR1!
CCL26! IKBKAP! SKI! CTSS! PTPN6! IKBKAP! C4A/B!
CCR1! IKZF1! SLAMF1! CXCR2! PTPRC_all! IRAK4! CD4!
CCR5! IKZF2! SMAD5! CYBB! PYCARD! IRF3! SELPLG!
CD164! IL13RA1! SOCS1! FAS! RAF1! MAP4K2! IFNAR1!
CD1A! IL1R1! SPP1! FCER1G! RARRES3! TBK1! CCR1!
CD209! IL1R2! STAT5B! FCGRT! S100A8! APP! MR1!
CD276! IL1RAP! TAL1! FYN! S100A9! ATM! CASP10!
CD36! IL1RL2! TGFBI! HLABA! SELL! CD46! XBP1!
CD45R0! IL32! TIGIT! HLABB! SIGIRR! IRF1! MCL1!
CD46! IRF4! TIRAP! HLABC! STAT5B! NLRP3! BAX!
CD53! IRF5! TNFRSF11A! ICAM3! STAT6! PPBP!
!CD59! ITGA2B! TNFRSF14! IFNAR2! SYK! TRAF3!
!CD74! ITGAM! TOLLIP! IGF2R! TAGAP! IKBKB!
!CD81! ITGAX! TP53! IKBKE! TIRAP! ITGAE!
!CD8A! ITGB1! TRAF4! IKBKG! TLR2! NCR1!
!CD99! KLRF1! TRAF5! IL10RA! TLR4! TGFB1!
!CDKN1A! LTA! UBE2L3! IL11RA! TLR5! CD40LG!
!CFH! LTBR! !! IL6R! TLR8! FCGR1A/B!
!CFI! LY96! !! IRAK1! TMEM173! ITGAM!
!CISH! MAF! !! IRAK3! TNFRSF10C! IL12RB1!
!!!
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blood%cDC2%LPS%stim% !! blood%cDC2% !!
ADA! ETS1! MUC1! C14orf166! CD79A!
ATG10! GBP1! MX1! C1QBP! UBE2L3!
B2M! GPR183! NFKB1! CASP1! BID!
BATF! HAMP! NFKB2! CCR2! CFP!
BCL3! ICAM1! NFKBIA! CD2! TYK2!
C3! ICAM4! NFKBIZ! CD22! BTLA!
C4BPA! ICAM5! NOTCH2! CD3EAP! IKBKAP!
CASP1! IDO1! PDCD1! CD79B! SYK!
CASP3! IFIH1! PDCD1LG2! CIITA! ITGAX!
CCL19! IFNA1/13! PPBP! CX3CR1! CD45RA!
CCL20! IL10! PRDM1! FCER1A! MIF!
CCL22! IL12A! PSMB5! HLABDMA! C1S!
CCL24! IL12B! PTGS2! ICAM2! MR1!
CCL3! IL15! PTPN2! ICAM3!
!CCL4! IL19! S1PR1! IKZF1!
!CCL5! IL1A! SLAMF1! IL16!
!CCR7! IL1B! SLAMF7! ITGAE!
!CD274! IL1R1! SOCS1! LTB4R2!
!CD40! IL1RN! SOCS3! MAP4K1!
!CD44! IL20! SRC! MYD88!
!CD58! IL21R! STAT4! PTPN22!
!CD59! IL23A! STAT5A! SELL!
!CD70! IL23R! STAT5B! TP53!
!CD80! IL27! TAP2! ABL1!
!CD82! IL2RA! TBX21! ATG16L1!
!CD83! IL2RG! TCF7! CD1D!
!CD86! IL4R! TFRC! HLABDMB!
!CDKN1A! IL6! TICAM1! IL18!
!CFB! IL7R! TNF! SIGIRR!
!CLEC5A! IL8! TNFAIP3! CD244!
!CRADD! IRAK2! TNFAIP6! PSMB7!
!CSF1! KCNJ2! TNFRSF1B! TLR5!
!CSF2! KIR_Activ!1! TNFRSF4! CCND3!
!CTNNB1! LAMP3! TNFRSF9! IL6R!
!CXCL1! LGALS3! TNFSF15! KIT!
!CXCL13! LILRA3! TRAF1! PSMB8!
!CXCL2! LILRB2! TRAF2! PTPN6!
!CXCR3! LITAF! TRAF3! CD4!
!DPP4! LTA! TRAF4! CUL9!
!EBI3! MAP4K4! ZEB1! SMAD5!
!EGR2! MAPKAPK2!
!
ARHGDIB!
! !
